Back grey_arrow_rt.gif
 
Latest articles on Hepatitis B.
 
null.gif
 
 
  1. HBV Patient Declaration of Rights - (05/15/23)
     
  2. Glasgow: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Naïve People With Both HIV-1 and Hepatitis B: 3-Year Outcomes From ALLIANCE - (11/16/24)
     
  3. ID Week: Comparison of Renal Outcomes by Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) Containing Regimens for Prevention, and Treatment of HIV and/or HBV Treatment: A Systematic Literature Review and Meta-Analysis - (10/22/24)
     
  4. ID Week: High HBV Screening Rate in US Veterans Group With HIV - Mark Mascolini (10/22/24)
     
  5. ID Week: HBV HIV Screening Among HIV+ US Veterans Administration - (10/22/24)
     
  6. ID Week: Optimizing 2-Drug Switch HBV Screening: pilot intervention to increase HBV screening - (10/20/24)
     
  7. GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B - (08/12/24)
     
  8. IAS: Efficacy of dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B core antibody (anti-HBc): results from the phase 3/3b GEMINI-1/-2, STAT, TANGO, and SALSA - (07/31/24)
     
  9. Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia - encourages earlier treatment in HBV monoinfection - (07/10/24)
     
  10. EASL: Clinical evidence for expanding the treatment guidelines - (07/04/24)
     
  11. EASL: Experimental and clinical evidence for expanding HBV treatment guidelines - (07/04/24)
     
  12. EASL: Evaluating the effectiveness and safety of tenofovir alafenamide fumarate for preventing mother to child transmission of hepatitis B virus - (06/18/24)
     
  13. EASL: Efficacy and safety of tenofovir alafenamide fumarate in preventing HBV vertical transmission in high maternal viral load: a multi-centre, prospective cohort study - (06/18/24)
     
  14. EASL: Off-treatment Outcomes After Discontinuing Tenofovir-based Treatment in Hepatitis B e Antigen-positive and Hepatitis B e Antigen-negative Patients With Chronic Hepatitis B Virus - (06/18/24)
     
  15. EASL: Extended Treatment of HBeAg+ CHB Subjects with the Capsid Assembly Modulator ALG-000184 with or without Entecavir is Associated with Reductions in Viral Markers and Favorable Anti-HBeAg trends - (06/18/24)
     
  16. EASL: Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B - (06/18/24)
     
  17. EASL: Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis TAF Slices Serious Liver Outcomes 80% in People Without High ALT - Mark Mascolini (06/18/24)
     
  18. EASL: Association Between Post-treatment ALT Elevation and Subsequent HBsAg Seroclearance in Chronic Hepatitis B Patients Stopping NUC Therapy - (06/18/24)
     
  19. EASL: Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D (CHD) and baseline HBsAg levels below 10,000 IU/mL: Part 2 of the REEF-D study - (06/18/24)
     
  20. EASL: Pharmacokinetics and Safety of Single Dose of the Monoclonal Antibody Tobevibart (VIR-3434) Administered as Monotherapy or in Combination with the Small Interfering RNA Elebsiran (VIR-2218) in Cirrhotic Participants with Mild Hepatic Impairment - (06/18/24)
     
  21. EASL: Hepatic flares after nucleos (t)ide analogue cessation in HBeAg negative hepatitis B: results from the Nuc-Stop study - (06/17/24)
     
  22. EASL: Progression and risk factors after treatment with tenofovir or entecavir for chronic hepatitis B based on a multistate modeling approach - (06/17/24)
     
  23. EASL: Evaluation of a novel HBV DNA test from fingerstick capillary blood at the point-of-care as a tool to enhance clinical management - (06/17/24)
     
  24. EASL: Efficacy, safety, tolerability, and immunogenicity of JNJ-0535 following a reduction of viral antigen levels through administration of siRNA JNJ-3989 in patients with chronic HBeAg negative hepatitis B - interim data of the OSPREY study - (06/17/24)
     
  25. EASL: VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels - (06/17/24)
     
  26. EASL: Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone - (06/17/24)
     
  27. EASL: Tobevibart (VIR-3434), a Monoclonal Antibody, Resistance Analysis in Participants With Chronic HBV: Results From a Phase 1, Single-dose Study - (06/17/24)
     
  28. EASL: Therapeutic Vaccine (BRII-179 Plus siRNA (BRII-835) Stir T-Cell Response Tied to Lower HBsAg - Mark Mascolini (06/17/24)
     
  29. EASL: Tenofovir-Based HBV Treatment Cuts HCC Risk After Several Years - Mark Mascolini (06/17/24)
     
  30. EASL: Long-term hepatitis B surface antigen response after finite treatment with siRNAs ARC-520 or JNJ-3989 - (06/17/24)
     
  31. EASL: Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA) - (06/17/24)
     
  32. EASL: Tobevibart (VIR-3434), a Monoclonal Antibody, Resistance Analysis in Participants With Chronic HBV: Results From a Phase 1, Single-dose Study - (06/14/24)
     
  33. EASL: Tenofovir disoproxil fumarate and tenofovir alafenamide interruption in hepatitis B and human immunodeficiency virus co-infected individuals in the United States: monitoring practices and incidence of hepatitis B reactivation or hepatitis flare - (06/12/24)
     
  34. EASL: VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels - (06/12/24)
     
  35. EASL: siRNA (JNJ-3989)Plus NRTI and PD-1 Inhibitor Lower But Do Not Clear HBsAg: A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos(t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B - Interim results of the OCTOPUS-1 study - Mark Mascolini (06/12/24)
     
  36. EASL: Tenofovir-based antiviral therapy reduces long-term incidence of hepatocellular carcinoma in chronic hepatitis B - (06/12/24)
     
  37. EASL: A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos(t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B - Interim results of the OCTOPUS-1 study - (06/12/24)
     
  38. EuroHIV-HepMtg2024: Acute Hepatitis B Infections after Reducing ART among Vaccinated Patients Living with HIV: HBV "PrEP-effect" of TDF/FTC? - (05/23/24)
     
  39. DDW: TO DETERMINE THE TRANSIENT ELASTOGRAPHY CUT-OFF FOR ADVANCED FIBROSIS IN CHRONIC HEPATITIS B PATIENTS WITH CONCUEERNT HEPATIC STEATOSIS - (05/21/24)
     
  40. DDW: LONG-TERM SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS - FINAL 8-YEAR RESULTS OF 2 PHASE 3 STUDIES - (05/21/24)
     
  41. DDW: Metabolics Linked to Increased Risk of Liver & Non-Liver Complications in HBV+ - (05/21/24)
     
  42. DDW: LONG-TERM EFFICACY OF TENOFOVIR ALAFENAMIDE IN HBEAG-POSITIVE AND -NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED FOR UP TO 8 YEAR IN 2 PHASE 3 STUDIES - (05/21/24)
     
  43. WHO sounds alarm on viral hepatitis infections claiming 3500 lives each day - (04/15/24)
     
  44. New WHO HBV Treatment Recommendations, HDV Too; HCC monitoring; mother-to-child HBV transmission prevention - (04/15/24)
     
  45. CROI: Summary from CROI 2024 for HIV and liver disease - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/25/24)
     
  46. CROI: Hepatitis B Reactivation in PLWH With Anti-Core Antibody After Switch to an Anti-HBV Sparing Regimen - (03/21/24)
     
  47. CROI: HepB-CpG Vaccine Superior to HepB-alum in HIV Group With Prior Nonresponse - Mark Mascolini (03/21/24)
     
  48. CROI: HepB-CpG vaccine is superior to HepB-alum in people with HIV and prior vaccine non-response (A5379) - (03/15/24)
     
  49. CROI: Factors Associated With HBV Response to B/F/TAF Versus DTG + F/TDF at Week 96 in People With HIV-1 and HBV - (03/15/24)
     
  50. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy: 96-week pooled analysis - (02/15/23)
     
  51. Moving beyond the guidelines to improve detection of viral hepatitis (HBV) and linkage to care - (02/07/23)
     
  52. HBV functional cure finding-Cytosine base editing inhibits Hepatitis B Virus replication and reduces HBsAg expression in vitro and in vivo - (01/08/23)
     
  53. AASLD: Higher-Than-Expected Isolated Hep B Core Antibodies in Philadelphia Screening - Mark Mascolini (11/29/23)
     
  54. AASLD: Re-vaccination against hepatitis B in previous non-responders following hepatitis C eradication - Mark Mascolini (11/29/23)
     
  55. AASLD: Metabolomic profiling to predict histologic progression of liver fibrosis in patients with HIV and HBV coinfection: 20% have fibrosis progression in 3 years - Mark Mascolini (11/29/23)
     
  56. AASLD: HBV Vaccine Improves Survival With Liver Diseases Beyond HBV Infection - Mark Mascolini - (11/29/23)
     
  57. AASLD: MUSCLE FAT INFILTRATION IS ELEVATED IN PREFRAIL AND MODERATELY PHYSICALLY IMPAIRED PATIENTS - INTERIM RESULTS FROM THE PROSPECTIVE MULTI-CENTER CIRRHOSIS COHORT STUDY ACCESS-ESLD - (11/21/23)
     
  58. AASLD: Long term HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg and HBcAg mixed with mucoadhesive CVP (CVP-NASVAC) in patients with chronic HBV infection: The results of 48 months follow up - (11/21/23)
     
  59. AASLD: Global inequities - WHO perspectives and policies for reducing hepatitis related health disparities in low and middle income countries - (11/21/23)
     
  60. AASLD: Continued TDF for High HBV Load and Mild ALT Elevation Improves Fibrosis - Mark Mascolini (11/20/23)
     
  61. AASLD: Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B (CHB): Primary endpoint results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA) - (11/20/23)
     
  62. AASLD: Long-term effectiveness and safety of tenofovir alafenamide for treatment-naïve and experienced patients with chronic hepatitis B: Results from a real-world, multicenter study - (11/20/23)
     
  63. AASLD: Pegylated Interferon Reduces Relapses Following Bepirovirsen Treatment in Participants With Chronic Hepatitis B Virus Infection on Nucleos(t)ide Analogues: End of Study Results From the Phase 2b B-Together Study - (11/20/23)
     
  64. AASLD: AN OPEN-LABEL ROLLOVER STUDY FOLLOWING A RANDOMIZED TRIAL FOR CHRONIC HEPATITIS B WITH HIGH SERUM VIRAL LOAD BUT MILD ELEVATED AMINOTRANSFERASE - (11/16/23)
     
  65. AASLD: Peripheral Single Cell Gene Expression Changes in Response to Toll-Like Receptor 8 Agonist Treatment in Chronic Hepatitis B Patients - (11/16/23)
     
  66. AASLD: The Share of Total HBV Infections by Age at the Global and Regional Level, 2022 - (11/16/23)
     
  67. AASLD: Hepatitis Debrief at AASLD 2023 (HCV, HBV, HDV), Jennifer Price MD - (11/15/23)
     
  68. AASLD: Tenofovir versus entecavir in preventing HCC and death: answer from a large integrated health plan population - Mark Mascolini(11/15/23)
     
  69. AASLD: IMMEDIATE POSTPARTUM CESSATION OF TENOFOVIR IN HIGHLY VIREMIC PREGNANT MOTHERS WITH CHRONIC HEPATITIS B INFECTION: MATERNAL AND INFANT OUTCOMES - (11/15/23)
     
  70. AASLD: A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND TREATMENT REGIMENS OF VTP-300 COMBINED WITH LOW-DOSE NIVOLUMAB IN CHRONIC HEPATITIS B INFECTION - (11/15/23)
     
  71. AASLD: VIR-2218 and VIR-3434 with or without Pegylated Interferon Alfa-2a for the Treatment of Chronic HBV Infection: End-of-Treatment Results After 24 Weeks of Therapy (MARCH Study Part B) - (11/15/23)
     
  72. AASLD: The efficacy and safety of 12-week SOF/VEL regimen combined with prophylactic use of TAF for treatment-naive genotype1-6 HCV/HBV co-infection adult patients with or without compensated cirrhosis in China: a multi-center prospective, single-arm, open-label trial - (11/15/23)
     
  73. AASLD: Vir Biotechnology to Present Late-Breaking Data from
    Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials
    at AASLD's The Liver Meeting® 2023     - (11/14/23)
     
  74. AASLD: Bone and Renal Safety of Tenofovir Alafenamide at 8 Years in Chronic HBV Patients With Underlying Risk Factors for Use of Tenofovir Disoproxil Fumarate - (11/14/23)
     
  75. AASLD: Preliminary Off-Treatment Responses Following 48 Weeks of Vebicorvir, Nucleos(t)ide Reverse Transcriptase Inhibitor, and AB-729 Combination in Virologically Suppressed Patients With Hepatitis B e Antigen Negative Chronic Hepatitis B: Analysis From an Open-Label Phase 2 Study - (11/14/23)
     
  76. AASLD: Pegylated interferon reduces relapses following bepirovirsen treatment in participants with chronic hepatitis B virus infection on nucleos(t)ide analogs: end of study results from the Phase 2b B-Together study - (11/14/23)
     
  77. AASLD: Intrahepatic changes in viral and immune markers following treatment with JNJ-73763989 (JNJ-3989) and nucleos(t)ide analogs (NAs), in patients with chronic hepatitis B (CHB): INSIGHT Week 40 interim results - (11/14/23)
     
  78. AASLD: HBV Treatment Can Reduce Risk of Kidney Disease Among Patients With Hepatitis B, Yet Treatment in the US Reflects Inequities in Care - (11/14/23)
     
  79. AASLD: Impact of Long-term Treatment With Continuous Tenofovir Alafenamide or After Switching From Tenofovir Disoproxil Fumarate on Hepatocellular Carcinoma Incidence in Patients With Chronic Hepatitis B - (11/14/23)
     
  80. AASLD: Pharmacokinetics and Safety of VIR-2218 Monotherapy in & Adult Cirrhotic Participants with Moderate Hepatic Impairment - (11/14/23)
     
  81. AASLD: Predictors of treatment initiation among high-risk and grey area chronic hepatitis B patients in a real-world clinical practice setting in the United States - (11/14/23)
     
  82. AASLD: Initial Evaluation of Immune Complex Binding in a Phase 1 Safety and Tolerability Study of Chronic HBV Participants Given a Single Dose of VIR-3434 - (11/14/23)
     
  83. AASLD: Baseline nucleotide polymorphisms within HBV target site in chronic hepatitis B subjects do not impact HBsAg reductions mediated by RNA interference therapeutic Imdusiran (AB-729) - (11/14/23)
     
  84. AASLD: Assessment of Regional Impact on the Pharmacokinetics of VIR-2218 (BRII-835) in Participants with Chronic Hepatitis B Infection - (11/14/23)
     
  85. AASLD: Efficacy and Safety of siRNA JNJ-73763989, Capsid Assembly Modulator-E JNJ-56136379, and Nucleos(t)ide Analogs With Pegylated Interferon Alpha-2a Added in Immune-tolerant Patients With Chronic Hepatitis B Virus Infection: Interim Results From the Phase 2 REEF-IT Study - (11/14/23)
     
  86. AASLD: The Impact of Changing HBV Treatment Eligibility on Portion Eligible for Treatment by Region, 2024 - (11/14/23)
     
  87. AASLD: TENOFOVIR ALAFENAMIDE FUMARATE WAS EFFECTIVE AND SAFE FOR CHB PATIENTS WITH LIVER CIRRHOSIS: A REAL-WORD EVIDENCE IN CHINA - (11/14/23)
     
  88. EACS: HDV Prevalence 16% in French Group With HBV and HIV - Mark Mascolini (10/26/23)
     
  89. ID Week : HBV Screening and Vaccination Dropping in PrEP Users; Vaccinations Adherence - Mark Mascolini (10/17/23)
     
  90. ID Week : Hepatitis B Reactivation in Persons with HIV with Positive Hepatitis B Core Antibody after Switching to Antiretroviral Therapy without Hepatitis B Activity - (10/13/23)
     
  91. Brief Report: Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion - (09/19/23)
     
  92. IAS: Triple Test and Treat for HIV/HBV/HCV-Simple Way to Slow Hep Epidemics? - Mark Mascolini (08/03/23)
     
  93. IAS: Week-96 Results of ALLIANCE, a Phase 3, Randomized, Double-Blind Study Comparing B/F/TAF Versus DTG + F/TDF in Treatment-Naïve People With Both HIV-1 and Hepatitis B - (07/27/23)
     
  94. EASL: A gene editing approach for chronic hepatitis B: elimination of hepatitis B virus in vivo by targeting cccDNA and integrated viral genomes with a sequence-specific ARCUS nuclease - (07/11/23)
     
  95. AASLD: IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) - (07/12/23)
     
  96. Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America - (07/05/23)
     
  97. EASL: HCV and HBV prevalence and associated risk factors among people who inject drugs in Kenya - (07/05/23)
     
  98. EASL: Improving hepatitis B screening and linkage to care rates via the electronic medical record, provider engagement, and patient navigation in a large, urban health system - (07/05/23)
     
  99. EASL: Tenofovir prophylaxis during pregnancy for the elimination of mother-to-child transmission of hepatitis B virus: A cost-effectiveness analysis - (07/05/23)
     
  100. EASL: Improving hepatitis B screening and linkage to care rates via the electronic medical record, provider engagement, and patient navigation in a large, urban health system - (07/04/23)
     
  101. EASL: Identification of Liver-associated Gene Signatures from Serum Exosomes in Patients with Chronic Hepatitis B - (07/04/23)
     
  102. EASL: The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: Interim results from a Phase 1 study in healthy volunteers - (07/04/23)
     
  103. EASL: Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: Findings from a Phase 2, randomized open-label study in China - (07/04/23)
     
  104. EASL: Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International Network (HDIN) - (07/03/23)
     
  105. EASL: Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target WED-114 coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors - (07/03/23)
     
  106. EASL: Safety, pharmacokinetics, and antiviral activity of the next-generation hepatitis B core inhibitor ABI-H3733 in patients with hepatitis B e antigen negative chronic hepatitis B infection: Preliminary results from a randomized, blinded, Phase 1b study - (07/03/23)
     
  107. EASL: Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target WED-114 coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors - (07/03/23)
     
  108. EASL: A Novel Class of Orally Available Small Molecules Potently Inhibit Hepatitis B and D Virus Entry - (07/03/23)
     
  109. EASL: RBD1016, an siRNA, Lowers HBsAg for 24 Weeks in Phase 1 Placebo Trial - Mark Mascolini (07/03/23)
     
  110. EASL: The TLR8 agonist Selgantolimod modulates Kupffer cell differentiation status and indirectly impairs HBV entry into hepatocytes via an IL-6-dependent mechanism - (07/03/23)
     
  111. EASL: Transcriptional analysis of HBV infected liver after treatment with Selgantolimod reveals longitudinal changes in both inflammation-related pathways and B cell receptor repertoire - (07/03/23)
     
  112. EASL: Results of a Phase 1b, Open-label, Multicenter Study of Selgantolimod (GS-9688) in Special Populations of Patients With Chronic Hepatitis B - (07/03/23)
     
  113. EASL: Long-term Safety Profile of Tenofovir Alafenamide in Chronic Hepatitis B Patients: Final 8-Year Results of 2 Phase 3 Studies - (07/03/23)
     
  114. EASL: Trends in hepatitis B and hepatitis C related hepatocellular carcinoma - Increasing Cases, 2015 to 2030 - (07/02/23)
     
  115. EASL: Risk of developing cancer - comparison of HBV, HCV, and smoking - (07/02/23)
     
  116. EASL: Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection - (07/01/23)
     
  117. EASL: Model-based meta-analysis of pegylated IFN-alpha induced HBsAg loss at end of treatment and 24 weeks post treatment in chronic hepatitis B virus infection - (06/30/23)
     
  118. EASL: Hepatitis B surface antigen loss rate and safety and discontinuations with pegylated interferon alpha in chronic hepatitis B virus infection, a systematic review - (06/30/23)
     
  119. EASL: Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report - (07/01/23)
     
  120. EASL: The impact of removing all hepatitis B virus (HBV) testing and treatment restrictions - (06/30/23)
     
  121. EASL: Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in DAA failure patients: an integrative analysis - (07/01/23)
     
  122. EASL: Fast Response to REP 2139-Mg in 3 With HDV/HBV and Decompensated Cirrhosis - Mark Mascolini (06/30/23)
     
  123. EASL: HCV & HBV Summary Wrap-Up/ Lost Our Way on HCV - (06/30/23)
     
  124. EASL: Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study - (06/30/23)
     
  125. EASL: New Tool for Self-stigma in Chronic Hepatitis B: Content and Psychometric Validation of a New Patient-reported Outcome Instrument - (06/26/23)
     
  126. EASL: Association of Post-treatment Virologic Relapse and Biochemical Flares With HBV Serum Biomarkers in Long-term Virologically Suppressed HBeAg negative Patients Stopping NA Treatment: Exploratory Analyses From the Control Arm of the REEF-2 Study - (06/26/23)
     
  127. EASL: Intrahepatic Characterization of Virological and Immunological Markers in Two Distinct Populations of Chronic Hepatitis B: Baseline Assessment of Core Liver and Fine Needle Aspiration Biopsies From the Investigational INSIGHT Study - (06/26/23)
     
  128. EASL: Treatment eligibility and initiation among chronic hepatitis B patients in a real-world setting in the United States - (06/26/23)
     
  129. EASL: VIR-2218 and VIR-3434 Therapy Is Efficacious in Preclinical Models of Hepatitis Delta Virus Infection - (06/26/23)
     
  130. EASL: Single-dose pharmacokinetics of VIR-3434, a novel neutralizing monoclonal antibody, in participants with chronic hepatitis B virus infection - (06/26/23)
     
  131. EASL: siRNA VIR-2218 + Vaccinal Monoclonal Antibody VIR-3434 Phase 2 Post-Treatment Follow-up MARCH Trial - (06/26/23)
     
  132. EASL: Long-term Efficacy of Tenofovir Alafenamide in HBeAg-positive and HBeAg-negative Chronic Hepatitis B Patients Treated for up to 8 Years in 2 Phase 3 Studies - (06/26/23)
     
  133. EASL: Continued Treatment of Early Nonresponders or Partial Virologic Responders With Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta Through Week 96 Leads to Improvement in Virologic and Biochemical Responses - (06/26/23)
     
  134. EASL: Predictors of severe flares after nucleos (t)ide analogue cessation-results of a global cohort study (RETRACT-B study) - (06/26/23)
     
  135. EASL: Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial - (06/26/23)
     
  136. EASL: Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: a nationwide cohort study (TDF v Entecavir) - (06/26/23)
     
  137. EASL: Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis - (06/26/23)
     
  138. EASL: Intrahepatic Characterization of Virological and Immunological Markers in Two Distinct Populations of Chronic Hepatitis B: Baseline Assessment of Core Liver and Fine Needle Aspiration Biopsies From the Investigational INSIGHT Study - (06/26/23)
     
  139. EASL: Association of Post-treatment Virologic Relapse and Biochemical Flares With HBV Serum Biomarkers in Long-term Virologically Suppressed HBeAg negative Patients Stopping NA Treatment: Exploratory Analyses From the Control Arm of the REEF-2 Study - (06/26/23)
     
  140. EASL: LOW HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT SUSTAINED RESPONSE AND HBSAG LOSS IN PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY - (06/26/23)
     
  141. EASL: Intrahepatic Characterization of Virological and Immunological Markers in Two Distinct Populations of Chronic Hepatitis B: Baseline Assessment of Core Liver and Fine Needle Aspiration Biopsies From the Investigational INSIGHT Study - (06/26/23)
     
  142. EASL: Treatment With siRNA JNJ-73763989 Plus Nucleos(t)ide Analogue (NA) Decreases HBsAg and HDV RNA Levels in Patients With Chronic Hepatitis D (CHD): Part 1 of the REEF-D Study - (06/26/23)
     
  143. EASL: Comparable Risk of Cardiovascular Events in Chronic Hepatitis B Patients Treated with Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide - (06/26/23)
     
  144. EASL: Increased Baseline Comorbidity Burden Among Commercially Insured Patients With Hepatitis Delta Virus Infection vs Hepatitis B Virus Monoinfection in the United States - (06/26/23)
     
  145. HBV Treatment Reduces HCC. Editorial: Re-assessing antiviral treatment criteria for chronic hepatitis B - (06/01/23)
     
  146. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals - (05/12/23)
     
  147. Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFN and an NRTI - (05/12/23)
     
  148. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals - (05/10/23)
     
  149. HBV Reactivation in PWH Switching to TDF/TAF Sparing Therapy - (05/08/23)
     
  150. HBV/HDV Debrief at Global Hepatitis Summit 2023 - Markus Cornberg - (05/08/23)
     
  151. Treatment for >12 Weeks with the Capsid Assembly Modulator (CAM) ALG-000184 and Entecavir (ETV) Dose Dependently Reduces HBsAg in HBeAg+ Subjects with Chronic Hepatitis B (CHB) (Global Hepatitis Summit 2023 April 28 Paris) - (05/04/23)
     
  152. Public Health Tools for Eliminating Hepatitis - (05/02/23)
     
  153. Death Rates for HCV & HBV Surpass HIV, TB, Malaria - (05/02/23)
     
  154. Low HCV Testing & Treatment Rates - (05/02/23)
     
  155. Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023 - (05/02/23)
     
  156. Preclinical Antiviral Profiling of AB-161, an Oral HBV Inhibitor that Destabilizes HBV RNA and Suppresses HBsAg (Global Hepatitis Summit 2023 Paris April 28) - (05/02/23)
     
  157. LB/O99: 48 weeks of AB-729 + nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy (Global Hepatitis Summit 2023 Paris April 28) - (05/02/23)
     
  158. Updated Prevalence of Chronic Hepatitis B and Hepatitis Delta Infection Among Foreign-Born Individuals in the United States (Global Hepatitis Summit 2023, Paris April 28) - (05/01/23)
     
  159. Global epidemiology of HBV (Global Hepatitis Summit 4/28/2023 Paris) - (05/01/23)
     
  160. Updated Prevalence of Chronic Hepatitis B and Hepatitis Delta Infection Among Foreign-Born Individuals in the United States (Global Hepatitis Summit 2023, Paris April 28) - (04/29/23)
     
  161. Global epidemiology of HBV - (HDV, Fatty Liver), Global Hep Summit 2023 - (04/27/23)
     
  162. Bulevirtide+PegIFN HBsAg response - (04/09/23)
     
  163. CROI: Summary from CROI 2023 for HIV and liver disease What is new in viral hepatitis coinfection? Is fatty liver disease a growing concern? New insights from CROI 2023. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/16/23)
     
  164. CROI: THE PATH TO HEPATITIS B CURE - (04/09/23)
     
  165. The number of new cases and deaths from liver cancer could rise by >55% by 2040. Global burden of primary liver cancer in 2020 and predictions to 2040 - (04/09/23)
     
  166. CROI: BULEVIRTIDE +/- PEG-IFN IN HIV/HBV/HDV CO-INFECTED PATIENTS IN REAL-LIFE SETTINGS - (03/22/23)
     
  167. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection - (03/16/23)
     
  168. CROI: PREDICTORS OF HEPATITIS B TREATMENT RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION - (02/20/23)
     
  169. Global- Only 2% & 13% of HCV & HBV Infections Treated - (02/15/23)
     
  170. New Approaches to Chronic Hepatitis B - (01/06/23)
     
  171. HBV Panel: New Screening/Treatment Recommendations - It Is Time for a Simplified Approach to Hepatitis B Elimination, Editorial too. - (01/06/23)
     
  172. AASLD: Low level of hepatitis B viremia increases the risk of hepatocellular carcinoma in patients with untreated compensated cirrhosis - (11/28/22)
     
  173. AASLD: Profile of HBV DNA integration in the natural history of chronic hepatitis B - (11/28/22)
     
  174. AASLD: Comparable outcomes between immune-tolerant and active phases in non-cirrhotic chronic hepatitis B: a meta-analysis - (11/28/22)
     
  175. AASLD: Tenofovir-DF Therapy Prevents Hepatitis B Vertical Transmission in Highly Viremic Mothers Without HBV Immunoglobulin for Infants - (11/17/22)
     
  176. AASLD: Compassionate use of subcutaneously administered REP 2139-Mg in cirrhotic HBV / HDV co-infection - (11/14/22)
     
  177. AASLD: Evaluation of the vebicorvir, NrtI and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: Interim analysis from an open label Phase 2 study - (11/11/22)
     
  178. AASLD: Combination Treatment with HBV-Targeting GalNAc-siRNA and Small-Molecule PD-L1 Inhibitor Increases HBV Specific Immune Responses in a Chronic Hepatitis B Infection Mouse Model - (11/11/22)
     
  179. AASLD: Hepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects still on NA therapy - (11/11/22)
     
  180. AASLD: Novel Anti-HBV Agent (VIR-2218) Aims for Functional Cure With PEG-IFN - Mark Mascolini (11/11/22)
     
  181. AASLD: Anti-HBV Therapy at or Before HCC Diagnosis Improves Survival, only 37% received therapy - Mark Mascolini (11/11/22)
     
  182. AASLD: GS-2829 and GS-6779 HBV therapeutic vaccine generates robust, polyfunctional, genotype cross-reactive CD8 T cell responses accompanied by high titers of anti-HBsAg antibodiess - (11/11/22)
     
  183. AASLD: Low Level of HBV Viremia Increases Risk of HCC in Patients with Untreated Compensated Cirrhosis - (11/11/22)
     
  184. AASLD: Preclinical characterization of a novel liver-focused small molecule efficiently inhibiting hepatitis B virus by activating type I interferon signaling - (11/11/22)
     
  185. AASLD: Preclinical Characterization of a Novel Class of Highly Potent Small Molecule Hepatitis B and D Virus Entry Inhibitors - (11/11/22)
     
  186. AASLD: Young Recent Drug Injectors Run High HCV Reinfection Risk in BC - (11/11/22)
     
  187. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection - (11/10/22)
     
  188. AASLD: Evaluation of the vebicorvir, NrtI and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: Interim analysis from an open label Phase 2 study - (11/10/22)
     
  189. AASLD: Safety, Tolerability, and Antiviral Activity of the siRNA VIR-2218 in Combination With the Investigational Neutralizing Monoclonal Antibody VIR-3434 For the Treatment of Chronic Hepatitis B Virus Infection: Preliminary Results From the Phase 2 MARCH Trial - (11/10/22)
     
  190. AASLD: Preliminary 48-week Safety and Efficacy Data of VIR-2218 Alone and in Combination With Pegylated Interferon Alfa in Participants With Chronic HBV Infection - (11/10/22)
     
  191. AASLD: Updated evaluation of global progress towards HBV and HCV elimination, preliminary data through 2021 (not good) - (11/10/22)
     
  192. AASLD: Liver-Related Mortality Soared in US After COVID-19 Arrived - Mark Mascolini (11/10/22)
     
  193. AASLD: Viral Sequence Analysis of Not-currently Treated Chronic Hepatitis B Patients Enrolled in the REEF-1 Study and Impact of Baseline Nucleotide Polymorphisms in the Small Interfering RNA JNJ-3989 Trigger Target Regions on Viral Antigen Declines - (11/10/22)
     
  194. AASLD: RNA LAUNCH SYSTEM ENABLES IN VITRO EVALUATION OF BEPIROVIRSEN EFFICACY AGAINST HBV VARIANTS - (11/10/22)
     
  195. AASLD: HBV DNA and HBsAg loss with bepirovirsen monotherapy in patients with chronic hepatitis B infection not on nucleos(t)ide analogue therapy: B-Clear study end-of-study results - (11/10/22)
     
  196. AASLD: Efficacy and Safety of siRNA JNJ-73763989, Capsid Assembly Modulator JNJ-56136379, Nucleos(t)ide Analog, and Pegylated Interferon Alpha-2a for the Treatment of Chronic Hepatitis B: Week 24 Results From the Phase 2 PENGUIN Study - (11/10/22)
     
  197. AASLD: Efficacy and safety of combination treatment with siRNA JNJ-73763989 and capsid assembly modulator JNJ-56136379 (bersacapavir) in HBeAg negative virologically suppressed chronic hepatitis B patients: Follow-up week 48 end of study results from REEF-2 - (11/10/22)
     
  198. AASLD: Bepirovirsen (BPV) in patients with chronic hepatitis B virus (HBV) infection controlled by nucleos(t)ide analogue therapy: HBV DNA and HBsAg loss 6 months after end of BPV treatment (B-Clear study) - (11/10/22)
     
  199. AASLD: HBV Therapy Slices HCC Risk in HBV's Indeterminate Phase - Mark Mascolini (11/10/22)
     
  200. AASLD: Characteristics of Chronic Hepatitis B Patients in a 20-Year, Real-World Study of Treatment Patterns in a US Health Care Delivery System - (11/10/22)
     
  201. AASLD: Metabolic Comorbidities Tied to Shorter HCC-Free Survival With HBV - Mark Mascolini (11/10/22)
     
  202. AASLD: CHANGES IN MORTALITY DUE TO CHRONIC LIVER DISEASES (CLD) DURING THE COVID- 19 PANDEMIC: DATA FROM THE UNITED STATES' NATIONAL VITAL STATISTICS SYSTEM - (11/10/22)
     
  203. AASLD: The Incidence of Chronic HBV by Age, 2022 - (11/08/22)
     
  204. AASLD: Reduction in Hepatitis B Viral DNA and Hepatitis B Surface Antigen Following Administration of a Single Dose of VIR-3434, an Investigational Neutralizing Monoclonal Antibody: First Experience in a Population With Viremia - (11/08/22)
     
  205. AASLD: Safety, Tolerability, and Antiviral Activity of the siRNA VIR-2218 in Combination With the Investigational Neutralizing Monoclonal Antibody VIR-3434 For the Treatment of Chronic Hepatitis B Virus Infection: Preliminary Results From the Phase 2 MARCH Trial - (11/08/22)
     
  206. AASLD: CURE OF HEPATITIS DELTA INFECTION FOLLOWING 3 YEARS OF BULEVIRTIDE MONOTHERAPY IN A PATIENT WITH COMPENSATED ADVANCED CIRRHOSIS - (11/08/22)
     
  207. AASLD: Assembly Biosciences Presents New Data at AASLD The Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV 'ABI-4334' - (11/08/22)
     
  208. AASLD: Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting - (11/08/22)
     
  209. AASLD: Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD's The Liver Meeting 2022 - (11/08/22)
     
  210. ID Week: A Case Series of Lo-Level HBV Viremia After Switching to Long-Acting Injectable Cabotegravir/Rilpivirine in Patients with HIV, Hepatitis B Core Antibody Positivity, and Hepatitis B Surface Antigen Negativity - (10/26/22)
     
  211. HDV/HBV+ Immigrants in USA - (10/03/22)
     
  212. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review - 2017 - (09/30/22)
     
  213. HBV Drug Pipeline - at HBV Intl Meeting 2022 Paris - (09/26/22)
     
  214. HBV Meeting Paris: Replicor expands efficacy and safety envelope in decompensated cirrhosis with compassionate use of subcutaneous REP 2139-Mg - (09/26/22)
     
  215. HBV Meeting Paris: Dose-Dependent Durability of Hepatitis B Surface Antigen Reductions Following Administration of a Single Dose of VIR-3434, an Investigational, Neutralizing Vaccinal Monoclonal Antibody - (09/26/22)
     
  216. VIR-2218 Plus VIR-3434 Combination Therapy Reduces Hepatitis B Virus Surface Antigen Levels In Vivo - (09/26/22)
     
  217. Pharmacokinetics of ATI-1428, a Novel Ultra-potent Capsid Assembly Modulator - (09/26/22)
     
  218. HBV Meeting Paris: Next-generation core inhibitors demonstrate increased potency and distinct biochemical properties compared to first-generation core inhibitors - (09/26/22)
     
  219. HBV Meeting Paris: Combination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse model - (09/26/22)
     
  220. CROI: Summary from virtual CROI 2022 for HIV and liver disease Hepatitis elimination for 2030 on track? Is fatty liver disease a growing concern? New insights from CROI 2022. - Prof. Dr. Jurgen K. Rockstroh Department of Medicine I University Hospital Bonn Venusberg-Campus 1 53127 Bonn Germany - (03/21/22)
     
  221. EASL: EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients - (09/03/22)
     
  222. EASL: EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Results of a 28-day Phase 1b Study in NUC-suppressed CHB Patients - (09/03/22)
     
  223. HIV Infection and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus (HBV) Co-infection: a Propensity Score-matched Cohort Study HIV/HBV confected 1.2% HCC (n=7) vs HBV Monoinfected 3.2% (n=75). - (08/17/22)
     
  224. IAC: HIV/HBV coinfection in pregnancy and response to antiretroviral therapy - (08/09/22)
     
  225. IAC: Putting HBV/HCV Testing and Treatment in HIV Clinics Has Benefits in Vietnam - Mark Mascolini - (08/03/22)
     
  226. IAC: Week 48 of a phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/ tenofovir disoproxil fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE) - Mark Mascolini - (07/30/22)
     
  227. EASL: Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB on nucleos(t)ide analogues - (07/25/22)
     
  228. EASL: Mechanistic pharmacokinetics/pharmacodynamics modelling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen and alanine transaminase changes in chronic hepatitis B patients: Phase 2b analysis to inform Phase 3 decision-making - (07/25/22)
     
  229. EASL: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos(t)ide analogue therapy: interim results from the randomised Phase 2b B-Clear study - (07/25/22)
     
  230. EASL: Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study - (07/25/22)
     
  231. EASL: Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model - (07/25/22)
     
  232. EASL: Estimations of the global prevalence of occult hepatitis B virus infection (OBI): a systematic review and meta-analysis - (07/18/22)
     
  233. EASL: The Comparison of Tenofovir Alafenamide Fumarate with Tenofovir Disoproxil Fumarate in Preventing Hepatitis B Transmission in Mothers with High Viral Load: A Retrospective Cohort Study - (07/18/22)
     
  234. EASL: Characterizing of hepatitis B virus serum RNA kinetics during TDF plus pegylated interferon alfa-2a with and without nucleic acid polymers - (07/18/22)
     
  235. EASL: Tenofovir Alafenamide for Chinese Pregnant Women with Active Chronic Hepatitis B: A Multicenter Prospective Study - (07/18/22)
     
  236. EASL: Safety, Pharmacokinetics, and Antiviral Activity of the Class II Capsid Assembly Modulator ALG-000184 in Subjects with Chronic Hepatitis B and other Aligos studies - (07/14/22)
     
  237. EASL: The Value of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals - cost effectiveness analysis - (07/14/22)
     
  238. EASL: Concordance of the Xpert hepatitis B viral load test and conventional quantitative PCR in detecting and quantifying viremia using stored plasma and dried blood spot samples in West Africa - (07/11/22)
     
  239. EASL: Utilizing Phenotyping Algorithms as Tools for Increasing Linkage to Guideline-Concordant Care in Patients at Risk for Hepatitis B - (07/08/22)
     
  240. EASL: Establishment of a new diagnostic model for significant liver tissue damage in patients with chronic hepatitis B virus infection in the immune tolerance phase - (07/08/22)
     
  241. EASL: Towards elimination: A clinical and public health approach to control of hepatitis C and B infection in England - (07/07/22)
     
  242. EASL: Higher rates of virological relapse after nucleos(t)ide analogue withdrawal in HBeAg-negative versus positive chronic hepatitis B patients: Results from a global, multi-ethnic cohort of patients with chronic hepatitis B virus infection - (07/07/22)
     
  243. EASL: Comparative risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving tenofovir- or entecavir-based regimens: a meta-analysis using individual patient data - (07/07/22)
     
  244. EASL: Impact of baseline viral load on hepatocellular carcinoma risk during antiviral treatment in non-cirrhotic patients with HBeAg-positive chronic hepatitis B - (07/07/22)
     
  245. EASL: Long-Read Sequencing of HCC Samples Reveals Complete Architecture of HBV Integrations and Chimeric mRNA Isoforms Associated With Oncogenes - (07/07/22)
     
  246. EASL: Decrease in the Burden of Integrated Hepatitis B Virus DNA in Chronic Hepatitis B Patients With Minimally Elevated Alanine Aminotransferase on Tenofovir Disoproxil Fumarate as Revealed by Long-Read DNA Sequencing - (07/07/22)
     
  247. EASL: Evaluation of Renal and Bone Safety at 4 Years in Post-Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis - (07/07/22)
     
  248. EASL: Real life efficacy, renal and lipid profile data of tenofovir alafenamide in switched chronic hepatitis B patients - (07/07/22)
     
  249. EASL: A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children and Adolescent Patients With Chronic Hepatitis B - (07/07/22)
     
  250. EASL: Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients - (07/06/22)
     
  251. EASL: Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells - (07/06/22)
     
  252. EASL: Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B subjects - (07/06/22)
     
  253. EASL: Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver - (07/06/22)
     
  254. EASL: Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update - (07/06/22)
     
  255. EASL: Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection - (07/06/22)
     
  256. EASL: VIR-2218 Plus VIR-3434 Combination Therapy Reduces Hepatitis B Virus Surface Antigen Levels In Vivo - (07/06/22)
     
  257. EASL: Dose-Dependent Durability of Hepatitis B Surface Antigen Reductions Following Administration of a Single Dose of VIR-3434, a Novel, Neutralizing Vaccinal Monoclonal Antibody - (07/06/22)
     
  258. EASL: Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program - press release - (07/06/22)
     
  259. EASL: Evaluation of the disposition and mass balance recovery of vebicorvir, a first-generation hepatitis B core inhibitor, in rats and humans - (07/06/22)
     
  260. EASL: Evaluation of the drug-drug interaction profile of vebicorvir, a first-generation hepatitis B core inhibitor: findings from Phase 1 and Phase 2a studies - (07/06/22)
     
  261. EASL: Greater sequence diversity during early hepatitis B virus decline on vebicorvir plus entecavir is associated with a lower level of virus rebound following switch to entecavir monotherapy - (07/06/22)
     
  262. EASL: The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding road New HBV and HCV Projected to Decline Thru 2030, But New HCC Cases Will Rise for both HCV & HBV, HBV liver related deaths expected to increase by 30% - Mark Mascolini - (07/01/22)
     
  263. EASL: Waist-to-Hip Ratio Predicts Liver Disease Better Than Body Mass Index - Mark Mascolini - (07/01/22)
     
  264. EASL: One Third With HDV Respond to Bulevirtide Monotherapy Through 24 Weeks (2 & 10 mg) - Integrated Analysis from 2 Phase 2 & 1 Phase 3 Trials - Mark Mascolini - (07/01/22)
     
  265. EASL: ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents cccDNA formation by disruption of incoming capsids - (06/30/22)
     
  266. EASL: Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022 - (06/30/22)
     
  267. EASL: Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects - (06/30/22)
     
  268. EASL: Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) - (06/30/22)
     
  269. EASL: Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and treatment-naïve chronic hepatitis B patients: 48-week treatment and post treatment follow up - (06/30/22)
     
  270. EASL: Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729 - (06/30/22)
     
  271. EASL: Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients - (06/27/22)
     
  272. EASL: Evidence of Past Hepatitis C and D Co-Infection in Hepatitis B Seronegative Individuals - (06/27/22)
     
  273. EASL: EASL 2022 HBV, HDV Wrap-Up - (06/27/22)
     
  274. EASL: Effects of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 on Viral Markers of Chronic Hepatitis B: Results From the REEF-1 Study - (06/27/22)
     
  275. EASL: Peginterferon Lambda (IFN-λ) combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under IFN-λ monotherapy: The LIFT-1 Study - (06/27/22)
     
  276. EASL: Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL's International Liver Congress™ - (06/27/22)
     
  277. EASL: The disease burden of hepatitis B and C from 2015- 2030: The long and winding road towards elimination - (06/27/22)
     
  278. EASL: The Global Burden of Liver Cancer (LC) and Chronic Liver Diseases (CLD) is Driven by Nonalcoholic Steatohepatitis (NASH) and Alcohol Liver Disease (ALD) - (06/27/22)
     
  279. EASL: Real life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort - (06/26/22)
     
  280. EASL: Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study - (06/26/22)
     
  281. EASL: Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities - (06/26/22)
     
  282. EASL: Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment-naïve patients with HBeAg positive chronic hepatitis B - (06/26/22)
     
  283. EASL: Sustained 12 Week Off Treatment Antiviral Efficacy of ATI-2173, a Novel Active Site Polymerase Inhibitor Nucleotide (ASPIN), Combined With Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients, a Phase 2a Clinical Trial - (06/26/22)
     
  284. EASL: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study - (06/26/22)
     
  285. EASL: Therapeutic Vaccine JNJ-0535 Induces a Strong HBV-specific T-cell Response in Healthy Adults and a Modest Response in Chronic HBV-infected Patients VOX/VEL/SOF Effective Rescue After DAA Failure-With Limits - (06/26/22)
     
  286. EASL: Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study - (06/25/22)
     
  287. EASL: Association between Hepatitis Delta Virus with Liver Morbidity and Mortality: A Systematic Literature Review and Meta-Analysis - (06/25/22)
     
  288. EASL: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Adults in the United States: An Analysis of All-Payer Claims Database - (06/25/22)
     
  289. EASL: Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide -Results of a "real world study" - (06/25/22)
     
  290. EASL: No Detectable Resistance to Bulevirtide in Participants With Chronic Hepatitis D Through 24 Weeks of Treatment - (06/25/22)
     
  291. EASL: Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results From a Phase 3 Randomized, Multicenter, Parallel Design Study - (06/24/22)
     
  292. EASL: Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta - Mark Mascolini (06/24/22)
     
  293. EASL: Evaluation of Global Progress towards HBV and HCV elimination - off track - (06/23/22)
     
  294. Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver's International Liver Congress™ 2022 - (06/17/22)
     
  295. Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 - (06/14/22)
     
  296. Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022 - (06/14/22)
     
  297. Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022 - (06/14/22)
     
  298. Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022 - (06/14/22)
     
  299. Global Hepatitis D 37% Prevalence in IVDUs - (06/14/22)
     
  300. About the Phase 3 D-LIVR Study: oral Lonafarnib/rtv +/- Peg-Lambda 48 weeks - (06/13/22)
     
  301. Antios Therapeutics Announces Oral Presentations on ATI-2173, ATI-1428, and ATI-1645 Hepatitis B Virus Programs at the EASL International Liver Congress™ 2022 - (06/08/22)
     
  302. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection - (06/08/22)
     
  303. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial - (06/07/22)
     
  304. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients - (06/07/22)
     
  305. PREVALENCE OF HEPATITIS DELTA VIRUS (HDV) INFECTION IN THE UNITED STATES: RESULTS FROM AN ICD-10 REVIEW - 25% of HDV in USA is In NYC (Bklyn, Bronx) & NYC Suburb - (06/06/22)
     
  306. A Phase 2 Study of Lonafarnib, Ritonavir & Peginterferon Lambda for 24 Weeks: Interim End-of-Treatment Results from the LIFT HDV Study - (05/31/22)
     
  307. Interferon therapy shows striking results against COVID-19 - (05/31/22)
     
  308. Treatment for hepatitis delta virus with the prenylation inhibitor lonafarnib: It's getting closer Editorial - (05/31/22)
     
  309. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study - (05/31/22)
     
  310. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease - (05/31/22)
     
  311. Lonafarnib-A new member of the Delta Force? Editorial - (05/27/22)
     
  312. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis - (05/27/22)
     
  313. Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV - (05/27/22)
     
  314. HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines - (05/27/22)
     
  315. Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta - (05/26/22)
     
  316. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes - (05/26/22)
     
  317. FDA Guidance for Industry - Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment - (04/26/22)
     
  318. ATI-2173 Monotherapy Results in Prolonged Off-Treatment Suppression in HBV DNA and RNA - (04/08/22)
     
  319. SAVE-1: Phase 2 Results of a Novel Active Site Polymerase Inhibitor Nucleotide (ASPIN), ATI-2173 + TDF in HBV-Infected Patients - (04/08/22)
     
  320. Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies - (03/30/22)
     
  321. CROI: Regional Variation in HBV Prevalence in People Living with HIV in Botswana - (03/22/22)
     
  322. CROI: LOW RATES OF HEPATITIS B VACCINATION AMONG PEOPLE WITH HIV - (03/22/22)
     
  323. CROI: Randomized Trial of HBV Revaccination in MSM Born in the Neonatal Vaccination Era - (03/22/22)
     
  324. CROI: NEW HEPATITIS B INFECTION AMONG HIV PATIENTS: WHO IS AT RISK? - (03/21/22)
     
  325. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  326. CROI: The role of HIV/HBV/HCV triple infection in end stage liver disease (ESLD) and all cause mortality in Europe (02/23/22)
     
  327. CROI: HBIg-Free Strategy Prevents Vertical HBV Transmission-If Mothers Start TDF Soon Enough - Mark Mascolini (02/22/22)
     
  328. Hepatitis D Changing Context Global Prevalence - (02/10/22)
     
  329. AASLD: LOW HBsAg LEVELS MAINTAINED FOLLOWING CESSATION OF THE GALNAC-siRNA, AB-729, IN CHRONIC HEPATITIS B SUBJECTS ON NUCLEOS(T)IDE ANALOGUE THERAPY (01/15/22)
     
  330. AASLD: Safety, PK, PD and antiviral activity of TLR7 agonist RO7020531 in patients with chronic hepatitis B not receiving antiviral treatment: a phase 1 study (12/28/21)
     
  331. AASLD: LIVER-DIRECTED TARGETING OF PD-L1 WITH RO7191863, A LOCKED NUCLEIC ACID, IN CHRONIC HEPATITIS B: FIRST REPORT OF PHASE 1 TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS (12/28/21)
     
  332. AASLD: Efficacy and Safety of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 for the Treatment of Chronic Hepatitis B Virus Infection : Results From the Phase 2b REEF-1 Study (12/15/21)
     
  333. AASLD: EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients (12/14/21)
     
  334. AASLD: EDP-514, A NOVEL PANGENOTYPIC CLASS II HEPATITIS B VIRUS CORE INHIBITOR: PRELIMINARY RESULTS OF A 28-DAY PHASE 1b STUDY IN NUC-SUPPRESSED CHB PATIENTS (12/14/21)
     
  335. AASLD: Safety and pharmacokinetics of ABI-H3733, a novel second-generation HBV core inhibitor: Results from a Phase 1a study in healthy volunteers (12/14/21)
     
  336. AASLD: Preclinical characterization of ABI-4334, a novel, highly potent core inhibitor for the treatment of chronic hepatitis B virus infection (12/14/21)
     
  337. AASLD: HBV pgRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued NrtI treatment in patients with HBeAg positive chronic hepatitis B virus infection: findings from a phase 2 open-label study (12/14/21)
     
  338. AASLD: LONG-TERM EVALUATION OF HCV RE-INFECTION RATES AMONG INNER CITY VULNERABLE POPULATIONS (12/14/21)
     
  339. AASLD: ALG-005398 is a Potent Non-HAP Class I HBV Capsid Assembly Modulator that Strongly Reduces HBsAg Levels In Vivo (12/13/21)
     
  340. AASLD: ALG-020572, a GalNAc-conjugated Antisense Oligonucleotide, Demonstrates In Vivo Efficacy and Favorable Preclinical Profile for the Treatment of Chronic Hepatitis B (12/13/21)
     
  341. AASLD: TRIPLE COMBINATION OF ANTI-HEPATITIS B VIRUS DRUGS DEMONSTRATES SYNERGISTIC ACTIVITY IN VITRO (12/13/21)
     
  342. AASLD: THE PHARMACOKINETIC AND SAFETY PROFILES OF RO7445482 siRNA [RG6346] ARE SIMILAR BETWEEN ASIAN AND NON-ASIAN HEALTHY VOLUNTEERS AND CHRONIC HEPATITIS B PATIENTS IN A PHASE 1 STUDY (12/13/21)
     
  343. AASLD: Tenofovir Alafenamide for Pregnant Chinese Women with Active Chronic Hepatitis B: A Multicenter Prospective Study (12/13/21)
     
  344. Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta - (12/10/21)
     
  345. AASLD: Hepatitis D Delta Overview; New AASLD 2021 Treatment Studies (12/06/21)
     
  346. AASLD: HBV Nuc Withdrawal -Cautionary Study Results at AASLD 2021 (12/06/21)
     
  347. AASLD: Hepatitis D (Delta) at AASLD 2021 (12/06/21)
     
  348. AASLD: CONCURRENT FATTY LIVER IS ASSOCIATED WITH HIGHER RISK OF HEPATOCELLULAR CARCINOMA AND MORTALITY IN PATIENTS WITH CHRONIC VIRAL HEPATITIS (12/03/21)
     
  349. AASLD: SIMULTANEOUS HEPATITIS B AND C SCREENING IN AN EMERGENCY DEPARTMENT: A BROAD LINKAGE TO CARE STRATEGY (12/02/21)
     
  350. AASLD: THE IMPACT OF IMMIGRATION ON THE NATIONAL HEPATITIS B PREVALENCE IN THE UNITED STATES (11/30/21)
     
  351. AASLD: ASSOCIATION BETWEEN DAILY ASPIRIN THERAPY AND HEPATOCELLULAR CARCINOMA ACCORDING TO METABOLIC RISK FACTOR BURDEN IN PATIENTS WITH CHRONIC HEPATITIS B (11/30/21)
     
  352. AASLD: Preliminary Results From a Phase 2 Study Evaluating VIR-2218 Alone and in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis B Infection (11/23/21)
     
  353. AASLD: ARO-HSD, an investigational RNAi therapeutic, demonstrates reduction in ALT and hepatic HSD17B13 mRNA and protein in patients with NASH or suspected NASH (11/23/21)
     
  354. AASLD: Rapid HBsAg Reduction in Chronic Hepatitis B Virus Infection: Preliminary Results From a Phase 1 Study Evaluating a Single Dose of VIR-3434, a Novel Neutralizing, Vaccinal Monoclonal Antibody (11/23/21)
     
  355. AASLD: Understanding Patient Experiences with Chronic Hepatitis B Virus and its Treatments (11/23/21)
     
  356. AASLD: Changes in Viral Antigens are More Strongly Associated with HBV pgRNA than HBV DNA in Studies of Vebicorvir and NrtI in Treatment-naïve Patients with Chronic HBV Infection (11/23/21)
     
  357. AASLD: EFFICACY OF LONG-TERM TREATMENT OF CHRONIC HEPATITIS D PATIENTS WITH BULEVIRTIDE - RESULTS OF A "REAL WORLD" STUDY (11/23/21)
     
  358. AASLD: TREATMENT WITH BEPIROVIRSEN (GSK3228836) LEADS TO HEPATITIS B SURFACE ANTIGEN (HBsAg) REDUCTION AND CYTOKINE/ CHEMOKINE RESPONSES LINKED TO INNATE AND ADAPTIVE IMMUNITY IN A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (11/23/21)
     
  359. AASLD: Amino Acid Substitutions in the Inhibitor Binding Pocket of HBV Core Protein Confer Differential Changes in Susceptibility to Three Generations of HBV Core Inhibitors (11/23/21)
     
  360. AASLD: Analysis of the longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open-label extension study (11/23/21)
     
  361. AASLD: Persistently detectable serum HBV DNA and pgRNA is associated with subsequent hepatocellular carcinoma development in chronic hepatitis B patients receiving chronic NRTI treatment (11/23/21)
     
  362. AASLD: GLOBAL TRENDS IN CAUSE-SPECIFIC MORTALITY AND DISABILITY ADJUSTED LIFE YEARS RELATED TO HEPATITIS B VIRUS AND HEPATITIS C VIRUS FROM 2010 TO 2019 (11/22/21)
     
  363. AASLD: Exploring the Patient Voice in Hepatitis B Care, Education, and Cure Research (11/22/21)
     
  364. AASLD: Safety and Efficacy at 4 Years in Post-Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide [vs TDF] for HBV Prophylaxis - (11/20/21)
     
  365. AASLD: Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in Chronic HBV Patients Treated for 2 Years - (11/20/21)
     
  366. AASLD: HDV Hospital Admissions Rare-But Sometimes Severe-in United States - Mark Mascolini (11/20/21)
     
  367. AASLD: MOLECULAR AND CLINICAL EPIDEMIOLOGY OF HEPATITIS D VIRUS INFECTION IN CANADA - (11/19/21)
     
  368. AASLD: Low adherence to guidelines recommendations for hepatitis D testing in HBsAg-positive patients leads to high undiagnosis rates - (11/19/21)
     
  369. AASLD: Hepatitis D-Associated Hospitalizations in the United States: 2010-2018 - (11/19/21)
     
  370. AASLD: Over 90% of Clinicians Ignore EACS Hep D Screening Advice - Mark Mascolini (11/19/21)
     
  371. Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs) - (11/17/21)
     
  372. AASLD: Safety and Efficacy of 2 mg Bulevirtide in Patients with Chronic HBV/HDV Co-Infection: First Real-World Results - (11/17/21)
     
  373. AASLD: Prevalence and Characteristics of Hepatitis Delta in the United States: an Analysis of All-Payer Claims Databases - (11/17/21)
     
  374. AASLD: ETHNIC VARIATIONS IN CLINICAL PRESENTATION AND TREATMENT ELIGIBILITY FOR HEPATITIS DELTA VIRUS INFECTION AT A US REFERRAL CENTER - (11/17/21)
     
  375. AASLD: TAF and TDF Safe, Effective for Pregnant Mothers With HBV and Infants - Mark Mascolini (11/16/21)
     
  376. AASLD: Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48 weeks of treatment with Bulevirtide in chronic HBV/HDV co-infected patients: Interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301) - (11/16/21)
     
  377. AASLD: Global HBV Cascade of Care - (11/16/21)
     
  378. AASLD: Nucleos(t)ide analogue withdrawal in chronic hepatitis B patients leads to limited sustained remission in the absence of HBsAg loss: results from the RETRACT-B study Sustained HBV Remission in Only 20% 4 Years After Nucs Stop Without HBsAg Loss - Mark Mascolini (11/16/21)
     
  379. AASLD: Higher Baseline Comorbidities and Liver Disease Severity Among Patients With Hepatitis Delta Infection vs Hepatitis B Monoinfection: a National US Claims Database Analysis - (11/15/21)
     
  380. AASLD: Cost-Effectiveness Analysis of Treating All HBsAg+ Individuals in the United States - (11/15/21)
     
  381. AASLD: Preliminary Results From a Phase 2 Study Evaluating VIR-2218 Alone and in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis B Infection - (11/15/21)
     
  382. AASLD: HBV pgRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued NrtI treatment in patients with HBeAg positive chronic hepatitis B virus infection: findings from a phase 2 open-label study - (11/15/21)
     
  383. AASLD: Severe Hepatitis Flare and Subsequent Mortality after Discontinuation of Oral Antiviral Treatment in Patients with Chronic Hepatitis B: a Population-based Study - (11/15/21)
     
  384. AASLD: Hospital Rate Falls More Than 12% With COVID Vax for Cirrhosis Patients - Mark Mascolini (11/15/21)
     
  385. AASLD: COVID Takes Big Bite Out of HBV/HCV Care in 37-Center Global Study - Mark Mascolini (11/15/21)
     
  386. AASLD: One in 5 With Cirrhosis Suffers Anxiety-1 in 12 Also Has Depression - Mark Mascolini (11/15/21)
     
  387. AASLD: Nucleos(t)ide analogue withdrawal in chronic hepatitis B patients leads to limited sustained remission in the absence of HBsAg loss: Results from the RETRACT-B study Response after End of Treatment with Antivirals in Chronic Hepatitis B (RETRACT-B Study) - (11/13/21)
     
  388. AASLD: Severe Hepatitis Flare in Over 6% Stopping HBV Therapy in Taiwan - Mark Mascolini (11/13/21)
     
  389. AASLD: Safety and Efficacy of 2 mg Bulevirtide in Patients with Chronic HBV/HDV Co-Infection: First Real-World Results French Early Access Program - (11/13/21)
     
  390. AASLD: TREATMENT WITH BULEVIRTIDE IMPROVES PATIENT REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS DELTA (CHD): AN INTERIM EXPLORATORY ANALYSIS AT WEEK 24 - (11/13/21)
     
  391. AASLD: HBV and HCV are Each Associated with Adverse Pregnancy Complications: a 7-year Nationwide Inpatient Sample Study - (11/13/21)
     
  392. AASLD: HDV seropositivity was common amongst HBsAg+ women enrolled in WIHS. 26 (22%) of the 117 HBsAg+ women were HDV seropositive - (11/12/21)
     
  393. Safety and effectiveness of up to 3 years- bulevirtide monotherapy in patients with HDV-related cirrhosis - (10/25/21)
     
  394. Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs) - (10/25/21)
     
  395. Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection - (10/20/21)
     
  396. Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection - (10/20/21)
     
  397. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice - (09/10/21)
     
  398. An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States - (09/08/21)
     
  399. IAS: Epidemiological trends of hepatitis B morbidity and mortality in Greece, Italy, Portugal and Spain, 2000-2019: a systematic analysis from the Global Burden of Disease Study 2019 - (08/25/21)
     
  400. EASL: The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry - (07/12/21)
     
  401. EASL: Free-immunoglobulin alternative strategy to prevent HBV mother-to-child transmission in Cambodia: the ANRS 12345 TA-PROHM study - (07/10/21)
     
  402. EASL: Current or Past HBV Not Tied to Death With COVID in Hong Kong - Mark Mascolini (07/10/21)
     
  403. EASL: Safety and Efficacy of Bulevirtide Monotherapy and in Combination with Peginterferon Alfa-2a in Patients with Chronic Hepatitis Delta: 24 Weeks Interim Data of MYR204 Phase 2b Study - (07/03/21)
     
  404. EASL: Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results HBV Functional Cure Candidate, an siRNA, Passes Phase 2 Test of Activity - (06/29/21)
     
  405. EASL: Phase 1 Results for ATI-2173, a Novel Active Site Polymerase Inhibitor Nucleotide (ASPIN), in HBV-Infected Subjects - (06/28/21)
     
  406. EASL: Treatment with GSK3228836 leads to HBsAg reduction and induction of interferon gamma related proteins and chemokines in a Phase 2a, randomized, double-blind, placebo-controlled study - (06/28/21)
     
  407. EASL: Single Dose of Monoclonal Antibody Quickly Cuts HBsAg in Phase 1 Trial - Mark Mascolini (06/28/21)
     
  408. EASL: Second-generation hepatitis B virus core inhibitors ABI-H2158 and ABI-H3733 have enhanced potency and target coverage for both antiviral inhibition and covalently closed circular DNA establishment activities - (06/28/21)
     
  409. EASL: Preclinical antiviral profile of AB-836, a potent, highly selective hepatitis B virus capsid inhibitor - (06/28/21)
     
  410. EASL: Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression - (06/27/21)
     
  411. EASL: Short interfering RNA JNJ-3989 combination therapy - Mark Mascolini (06/27/21)
     
  412. EASL: IMPROVING THE ACCURACY OF NON-INVASIVE TESTS FOR PREDICTION OF CIRRHOSIS IN CHRONIC HEPATITIS DELTA: INSIGHTS FROM 230 PATIENTS OF THE D-LIVR STUDY - (06/27/21)
     
  413. EASL: Safety and Efficacy of Bulevirtide Monotherapy and in Combination with Peginterferon Alfa-2a in Patients with Chronic Hepatitis Delta: 24 Weeks Interim Data of MYR204 Phase 2b Study - Mark Mascolini (06/27/21)
     
  414. EASL: TDF-Based Hep B Immunoglobulin-Free Strategy Stalls HBV MTCT - (06/27/21)
     
  415. EASL: Bulevirtide With or Without PEG-IFN Shows 24-Week Activity Against Hep D - Mark Mascolini (06/27/21)
     
  416. EASL: New WHO Guidance on Viral Hepatitis Elimination - (06/26/21)
     
  417. EASL: Estimating the contribution of viral hepatitis and other etiologies to the burden of cirrhosis: a worldwide systematic review - (06/26/21)
     
  418. EASL: Estimating the contribution of viral hepatitis and other etiologies to the burden of cirrhosis: a worldwide systematic review Together, HBV and HCV Less Prevalent in Cirrhosis Than in HCC Cases Worldwide - Mark Mascolini (06/26/21)
     
  419. EASL: Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in Children with Chronic Hepatitis B: Final Results from a Placebo-Controlled Trial - (06/25/21)
     
  420. EASL: Safety and Efficacy of Oral TLR8 Agonist Selgantolimod in Viremic Adult Patients With Chronic Hepatitis B - (06/25/21)
     
  421. EASL: Bulevirtide Monotherapy at Low and High Doses in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study - (06/24/21)
     
  422. EASL: Switching From Tenofovir Disoproxil Fumarate and/or Other Oral Antivirals to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Hepatic Impairment: Final 2-Year Efficacy and Safety Results From a Phase 2 Open-label Study - (06/24/21)
     
  423. EASL: Switching From Tenofovir Disoproxil Fumarate and/or Other Oral Antivirals to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Moderate or Severe Renal Impairment, or With End-stage Renal Disease on Hemodialysis: Final Week-96 Efficacy and Safety Results From a Phase 2 Open-label Study - (06/24/21)
     
  424. EASL: Tenofovir May Trim COVID-19 Severity in People With Chronic HBV - Mark Mascolini - (06/23/21)
     
  425. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analog therapy - Expert Opinion - (05/04/21)
     
  426. Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B VirusCoinfected Persons in North America - (05/03/21)
     
  427. CROI: Summary from virtual CROI 2021 for HIV and liver disease HIV and the liver: hot topics - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (04/10/21)
     
  428. CROI: FREQUENT HBsAg CLEARANCE DURING TENOFOVIR THERAPY IN HIV/ HBV COINFECTION - (03/25/21)
     
  429. CROI: HEPATITIS B SEROPROTECTION AMONG YOUNG ADULTS LIVING WITH PERINATALLY ACQUIRED HIV - (03/23/21)
     
  430. CROI: Complex Vaccine-Escape Mutation Profiles in 947 People With HBV - Mark Mascolini - (03/11/21)
     
  431. CROI: Tight HBV Control Essential to HCC Prevention in People With HIV - Mark Mascolini (03/09/21)
     
  432. EASL: Very Low Rates of Receiving Antiviral Therapy Among Treatment - Eligible Chronic Hepatitis B Virus Infected Patients - (03/04/21)
     
  433. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study - (04/20/21)
     
  434. AdverseReactComor: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (12/18/20)
     
  435. HBV & HCV & Accelerated Senescence: premature aging - (12/18/20)
     
  436. Hepatitis A, B and C in New York City: 2019 Annual Report - (12/16/20)
     
  437. AASLD: Infant Outcomes in HIV/Hepatitis B Co-Infected Women Initiating ART in the Promoting Maternal and Infant Survival Everywhere Study - (12/10/20)
     
  438. AASLD: Safety And HBV Efficacy Of Antiretroviral Therapy In Women With HIV And HBV In The Promoting Maternal And Infant Survival Everywhere Study (PROMISE) - (12/10/20)
     
  439. AASLD: Impact of Pretreatment Plasma HBV DNA Levels on the Rate of ALT Normalization During Antiviral Therapy With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B - (11/23/20)
     
  440. AASLD: Amino Acid Substitutions in the Inhibitor Binding Pocket of HBV Core Protein Confer Differential Changes in Susceptibility to Three Generations of HBV Core Inhibitors - (11/23/20)
     
  441. AASLD: Persistently detectable serum HBV DNA and pgRNA is associated with subsequent hepatocellular carcinoma development in chronic hepatitis B patients receiving chronic NRTI treatment - (11/23/20)
     
  442. AASLD: Analysis of the longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open-label extension study - (11/23/20)
     
  443. AASLD: HBV RNAi INHIBITOR RG6346 IN PHASE 1b-2a TRIAL WAS SAFE, WELL-TOLERATED, AND RESULTED IN SUBSTANTIAL AND DURABLE REDUCTIONS IN SERUM HBsAg LEVELS - (11/23/20)
     
  444. AASLD: Short-term therapy with GSK3228836 in chronic hepatitis B (CHB) patients results in reductions in HBcrAg and HBV RNA: Phase 2a, randomized, double-blind, placebo-controlled study - (11/23/20)
     
  445. AASLD: Changes in Viral Antigens are More Strongly Associated with HBV pgRNA than HBV DNA in Studies of Vebicorvir and NrtI in Treatment-naïve Patients with Chronic HBV Infection - (11/23/20)
     
  446. AASLD: FUNCTIONAL CURE OF CHRONIC HEPATITIS B IS ASSOCIATED WITH CO-OCCURRENCE OF HBsAg/anti-HBsIMMUNE COMPLEXES WITH ALT FLARES, AND SEROCONVERSION TO NEUTRALISING anti-HBs - (11/23/20)
     
  447. AASLD: Impact of HBV on Patients - A Qualitative Literature Review to Build a Patient-Focused Outcome Measurement Strategy for Chronic Hepatitis B - (11/23/20)
     
  448. AASLD: Timing of Administration of Anti-PD-1 is Important to Increase HBV-specific Immune Responses in AAV-HBV Mice - (11/23/20)
     
  449. AASLD: Impact of Coadministration With or Without Food on the 96-Week Efficacy and Safety of TAF in Virally Suppressed Chronic HBV Patients Switched From Tenofovir Disoproxil Fumarate to TAF - (11/20/20)
     
  450. AASLD: Risk of HCC in Patients With HBV Infection With and Without HIV Coinfection: a US Administrative Claims Analysis - (11/20/20)
     
  451. AASLD: MACHINE LEARNING BASED QUANTIFICATION OF HISTOLOGY FEATURES FROM PATIENTS TREATED FOR CHRONIC HEPATITIS B IDENTIFIES FEATURES ASSOCIATED WITH VIRAL DNA SUPPRESSION AND HBEAG LOSS - (11/20/20)
     
  452. AASLD: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/ PD) MODELS OF JNJ-64794964, A TOLL-LIKE RECEPTOR (TLR)-7 AGONIST, IN HEALTHY ADULT SUBJECTS - (11/20/20)
     
  453. AASLD: Viral Sequence Analysis of Chronic Hepatitis B (CHB) Patients Treated with the Capsid Assembly Modulator (CAM-N) JNJ-56136379 (JNJ-6379) as Monotherapy in the JADE Phase 2a Study - (11/20/20)
     
  454. AASLD: Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection - (11/20/20)
     
  455. AASLD: Association of aspirin with hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. - Mark Mascolini (11/20/20)
     
  456. AASLD: HBsAg loss is higher among Caucasians compared to Asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study) - Mark Mascolini (11/20/20)
     
  457. AASLD: HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well-tolerated, and resulted in substantial and durable reductions in serum HBsAg levels - (11/20/20)
     
  458. AASLD: The microbiome changes induced by bariatric surgery protects against obesity and nonalcoholic fatty liver disease by decreasing gastric inhibitory protein and increasing hepatic NKT cell expression - Mark Mascolini (11/20/20)
     
  459. AASLD: Longitudinal real world study on estimated glomerular filtration rate (eGFR) changes in entecavir (ETV) versus tenofovir disoproxil fumarate (TDF)-treated chronic hepatitis B patients: a Real-B Study. - Mark Mascolini (11/18/20)
     
  460. AASLD: Safety and Efficacy of 24 Weeks of Treatment With Oral TLR8 Agonist Selgantolimod in Viremic Adult Patients With Chronic Hepatitis B: a Phase 2 Study - (11/18/20)
     
  461. AASLD: Tenofovir Disoproxil Fumarate Treatment Reduces the Number of Transcriptionally Active Viral Integrations in Chronically Infected HBV patients - (11/18/20)
     
  462. AASLD: Safety and Efficacy of 24 Weeks of Treatment With Oral TLR8 Agonist Selgantolimod in Viremic Adult Patients With Chronic Hepatitis B: a Phase 2 Study - (11/18/20)
     
  463. AASLD: COUNTRY AND WHO REGIONAL TRENDS FOR HEPATITIS B VIRUS (HBV) MORTALITY, 1990-2019: AN ANALYSIS OF THE GLOBAL BURDEN OF DISEASE (GBD) STUDY - (11/18/20)
     
  464. AASLD: Tenofovir alafenamide to prevent perinatal hepatitis B transmission in mothers with high viral load: a multicenter, prospective, observational study. - Mark Mascolini - (11/18/20)
     
  465. AASLD: Real world single center experience on the efficacy of stopping long term nucleos(t)ide analog therapy in patients with chronic hepatitis B. - Mark Mascolini (11/18/20)
     
  466. AASLD: Long term nucleos(t)ide analogue therapy reduced the extent of HBV DNA integration in chronic hepatitis B patients - Mark Mascolini (11/18/20)
     
  467. AASLD: Real World Single Centre Experience on the Efficacy of Stopping Long Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B - (11/18/20)
     
  468. AASLD: Long-term Follow-up of Safety and Efficacy of Sofosbuvir-Based HCV DAAs in Pediatric Patients - (11/18/20)
     
  469. AASLD: Real world single center experience on the efficacy of stopping long term nucleos(t)ide analog therapy in patients with chronic hepatitis B - (11/18/20)
     
  470. AASLD: Tenofovir alafenamide fumarate therapy for the prevention of hepatitis B vertical transmission in highly viremic mothers with chronic hepatitis B - Mark Mascolini (11/18/20)
     
  471. AASLD: Statins Tied to Lower HCC Risk in HBV Group Without Cirrhosis - Mark Mascolini (11/17/20)
     
  472. EASL: EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects - (09/28/20)
     
  473. EASL: Development of a Highly Sensitive Multiplex Platform Assay to Monitor Low Levels of HBV DNA and pgRNA - (09/28/20)
     
  474. EASL: Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive chronic hepatitis B infection in a long-term extension study - (09/28/20)
     
  475. EASL: Antiviral activity, pharmacokinetics, and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in a phase 1b study of patients with HBeAg positive chronic hepatitis B infection - (09/28/20)
     
  476. EASL: Serum and intrahepatic HBV markers and HBV-specific CD8 T cell responses after nucleos(t)ide analog therapy discontinuation in HBeAg-negative chronic hepatitis B patients - (09/23/20)
     
  477. EASL: Novel markers to predict virological and clinical relapse onset following antiviral treatment discontinuation in chronic hepatitis B patients - (09/18/20)
     
  478. EASL: A Once-per-week or Every-two-week Dosing Regimen is More Efficacious for the TLR7 Agonist JNJ-64794964 (JNJ-4964) to Induce an Anti-hepatitis B Virus (HBV) Effect and HBV-specific Immune Responses in AAV-HBV Mice - (09/18/20)
     
  479. EASL: Efficacy and Safety Results of the Phase 2 JNJ-56136379 JADE Study in Patients with Chronic Hepatitis B: Interim Week 24 Data - (09/18/20)
     
  480. EASL: Characterization of Serologic Responses Following ALT Flares in >3000 CHB Patients Pooled from 5 Clinical Trials - (09/18/20)
     
  481. EASL: Analysis of HBsAg levels, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and REP 401 studies - (09/18/20)
     
  482. EASL: Resistance monitoring data from treatment-naïve chronic HBV infected patients treated for 28 days with a new Class A core protein allosteric modulator RO7049389 monotherapy - (09/18/20)
     
  483. EASL: EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Resultsof a Phase 1 Study in Healthy Adult Subjects - (09/18/20)
     
  484. EASL: Better Survival With TDF Than Entecavir After Hepatectomy for HCC: "Tenofovir vs entecavir on post-operative recurrence-free and overall survival of patients with hepatitis B virus-related hepatocellular carcinoma" - Mark Mascolini (09/16/20)
     
  485. EASL: Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Renal Impairment: Week-48 Results From a Phase 2 Open-label Study - (09/16/20)
     
  486. EASL: Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Hepatic Impairment: Week-48 Results From a Phase 2 Open-label Study - (09/16/20)
     
  487. EASL: Safety and Efficacy of Tenofovir Alafenamide in Geriatric Patients With Chronic Hepatitis B: Experience From 4 Ongoing Phase 2 and Phase 3 Clinical Trials - (09/16/20)
     
  488. EASL: Updated Estimate for Prevalence of Chronic Hepatitis B Among Foreign-Born Persons Living in United States by Country of Origin - (09/16/20)
     
  489. EASL: Serum and intrahepatic HBV markers and HBV-specific CD8 T cell responses after nucleos(t)ide analog therapy discontinuation in HBeAg-negative chronic hepatitis B patients - (09/16/20)
     
  490. EASL: Transcriptome Analysis of Paired Liver Biopsies Identifies Correlates of HBsAg Response in Placebo- and TDF-treated CHB Patients - (09/16/20)
     
  491. EASL: Can More People Stops NRTIs for HBV? Hints From a 48-Week Study - Mark Mascolini (09/16/20)
     
  492. EASL: HBV Reactivation Rare in HBV Patients Who Used Immune Checkpoint Inhibitors - Mark Mascolini (09/16/20)
     
  493. EASL: A Phase 3 Study Comparing Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Final Week 96 Efficacy and Safety Results - (09/16/20)
     
  494. EASL: Preliminary safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in chronic hepatitis B patients - (09/16/20)
     
  495. EASL: Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment (08/27/20)
     
  496. EASL: Efficacy and Safety of 24 Weeks Treatment with Oral TLR8 Agonist Selgantolimod (GS-9688, SLGN) in Virally Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2 Study (08/27/20)
     
  497. EASL: Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg negative chronic hepatitis B infection (08/27/20)
     
  498. EASL: Hepatitis B Virus Surface Antigen Inhibition with GSK3228836 (ISIS 505358) in Chronic Hepatitis B Patients on Stable Nucleos(t)ide Analogue Regimen and in Nucleos(t)ide Analogue Naïve Patients: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study (08/27/20)
     
  499. EASL: RO7062931 ANTISENSE OLIGONUCLEOTIDE PHASE 1 STUDY DEMONSTRATES TARGET ENGAGEMENT IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) ON ESTABLISHED NUCLEOS(T)IDE THERAPY (08/27/20)
     
  500. SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections - (08/25/20)
     
  501. Hepatitis B and C Virus Considerations in COVID-19 - (08/25/20)
     
  502. CROI: Hepatitis, HCV, HBV & Fatty Liver at CROI 2020 - (04/29/20)
     
  503. VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial - press release - (04/20/20)
     
  504. Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection - (04/20/20)
     
  505. CROI: HBV New Agents (04/02/20)
     
  506. CROI: Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection (04/02/20)
     
  507. HBV Cure Therapies Research - (01/23/20)
     
  508. Global Efforts on HCV Elimination John Ward MD at African HCV Conference - (12/16/19)
     
  509. AASLD: Impact of Prior Tenofovir Disoproxil Fumarate Treatment Duration on Tenofovir Alafenamide Safety Profile in Virally Suppressed, Chronic HBV Patients Switched From TDF to TAF - (12/13/19)
     
  510. AASLD: Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients With Chronic Hepatitis B: a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study - (12/12/19)
     
  511. AASLD: Safety and Efficacy at 48 Weeks After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients With Risk Factors for TDF Use - (12/09/19)
     
  512. AASLD: Impact of Prior Tenofovir Disoproxil Fumarate Treatment Duration on Tenofovir Alafenamide Safety Profile in Virally Suppressed, Chronic HBV Patients Switched From TDF to TAF - (12/09/19)
     
  513. AASLD: Pilot Study of Add-on Peginterferon to Ongoing Nucleos(t)ide Analogues Therapy To Induce HBsAg Loss and To Investigate Mechanism of Action of Peginterferon - (12/03/19)
     
  514. AASLD: The Second-Generation Hepatitis B Virus (HBV) Core Inhibitor (CI) ABI-H2158 is Associated with Potent Antiviral Activity in a 14-Day Monotherapy Study in HBeAg-positive Patients with Chronic Hepatitis B (CHB) - (12/02/19)
     
  515. AASLD: Continued Therapy with ABI-H0731 + NrtI Results in Sequential Reduction/Loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg-Positive Patients - (12/02/19)
     
  516. AASLD: A novel liver-directed locked nucleic acid targeting PD-L1 expression reverts HBV-specific immune tolerance and induces sustained clearance of HBV infection - (12/02/19)
     
  517. AASLD: LIVER-TARGETED INHIBITION OF PAPD5 AND PAPD7 LEADS TO SUSTAINABLE HBsAg REDUCTION IN THE AAV-HBV MOUSE MODEL - (12/02/19)
     
  518. AASLD: Combination treatment of liver-targeted HBV locked nucleic acid antisense oligonucleotide and TLR7 agonist RO7020531 leads to a prolonged off-treatment anti-viral effect in the AAV-HBV mouse model - (12/02/19)
     
  519. AASLD: Safety, pharmacokinetic, pharmacodynamics and viral data after 6-weeks of dosing with TLR7 agonist RO7020531 in chronic hepatitis B patients - (12/02/19)
     
  520. AASLD: INTERIM RESULTS OF A PHASE 1 STUDY OF RO7062931: A NOVEL LIVER-TARGETED SINGLE-STRANDED OLIGONUCLEOTIDE (SSO) WITH LOCKED NUCLEIC ACID (LNA) THAT TARGETS HBV TRANSCRIPTS - (12/02/19)
     
  521. AASLD: Phase 2a, Randomized, Double-blind, Placebo-controlled Study of an Antisense Inhibitor (ISIS 505358) in Treatment-naïve Chronic Hepatitis B (CHB) Patients: Safety and Antiviral Efficacy - (11/19/19)
     
  522. AASLD: Results after 12 weeks treatment of multiple doses of GSK3389404 in chronic hepatitis B subjects on stable nucleos(t)ide therapy in a phase 2a double-blind, placebo-controlled study - (11/19/19)
     
  523. AASLD: Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B - (11/19/19)
     
  524. AASLD: First Clinical Experience with RNA Interference-based Triple Combination Therapy in Chronic Hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos(t)ide Analogue - (11/19/19)
     
  525. AASLD: JNJ-64530440 (JNJ-0440), A Novel, Class N Capsid Assembly Modulator (CAM-N): Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Ascending Doses in Patients with Chronic Hepatitis B - (11/19/19)
     
  526. Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other? - (09/09/19)
     
  527. Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection - (09/05/19)
     
  528. A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection (REEF-1) - (09/05/19)
     
  529. IAS: High STI Prevalence in German MSM, But Low Rates of HIV, HCV, HBV - Mark Mascolini - (07/25/19)
     
  530. EASL: Antigen suppression effect of the core protein allosteric modulator RO7049389 in AAV-HBV mice is accompanied by transient upregulation of immune-cell gene signatures in the liver - (06/12/19)
     
  531. EASL: A first-in-class orally available HBV cccDNAdestabilizer ccc_R08 achieved sustainable HBsAg and cccDNA reduction in the HBVcircle mouse model - (06/12/19)
     
  532. EASL: RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients - (06/12/19)
     
  533. EASL: In vitro and in vivo antiviral characterization of RO7049389, a novel small molecule capsid assembly modulator, for the treatment of chronic hepatitis B - (06/05/19)
     
  534. EASL: RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients - (06/05/19)
     
  535. EASL: EDP-514, a Novel HBV Core Inhibitor with Potent Antiviral Activity both In Vitro and In Vivo - (06/05/19)
     
  536. AASLD: Limited sustained response and lack of HBsAg decline after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results of the prospective, randomized, open-label phase IV STOP study - (05/28/19)
     
  537. 20th Intnl Wrkshp Clin Pharm: Tenofovir plasma concentrations in pregnant women: comparison of hepatitis B and HIV-infected patients (05/24/19)
     
  538. EASL: CANCER RISK AMONG PEOPLE WITH HIV, HBV AND/OR HCV INFECTIONS - (05/16/19)
     
  539. EASL: CANCER RISK AMONG PEOPLE WITH HIV, HBV AND/OR HCV INFECTIONS - (05/16/19)
     
  540. EASL: Incidence and predictors of flares after discontinuing nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results from the randomized controlled STOP Study - (05/13/19)
     
  541. EASL: Is it possible to successfully link migrants to HBV, HCV and HIV services upon arrival in the European Union? - (05/13/19)
     
  542. EASL: A Novel Approach to Funding HCV and HBV Treatment for all -Uzbekistan Pilot Project - (05/08/19)
     
  543. EASL: Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H2158, a Novel Second-Generation HBV Core Inhibitor, In Healthy Volunteers - (04/29/19)
     
  544. EASL: Rapid Turnover of HBV cccDNA in Chronic Hepatitis B Patients During Drug Resistance Emergence and Breakthrough - (04/29/19)
     
  545. EASL: Safety, Antiviral Activity, and Pharmacokinetics of a Novel Hepatitis B Virus Capsid Assembly Modulator, JNJ-56136379, in Asian and Caucasian Patients with Chronic Hepatitis B - (04/29/19)
     
  546. EASL: A Phase 1, Double-Blind, Randomised, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral JNJ-64794964, a Toll-like Receptor-7 Agonist, in Healthy Adults - (04/29/19)
     
  547. EASL: JNJ-64530440, a Novel Capsid Assembly Modulator: Single- and Multiple-Ascending Dose Safety, Tolerability and Pharmacokinetics in Healthy Volunteers - (04/29/19)
     
  548. EASL: Sequence Analysis of Baseline and On-treatment Samples from HBV-infected Chronic Hepatitis B Patients Treated for 28 Days with JNJ-56136379 Monotherapy - (04/29/19)
     
  549. EASL: HBcrAg Decline in JNJ-56136379-treated Chronic Hepatitis B Patients: Results of a Phase 1 Study - (04/29/19)
     
  550. EASL: Evaluation of HBV Outcomes After Treatment Discontinuation From 4 Phase 3 Studies - (04/23/19)
     
  551. EASL: A Phase 3 Study Comparing Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Week 48 Efficacy and Safety Results - (04/23/19)
     
  552. EASL: Effect of treatment of hepatitis B patients with tenofovir disoproxilor entecaviron risk of hepatocellular cancer and death in a U.S. cohort - (04/19/19)
     
  553. EASL: Preclinical Profile of HBV Core Protein Inhibitor, ABI-H3733, a Potent Inhibitor of cccDNA Generation in HBV Infected Cells - (04/19/19)
     
  554. EASL: Antiviral activity of JNJ-4964 (AL-034/TQ-A3334),a selective Toll-Like Receptor 7 agonist, after oral administration for 12 weeks in AAV/HBV mice - (04/19/19)
     
  555. EASL: Short term RNA interference (RNAi) therapy in chronic hepatitis B (CHB) using JNJ-3989 brings majority of patients to HBsAg <100 IU/ml threshold - (04/19/19)
     
  556. EASL: Interim Safety and Efficacy Results of the ABI-H0731 Phase 2a Program Exploring the Combination of ABI-H0731 with Nuc Therapy in Treatment-Naive and Treatment-Suppressed Chronic Hepatitis B Patients - (04/19/19)
     
  557. EASL: Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B - (04/19/19)
     
  558. CROI: Hepatitis at CROI 2019: HCV, NASH, HBV; HIV+ MSM Reinfection in NYC; New HCV Cases Sharp Drop in London - (03/27/19)
     
  559. CROI: Can HBV Be Cured? - "Single hepatocyte analysis in HIV-HBV co-infection shows transcriptional silencing" - (03/22/19)
     
  560. CROI: High maternal HBV with HIV tied to low infant weight and HIV transmission - Mark Mascolini (03/22/19)
     
  561. The push is on to cure hepatitis B, a long-overlooked scourge of millions / Emerging Therapies Toward a Functional Cure for Hepatitis B Virus Infection - (02/25/19)
     
  562. AASLD: Establishment of High Rates of Functional Control and Reversal of Fibrosis Following Treatment of HBeAg Negative Chronic HBV Infection with REP 2139-Mg / REP 2165-Mg, Tenofovir Disoproxil Fumarate and Pegylated Interferon Alpha-2a - (02/25/19)
     
  563. AASLD: Safety, Pharmacokinetics and Antiviral Activity of Novel HBV Capsid Assembly Modulator, JNJ-56136379, in Patients with Chronic Hepatitis B - (02/13/19)
     
  564. AASLD: FINAL RESULTS OF A PHASE 1B 28-DAY STUDY OF ABI-H0731, A NOVEL CORE INHIBITOR, IN NON-CIRRHOTIC VIREMIC SUBJECTS WITH CHRONIC HBV - (02/13/19)
     
  565. AASLD: First results with RNA interference (RNAi) in chronic hepatitis B (CHB) using ARO-HBV - (02/13/19)
     
  566. AASLD: TLR7 agonist RO7020531 triggers immune activation after multiple doses in chronic hepatitis B patients - (02/13/19)
     
  567. AASLD: Limited sustained response and lack of HBsAg decline after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results of the prospective, randomized, open-label phase IV STOP study - (02/13/19)
     
  568. AASLD: Interim results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-IFNαin patientswithchronicHBV/HDV co-infection - (02/13/19)
     
  569. AASLD: PREDICTABILITY OF SERUM HBcrAg, HBsAg AND INTERFERON INDUCIBLE PROTEIN 10 (IP10) LEVELS IN NON-CIRRHOTIC HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS WHO DISCONTINUE ENTECAVIR (ETV) OR TENOFOVIR (TDF) THERAPY: RESULTS FROM THE PROSPECTIVE DARING-B STUDY - (01/02/19)
     
  570. AASLD: KINETICS OF SERUM HEPATITIS B CORE RELATED ANTIGEN (HBcrAg) IN NON-CIRRHOTIC HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe-) PATIENTS WHO DISCONTINUE EFFECTIVE LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) - (01/02/19)
     
  571. AASLD: Safety, Pharmacokinetics, and Pharmacodynamics of Oral TLR8 Agonist GS-9688 in Patients With Chronic Hepatitis B: a Randomized, Placebo-Controlled, Double-blind Phase 1b Study - (12/31/18)
     
  572. AASLD: No Resistance to Tenofovir Alafenamide Detected Through 144 Weeks of Treatment in Patients With Chronic Hepatitis B - (12/31/18)
     
  573. AASLD: 3-Year Efficacy and Safety of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in HBeAg-Negative and -Positive Patients With Chronic Hepatitis B - (12/31/18)
     
  574. AASLD: Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year After Switching to Tenofovir Alafenamide From Tenofovir Disoproxil Fumarate - (12/31/18)
     
  575. AASLD: Prediction and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients of the PAGE-B cohort - (12/17/18)
     
  576. AASLD: Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV) - (12/17/18)
     
  577. AASLD: In Vitro Antiviral Activity and Mode of Action of JNJ-64530440, a Novel Potent Hepatitis B Virus Capsid Assembly Modulator in Clinical Development - (12/17/18)
     
  578. AASLD: ALT levels and risk of hepatocellular carcinoma in Caucasian chronic hepatitis B (CHB) patients under long-term therapy with entecavir or tenofovir disoproxil fumarate - (12/17/18)
     
  579. AASLD: Early adoption of tenofovir alafenamide (TAF) for Hepatitis B in US clinical practice; real-world evidence from the TRIO network - (12/11/18)
     
  580. AASLD: Treatment of hepatitis B in the US; real-world evidence from the TRIO network - (12/11/18)
     
  581. Nucleic acid polymers: much-needed hope for hepatitis D? - Comment - (05/21/18)
     
  582. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial - (05/21/18)
     
  583. EASL: Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a - (05/21/18)
     
  584. EASL: Establishment of persistent functional remission of HBV and HDV infection following REP 2139-Ca and pegylated interferon alpha-2a therapy in patients with chronic HBV / HDV co-infection: 1.5 -2 year follow-up results from the REP 301-LTF study - (05/21/18)
     
  585. EASL: Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a - (05/18/18)
     
  586. EASL: Evaluation of Renal and Bone Safety in Post-Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis - (05/08/18)
     
  587. EASL: Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial - (05/01/18)
     
  588. EASL: Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of MyrcludexB in combination with Tenofovirin patients with HBV/HDV coinfection - (05/01/18)
     
  589. EASL: Rates and predictors of HBsAg loss after discontinuation of effective long-term entecavir or tenofovir therapy in non-cirrhotic HBeAg-negative chronic hepatitis B patients: Results from the prospective DARING-B Greek study. - (04/30/18)
     
  590. EASL: RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAgpositive and negative patients with chronic HBV - (04/30/18)
     
  591. EASL: Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection - (04/30/18)
     
  592. EASL: Effects of Inarigivir (SB9200) Therapy on Immune Responses in Patients with Chronic Hepatitis B (CHB) - (04/30/18)
     
  593. EASL: Preclinical antiviral drug combination studies utilizing novel orally bioavailable agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, an HBV RNA destabilizer - (04/30/18)
     
  594. EASL: Durable inhibition of hepatitis B virusreplication and antigenemia using subcutaneously administered siRNA agentAB-729 in preclinical models - (04/30/18)
     
  595. EASL: Safety And Efficacy At 1 Year After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide In Chronic HBV Patients With Risk Factors For TDF Use - (04/23/18)
     
  596. EASL: Novel and Potent HBV Capsid Modulator Reduces HBeAg and cccDNA in Core-site Directed T109I Mutant in HepNTCP Cells - (04/20/18)
     
  597. EASL: DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic HBV Infection, with Improvement During Treatment - (04/20/18)
     
  598. EASL: Interim Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM), in Healthy Volunteers and Non-Cirrhotic Viremic Subjects with Chronic Hepatitis B - (04/18/18)
     
  599. EASL: RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated - (04/18/18)
     
  600. EASL: Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAgloss in an AAV-HBV mouse model - (04/18/18)
     
  601. EASL: Safety, Pharmacokinetics and Antiviral Activity of Novel HBV Capsid Assembly Modulator, JNJ-56136379, in Non-cirrhotic, Treatment-naïve Patients with Chronic Hepatitis B - (04/18/18)
     
  602. APASL: Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Japanese Adult Healthy Volunteers - (03/22/18)
     
  603. APASL: Safety, Pharmacokinetics and Antiviral Activity of Novel HBV Capsid Assembly Modulator, JNJ-56136379, in Non-cirrhotic, Treatment-nave Patients with Chronic Hepatitis B - (03/21/18)
     
  604. Functional remission of HBeAg negative chronic HBV infection after withdrawal of combined therapy with REP 2139 or REP 2165, TDF and peg-IFN - (03/21/18)
     
  605. CROI: Prevalence of Active Hepatitis B Among New York City MSM Initiating PrEP and PEP, 2016-2017 - (03/16/18)
     
  606. CROI: High HBV and HIV Suppression With Treatment of HIV/HBV Coinfection in B/F/TAF Studies (03/10/18)
     
  607. HEP DART presentations 3 -7 Dec 2017 - (12/12/17)
     
  608. HBV - How Capsid Works - Allosteric conformational changes of human HBV core protein transform its assembly - (12/05/17)
     
  609. AASLD: Mean Week 24 HBsAg Declines Predict Subsequent Rate of HBsAg Seroclearance and Could Be a Valuable Endpoint for Early Development HBV Trials - (12/05/17)
     
  610. AASLD: The HBV capsid assembly modulator JNJ-379 is a potent inhibitor of viral replication across full length genotype A-H clinical isolates in vitro - (12/05/17)
     
  611. AASLD: AL-034 (or TQ-A3334), a Selective Toll-like Receptor 7 Agonist for Oral Treatment of Chronic Hepatitis B Virus Infection - (12/05/17)
     
  612. AASLD: HBcrAg, HBV-RNA Declines in A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in HBeAg-Positive and Negative Virally SuppressedPatientsWith Hepatitis B - (12/02/17)
     
  613. AASLD: Prospective, Randomized Assessment of HBV-associated and Other Clinical Outcome Events During Long-Term Therapy With Entecavir or Other HBV Nucleos(t)ide Analogues in Patients With Chronic HBV Infection - (12/02/17)
     
  614. HBV Therapies in Development - (11/15/17)
     
  615. Arbutus Presents HBV Data at 2017 AASLD Liver Meeting - (11/15/17)
     
  616. New HBV Drugs Chart - (11/15/17)
     
  617. AASLD: Immunological assessment of HBeAg-negative Chronic Hepatitis B patient responses following anti-PD-1 treatment - (11/10/17)
     
  618. AASLD: Bi-weekly Dosing of ARB-1467 LNP siRNA in HBeAgNegative, Virally Suppressed Patients with Chronic HBV Infection Leads to Deeper Declines in HBsAg and Potential Association with IL28b - (11/10/17)
     
  619. AASLD: Pharmacokinetics and exploratory exposure-response of siRNAs administered monthly as ARB-001467 (ARB-1467) in a Phase 2a study in HBeAg positive and negative virally suppressed subjects with chronic hepatitis B - (11/10/17)
     
  620. AASLD: In Vivo Study of a LNP siRNA Investigational Agent Applied Sequentially with Immunomodulatory Treatments for Chronic Hepatitis B Infection - (11/10/17)
     
  621. AASLD: Antiviral Characterization of a Next Generation Chemical Series ofHBV Capsid Inhibitors In Vitro and In Vivo - (11/10/17)
     
  622. AASLD: Identification and Characterization of AB-452, a Potent Small Molecule HBV RNA Destabilizer In Vitro and In Vivo - (11/10/17)
     
  623. AASLD: Single Dose Safety, Tolerability and Pharmacokinetics of AB-423 in Healthy Volunteers from the ongoing Single and Multiple Ascending Dose Study AB-423-001 - (11/10/17)
     
  624. AASLD: Phase 1b Clinical trial of TG1050, a novel HBV-targeted immunotherapy, in NUC suppressed chronic hepatitis B patients: safety and early immunological data following single administration - (11/10/17)
     
  625. AASLD: Novel anti-viral activity of SB 9200, a RIGI agonist; results from Cohort 1 of the ACHIEVE trial - (11/08/17)
     
  626. AASLD: Bi-weekly Dosing of ARB-1467 LNP siRNA in HBeAgNegative, Virally Suppressed Patients with Chronic HBV Infection Leads to Deeper Declines in HBsAg and Potential Association with IL28b - (11/08/17)
     
  627. AASLD: Rapid Turnover of cccDNA in Chronic Hepatitis B Patients Who Have Failed Nucleoside Treatment Due to Emerging Resistance - (11/08/17)
     
  628. AASLD: Preclinical Profile of Potent Second Generation CpAMs Capable of Inhibiting the Generation of HBsAg, HBeAg, pgRNA and cccDNA in HBV Infected Cells - (11/08/17)
     
  629. AASLD: Functional Activation of NK and CD8+ T Cells In Vitro by the Toll-Like Receptor 8 Agonist GS-9688 - (11/08/17)
     
  630. AASLD: Cytokines Induced by GS-9688, a Toll-Like Receptor 8 Agonist, Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (11/08/17)
     
  631. AASLD: Evaluation of Factors Associated With Differences in ALT Normalization Between Virally Suppressed TAF- and TDF-Treated CHB Patients - (11/08/17)
     
  632. AASLD: Effect of TenofovirDisoproxyl(TDF) on Hepatocellular Carcinoma (HCC) Incidence in Patients with Chronic Hepatitis B (CHB) Compared to Untreated Patients:A Multicenter Study with Propensity Score Matching (PSM) - (11/08/17)
     
  633. AASLD: Safety and Efficacy of Vesatolimod (GS-9620) in Patients With Chronic Hepatitis B Who Are Not Currently on Antiviral Treatment - (11/08/17)
     
  634. AASLD: Improved Bone and Renal Safety at 1 Year After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide: Results From 2 Phase 3 Studies in HBeAg-Positive and HBeAg-Negative Patients With Chronic Hepatitis B - (11/08/17)
     
  635. AASLD: Phase 1a Safety and Pharmacokinetics (PK) of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM) - (11/08/17)
     
  636. AASLD: Efficacy and Safety of Tenofovir Alafenamide at 96 Weeks in Chronic HBV Patients With Risk Factors for Use of Tenofovir Disoproxil Fumarate - (11/01/17)
     
  637. AASLD: Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Non-cirrhotic, Treatment-naïve Patients with Chronic Hepatitis B. - (11/01/17)
     
  638. AASLD: No Resistance to Tenofovir Alafenamide Detected Through 96 Weeks of Treatment in Patients with Chronic Hepatitis B - (10/26/17)
     
  639. HBV-New Approach May be Needed: Cure Not Likely - (10/16/17)
     
  640. Hepatitis B cure: From discovery to regulatory approval - Review - (09/05/17)
     
  641. Low-level viremia in hepatitis b patients on antiviral treatment: Can we ignore it? - Editorial - (09/05/17)
     
  642. DAA / HBV Reactivation - Making Do With What We Have - Editorial - (06/07/17)
     
  643. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System - (05/30/17)
     
  644. EASL: In Vitro and In Vivo Characterization of the Selective Toll-Like Receptor 8 Agonist GS-9688 - (05/18/17)
     
  645. EASL: Sustained Efficacy and Seroconversion With the Selective Toll-Like Receptor 8 Agonist GS-9688 in the Woodchuck Model of Chronic Hepatitis B - (05/18/17)
     
  646. EASL: In Vivo Pharmacodynamics of GS-5801, a Liver-Targeted Prodrug of a Lysine Demethylase-5 Inhibitor With Antiviral Activity Against Hepatitis B Virus - (05/18/17)
     
  647. EASL: Antiviral Activity of GS-5801, a Liver-Targeted Prodrug of a Lysine Demethylase-5 Inhibitor, in a Hepatitis B Virus Primary Human Hepatocyte Infection Model - (05/18/17)
     
  648. A Phase 3 Study Comparing Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate in Patients With HBeAg-Positive, Chronic Hepatitis B: Efficacy and Safety Results at Week 96 - (05/16/17)
     
  649. EASL: A Phase 3 Study Comparing Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate in Patients With HBeAg-Positive, Chronic Hepatitis B: Efficacy and Safety Results at Week 96 - (05/15/17)
     
  650. EASL: Rising healthcare utilization and cost of chronic hepatitis B: real-world analysis of 44,026 chronic hepatitis B patients and 121,568 matched non-chronic hepatitis B controls in the United States - (05/09/17)
     
  651. HBV - Arbutus Announces Corporate Update and First Quarter 2017 Financial Results - (05/09/17)
     
  652. EASL: Continued Improvement in Renal Laboratory Parameters in CHB Patients Treated With Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate Over 96 Weeks - (05/05/17)
     
  653. EASL: The cyclophilin inhibitor CRV431 prevents both HBx-cyclophilin complex formation and HBV replication - (05/05/17)
     
  654. EASL: Data Enhances Understanding of ContraVir's Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL™) and CRV431 Presentation Elucidating CRV431 Mode of Action Selected for EASL "Poster Tour" - (05/05/17)
     
  655. EASL: CRV431 and CMX157 (TXL; tenofovir exalidex): Anti-HBV combination effects in vitro between a cyclophilin inhibitor and a nucleotide prodrug - (05/05/17)
     
  656. EASL: Oral Presentation at EASL Highlights ContraVir's Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients - (05/05/17)
     
  657. EASL: Pharmacokinetics, Safety and Tolerability of Tenofovir exalidex (CMX157), a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects - (05/05/17)
     
  658. EASL: Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection - (05/05/17)
     
  659. EASL: No changes in the coding sequence for HBV core protein after 6 weeks of treatment of HBV infected humanized mice with NVR 3-778 - (05/05/17)
     
  660. EASL: A Phase 2a Study Evaluating the Multi-dose Activity of ARB-1467 in HBeAg-Positive and -Negative Virally Suppressed Subjects with Hepatitis B - (05/05/17)
     
  661. EASL: Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients - (04/26/17)
     
  662. EASL: A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer and HBV patient population - (04/26/17)
     
  663. EASL: Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen - (04/26/17)
     
  664. EASL: A Phase 1 Study Evaluating Anti-PD-1 Treatment With or Without GS-4774 in HBeAg Negative Chronic Hepatitis B Patients - (04/26/17)
     
  665. EASL: DARING-B: Discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy in non-cirrhotic HBeAg-negative chronic hepatitis B (CHBe-) patients: a prospective Greek study - (04/26/17)
     
  666. EASL: Improved Bone and Renal Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Preliminary Results From 2 Phase 3 Studies in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B - (04/26/17)
     
  667. EASL: A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-Negative, Chronic Hepatitis B (CHB): Efficacy and Safety Results at Week 96 - (04/26/17)
     
  668. CROI: CROI 2017 HCV/HBV Reports - - (04/05/17)
     
  669. CROI: TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP) - (03/22/17)
     
  670. CROI: INCREASED RATES OF HBV SEROCONVERSION UNDER LONG-TERM HBV ACTIVE THERAPY IN HBV/HIV - [16%] - (03/22/17)
     
  671. APASL: Correlation of Early Biochemical and Virologic Responses During Oral Antiviral Therapy for Chronic Hepatitis B - (03/16/17)
     
  672. APASL: Characterization of Host, Viral, and Treatment-Related Factors Associated With Antiviral Efficacy of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate - (03/16/17)
     
  673. APASL: HBV Genotype Is Associated With Early (Week 12) Virologic Response During Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Therapy in Patients With Chronic Hepatitis B - (03/16/17)
     
  674. APASL: Reduced Changes in Bone Mineral Density in Chronic HBV Patients Receiving Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (03/15/17)
     
  675. APASL: Improved Renal Laboratory Parameters in Chronic HBV (CHB) Patients Treated With Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) - (03/15/17)
     
  676. Hepatitis B Blood Tests - (01/27/17)
     
  677. TAF / HBV / Resistance - (01/25/17)
     
  678. European Commission Grants Marketing Authorization for Gilead's Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection - (01/18/17)
     
  679. HBV Reactivation on DAAs - Occult Hepatitis B and Risk of Reactivation After Hepatitis C Treatment With Direct-Acting Antivirals - (01/09/17)
     
  680. AASLD: Hepatitis B reactivation after interferon-based therapy versus pan-oral direct acting antiviral agents in chronic hepatitis C patients co-infected with hepatitis B virus: a systematic review and meta-analysis - (12/15/16)
     
  681. AASLD: Development of Second Generation RNA Interference Therapy for Hepatitis B Virus Infection - (12/07/16)
     
  682. AASLD: Exploring Combination Therapy for Curing HBV - Preclinical Combo Studies with Capsid Inhibitor AB-423 and siRNA Agent ARB-1740 - (12/07/16)
     
  683. AASLD: The HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additive/synergistic effects in in vitro combination studies - (12/07/16)
     
  684. PRAC (EMA) warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C ........Review of liver cancer risk not conclusive and further studies are needed - (12/07/16)
     
  685. AASLD: Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A review of Spontaneous Post-Marketing Cases - (12/06/16)
     
  686. AASLD: Hepatitis B Reactivation in Patients Receiving Interferon-Free Direct Acting Antiviral Agents for Chronic Hepatitis C Virus Infection - (11/23/16)
     
  687. AASLD: Predictors of HBeAg Loss in HBeAg-Positive Patients With Chronic Hepatitis B During Treatment With TAF or TDF - (11/22/16)
     
  688. AASLD: Correlation of Early Biochemical and Virologic Responses During Oral Antiviral Therapy for Chronic Hepatitis B - (11/22/16)
     
  689. AASLD: Features of the Metabolic Syndrome Are Associated With Lack of Serum ALT Normalization During Therapy for Chronic Hepatitis B - (11/22/16)
     
  690. AASLD: Characterization of Changes in FibroTest Values During Treatment With TAF or TDF in Patients With CHB - (11/22/16)
     
  691. AASLD: Characterization of Host, Viral, and Treatment-Related Factors Associated With Antiviral Efficacy of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate - (11/22/16)
     
  692. AASLD: No Resistance to Tenofovir Alafenamide Detected Through 48 Weeks of Treatment in Patients With Chronic Hepatitis B - (11/22/16)
     
  693. AASLD: HBV Genotype Is Associated With Early (Week 12) Virologic Response During Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Therapy in Patients With Chronic Hepatitis B - (11/22/16)
     
  694. AASLD: LUNAR™-HBV, a UNA Oligomer Combination for the Treatment of Chronic Hepatitis B Virus Infection - (11/22/16)
     
  695. AASLD: Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (11/22/16)
     
  696. AASLD: Improved Renal Laboratory Parameters in CHB Patients Treated With TAF Compared With TDF - (11/22/16)
     
  697. AASLD: HEPATITIS B (HBV) REACTIVATION DURING ANTI-HEPATITIS C (HCV) THERAPY WITH INTERFERON (IFN)-FREE REGIMENS: A PROSPECTIVE STUDY - (11/22/16)
     
  698. AASLD: Comparison of Markers of Bone Turnover Demonstrates Less Changes in CHB Patients Receiving Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (11/22/16)
     
  699. AASLD: Reduced Changes in Bone Mineral Density in Chronic HBV (CHB) Patients Receiving Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) - (11/22/16)
     
  700. AASLD: TLR-7 agonist GS-9620 can improve HBV-specific T cell and NK cell responses in nucleos(t)ide suppressed patients with chronic hepatitis B - (11/22/16)
     
  701. AASLD: Safety, tolerability and pharmacokinetics of JNJ-56136379, a novel HBV capsid assembly modulator, in healthy subjects - (11/22/16)
     
  702. AASLD: Capsid assembly modulator JNJ-56136379 prevents de novo infection of primary human hepatocytes with hepatitis B virus - (11/22/16)
     
  703. FDA Approved TAF [Vemlidy] for HBV - (11/15/16)
     
  704. European CHMP Adopts Positive Opinion for Gilead's Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection - (11/11/16)
     
  705. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus - (09/19/16)
     
  706. "Curing" HBV - New Drugs - (09/19/16)
     
  707. Fueled by heroin crisis, hepatitis B cases rise in Maine - (09/09/16)
     
  708. Curing HBV, New Drugs - [HBV at EASL 2016] - (09/09/16)
     
  709. Sliding Down the Cascade of Care for Chronic Hepatitis B Virus Infection - Infrequent clinical assessment of chronic hepatitis B patients in United States general healthcare settings - (09/09/16)
     
  710. HCV Treatment IS AS Effective For Drug Users / Drug Users Should Have Equal Access to Treatment - (09/09/16)
     
  711. HBV Reactivation/DAAs EMA/Japan Review - (05/11/16)
     
  712. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance - (05/11/16)
     
  713. EASL: CPI-431-32, A Novel Cyclophilin Inhibitor for Treatment of Chronic Hepatitis B: A Story of Clinical Utility - (05/05/16)
     
  714. EASL: Combination Therapy for Curing HBV - Arbutus BioPharma - (05/05/16)
     
  715. EASL: In Vitro and In Vivo Antiviral Activities of AB-423 a Potent Small Molecule Inhibitor of Hepatitis B Virus Capsid Assembly - (05/05/16)
     
  716. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance - (05/03/16)
     
  717. EASL: NVR 3-778, a First-in-class HBV Core Inhibitor, Alone and in Combination with Pegylated-interferon (peg-IFN alpha-2a), in Treatment-naïve HBeAg-positive Patients: Early Reductions in HBV DNA and HBeAg - (04/26/16)
     
  718. EASL: (NVR 3-778) Potential first-in-class treatment is well-tolerated in patients with chronic hepatitis B - EASL press release - (04/26/16)
     
  719. EASL: A Phase 3 Study of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in Patients With HBeAg-Positive, Chronic Hepatitis B: Week 48 Efficacy and Safety Results - (04/26/16)
     
  720. EASL: PRECLINICAL CHARACTERIZATION OF POTENT CORE PROTEIN ASSEMBLY MODULATORS FOR THE TREATMENT OF CHRONIC HEPATITIS B - (04/26/16)
     
  721. EASL: DIFFERENTIAL REDUCTIONS IN VIRAL ANTIGENS EXPRESSED FROM CCCDNA VS INTEGRATED DNA IN TREATMENT NAÏVE HBEAG POSITIVE AND NEGATIVE PATIENTS WITH CHRONIC HBV AFTER RNA INTERFERENCE THERAPY WITH ARC-520 - (04/26/16)
     
  722. EASL: TREATMENT OF CHRONICALLY HBV-INFECTED CHIMPANZEES WITH RNA INTERFERENCE THERAPEUTIC ARC-520 LED TO POTENT REDUCTION OF VIRAL MRNA, DNA AND PROTEINS WITHOUT OBSERVED DRUG RESISTANCE - (04/26/16)
     
  723. EASL: PREDICTING HBSAG CLEARANCE RESPONSES DURING ARC-520 RNA INTERFERENCE (RNAI) THERAPY BASED ON HBSAG EPITOPE PROFILE ANALYSIS - (04/26/16)
     
  724. EASL: Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection - (04/15/16)
     
  725. EASL: A Phase 3 Study of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in Patients With HBeAg-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results - (04/15/16)
     
  726. Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection - (04/12/16)
     
  727. EASL: Arbutus to Present Preclinical HBV Data at EASL 2016 - (04/07/16)
     
  728. EASL: Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL) - (04/07/16)
     
  729. European Medicines Agency Validates Gilead's Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B - (03/16/16)
     
  730. CROI: Tenofovir and the Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Persons - (03/14/16)
     
  731. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B - (03/02/16)
     
  732. European Medicines Agency Validates Gilead's Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B - (03/02/16)
     
  733. APASL: Flares in patients treated with Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) - (02/26/16)
     
  734. APASL: Comparison of Asians vs. Non-Asians treated with TDF Plus Peginterferon (PEG) - (02/26/16)
     
  735. New HBV Drugs / New /HBV-Cyclophillin Inhibitor - (02/11/16)
     
  736. New therapeutic agents for chronic hepatitis B - (02/09/16)
     
  737. CDC: [HBV Epidemic/IDUs] Increases in Acute Hepatitis B Virus Infections - Kentucky, Tennessee, and West Virginia, 2006-2013 - (02/09/16)
     
  738. New therapeutic agents for chronic hepatitis B - (01/27/16)
     
  739. HIV & HBV J&J Announcements - (01/08/16)
     
  740. AASLD: Antiviral Activity of TAF Against Drug-Resistant HBV Isolates in Vitro - (01/07/16)
     
  741. AASLD: Antiviral Activity of TAF Against Drug-Resistant HBV Isolates in Vitro - (01/07/16)
     
  742. Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection - (01/05/16)
     
  743. AASLD: Safety and Efficacy of GS-4774 in Patients With Chronic Hepatitis B on Oral Antiviral Therapy - (12/22/15)
     
  744. AASLD: Safety and Pharmacodynamics of Oral TLR-7 Agonist GS-9620 in Patients With Chronic Hepatitis B - (12/21/15)
     
  745. AASLD: Functional Activation of Natural Killer and CD8+ T Cells by the Toll-Like Receptor 7 Agonist GS-9620 - (12/21/15)
     
  746. AASLD: Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (12/21/15)
     
  747. AASLD: Antiviral Therapy for Chronic Hepatitis B Reduces the Incidence of Hepatocellular Carcinoma Regardless of Cirrhosis Status: Analysis with Adjustment for REACH-B Risk Score - (12/21/15)
     
  748. Antiviral Therapy for Chronic Hepatitis B Reduces the Incidence of Hepatocellular Carcinoma Regardless of Cirrhosis Status: Analysis with Adjustment for REACH-B Risk Score - (12/21/15)
     
  749. New Insights on HBV Biology from the ARC-520 Development Program - (12/21/15)
     
  750. Sustained reduction of HBV DNA, RNA and proteins, and HBeAg seroconversion in a chronically HBV-infected chimpanzee treated with nucleoside analog/ARC-520 combination therapy - (12/21/15)
     
  751. Johnson & Johnson Announces Completion Of Novira Therapeutics, Inc. Acquisition - (12/21/15)
     
  752. AASLD: Tenofovir Disoproxil Fumarate Reduces Perinatal Transmission of Hepatitis B Virus in Highly Viremic Mothers: A Multicenter Randomized Controlled Study - (12/18/15)
     
  753. AASLD: Integrated HBV DNA implicated in maintaining circulating HBsAg levels in chronically infected chimpanzees - (12/02/15)
     
  754. AASLD: Monthly dosing of ARC-520 in chronically hepatitis B virus infected chimpanzees produces rapid, deep and durable reductions in circulating viral antigens - (12/02/15)
     
  755. AASLD: Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA - (12/02/15)
     
  756. AASLD: ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B - (12/02/15)
     
  757. AASLD: Encapsidation and secretion of HBV RNA can be inhibited by Core Inhibitors but not by Nucleoside Analogs [NVR 3-778] - (12/02/15)
     
  758. AASLD: Phase 1b Efficacy and Safety of NVR 3-778, a First-In-Class HBV Core Inhibitor, in HBeAg-Positive Patients with Chronic HBV Infection - (12/02/15)
     
  759. AASLD: Inhibition of Hepatitis B Virus Replication by the HBV Core Inhibitor NVR 3-778 - (12/02/15)
     
  760. Johnson & Johnson Announces Agreement To Acquire Novira Therapeutics, Inc. - (11/05/15)
     
  761. Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection - (11/05/15)
     
  762. ICAAC: Protection Against Flu But Not HBV in Vaccinated Perinatally HIV-Infected Children - (09/21/15)
     
  763. IAS: No Hepatitis Flares When HBsAg+ iPrEx Participants Stop TDF/FTC - Mark Mascolini - (07/29/15)
     
  764. EASL: HCC Risk Scores: Application of the CU-HCC, GAG-HCC, and PAGE-B Scores to Chronic Hepatitis B Patients Treated With Tenofovir Disoproxil Fumarate (TDF) - (05/08/15)
     
  765. EASL: Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in HBeAg-negative, genotype D chronic hepatitis B patients fully suppressed on nucleot(s)ide analogue treatment The HERMES Study - (05/04/15)
     
  766. Inovio Pharmaceuticals and Roche Initiate Clinical Trial for Inovio's DNA Immunotherapy to Treat Chronic Hepatitis B Infection - (04/31/15)
     
  767. EASL: EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE TO PREVENT VERTICAL TRANSMISSION IN MOTHERS WITH LAMIVUDINE-RESISTANT HBV - (04/29/15)
     
  768. EASL: Effect of the combination of the HBV core inhibitor NVR 3-778 with Nucleoside Analogs or other HBV core inhibitors on the inhibition of HBV DNA Replication in HepG2.2.15 cells - (04/29/15)
     
  769. APASL: Long-Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Safe and Well Tolerated and Associated with Durable Virologic Response with No Detectable Resistance: 8 Year Results from Two Phase 3 Trials - (03/27/15)
     
  770. APASL: Characterization of HBsAg Decline in the Tenofovir Disoproxil Fumarate and Peginterferon Alfa-2a Combination Study for Chronic Hepatitis B - (03/27/15)
     
  771. APASL: HBsAg Loss With Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a in Chronic Hepatitis B: Results of a Global Randomized Controlled Trial - (03/27/15)
     
  772. APASL: HBV DNA and Clinical Characteristics of Patients Who Developed HCC While Receiving Tenofovir Disoproxil Fumarate Following 8 Years of Therapy - (03/27/15)
     
  773. APASL: Impact of Tenofovir Disoproxil Fumarate on the Fasting Lipid Profile of Chronic Hepatitis B Patients - (03/27/15)
     
  774. APASL: No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg+ and HBeAg- Patients With Chronic Hepatitis B (CHB) After Eight Years of Treatment - (03/27/15)
     
  775. CROI: Chronic Hepatitis B and C Infection and Risk for Non-Hodgkin Lymphoma in HIV Infected Patients - (03/09/15)
     
  776. Curing HBV, New Drugs - (01/22/15)
     
  777. AASLD: Phase 1a Safety and Pharmacokinetics of NVR 3-778, a Potential First-In-Class HBV Core Inhibitor - (01/16/15)
     
  778. Targeted In Vivo Delivery of siRNA and an Endosome-Releasing Agent to Hepatocytes - (01/13/15)
     
  779. Arrowhead Files IND for RNAi Therapeutic ARC-520 to Begin Phase 2b Multiple-Dose Studies in Chronic Hepatitis B Patients - (01/13/15)
     
  780. AASLD: Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection - (01/13/15)
     
  781. AASLD: HBV at AASLD - (01/13/15)
     
  782. AASLD: Curing HBV....attacking cccDNA "Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease" - (01/12/15)
     
  783. AASLD: Phase 1a Safety and Pharmacokinetics of NVR 3-778, a Potential First-In-Class HBV Core Inhibitor - (01/12/15)
     
  784. AASLD: Novira Therapeutics Announces Presentation of Phase 1a - Safety and Pharmacokinetic Data for NVR 3-778 - (01/12/15)
     
  785. AASLD: The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B is Associated With an Intrahepatic Cytotoxic T Cell Transcriptional Signature - (01/12/15)
     
  786. AASLD: Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (01/12/15)
     
  787. AASLD: Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in Caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF) - (01/09/15)
     
  788. AASLD: HBsAg Loss With Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a in Chronic Hepatitis B: Results of a Global Randomized Controlled Trial - (01/09/15)
     
  789. AASLD: Long-Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Safe and Well Tolerated and Associated with Durable Virologic Response with No Detectable Resistance: 8 Year Results from Two Phase 3 Trials - (01/09/15)
     
  790. AASLD: No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg+ and HBeAg- Patients With Chronic Hepatitis B (CHB) After Eight Years of Treatment - (01/09/15)
     
  791. AASLD: HBsAg Loss With Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a in Chronic Hepatitis B: Results of a Global Randomized Controlled Trial - (01/09/15)
     
  792. AASLD: The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B Is Associated With an Intrahepatic Cytotoxic T Cell Transcriptional Signature - (01/09/15)
     
  793. AASLD: Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (01/09/15)
     
  794. AASLD: The Safety and Efficacy of Entecavir and Tenofovir Combination Therapy for Chronic Hepatitis B in Patients with Previous Nucleos(t)ide Treatment Failure: Week 96 Results of the ENTEBE study - (01/09/15)
     
  795. AASLD: Entecavir reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B - (01/09/15)
     
  796. AASLD: A Baseline Predictive Tool for Selecting HBeAg-Negative Chronic Hepatitis B Patients Who Have a High Probability of Achieving Sustained Immune Control with Peginterferon Alfa-2a - (01/09/15)
     
  797. AASLD: A Predictive Tool for Selecting HBeAg-Positive Chronic Hepatitis B Patients Who Have a High Probability of HBV DNA Suppression and HBeAg Seroconversion with Peginterferon Alfa-2a - (01/09/15)
     
  798. AASLD: HBeAg Levels Predict HBeAg Seroconversion During the Immune Clearance Phase of Chronic Hepatitis B in Patients Receiving Nucleot(s)ide Analogue Therapy - (01/09/15)
     
  799. AASLD: Loss of Immune Tolerance Is Associated With HBV Genotype-Specific Patterns of Accumulation of Basal Core Promoter and Precore Variants, Leading to Decline in HBeAg and HBsAg Levels - (01/09/15)
     
  800. AASLD: Entecavir Safety & Effectiveness in a National Cohort of Chronic Hepatitis B Patients in the USA - the ENUMERATE Study - (01/07/15)
     
  801. AASLD: Tenofovir Montherapy in Chronic Hepatitis B Patients with Genotypic Resistance to Previous Antiviral Therapy - a Cohort Study - (01/07/15)
     
  802. AASLD: Efficacy of Entecavir plus Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multi-Drug Resistant Strains (2) - (01/07/15)
     
  803. AASLD: Efficacy of Entecavir plus Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multi-Drug Resistant Strains - (01/07/15)
     
  804. AASLD: Entecavir plus adefovir or entecavir plus tenofovir for patients with chronic hepatitis B resistant to neucleot(s)ide analogues - (01/07/15)
     
  805. GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees - (01/05/15)
     
  806. Targeting Innate Immunity [GS-9620]: A New Step in the Development of Combination Therapy for Chronic Hepatitis B - (01/05/15)
     
  807. Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection - (01/05/15)
     
  808. Risk stratification for hepatitis B virus related hepatocellular carcinoma - (01/05/15)
     
  809. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B - (01/05/15)
     
  810. HBV Treatment Reduces HCC Risk - (01/05/15)
     
  811. A new priority for the ANRS: "HBV Cure" - (01/05/15)
     
  812. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy - HBV Therapy Reduced HCC Risk by 50%, Patients with Cirrhosis Had Increased Risk: increased the unadjusted risk 22-fold - (07/17/14)
     
  813. IDSA: Hip Fracture Rate Higher With HIV/HBV Than HIV Alone in Medicaid Analysis - Mark Mascolini - (10/25/14)
     
  814. IDSA: Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection - (10/15/14)
     
  815. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial) - (09/29/14)
     
  816. IAC: Efficacy and Safety of Dolutegravir (DTG) in Hepatitis (HBV or HCV) Co-infected Patients: Results From the Phase 3 Program - (07/28/14)
     
  817. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: Virological and clinical implications - (07/16/14)
     
  818. Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B-A Nationwide Cohort Study - (07/16/14)
     
  819. Averting Hepatocellular Carcinoma in Chronic Hepatitis B With Antiviral Therapy: Tipping the Balance or Not Yet? - (07/16/14)
     
  820. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Safety of Tenofovir Alafenamide in Subjects With Mild or Moderate Hepatic Impairment - (05/29/14)
     
  821. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection - (05/15/14)
     
  822. Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA - (05/05/14)
     
  823. EASL: ADDING PEGINTERFERON TO ENTECAVIR INCREASES RESPONSE RATES IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS: WEEK 96 RESULTS OF A GLOBAL MULTICENTER RANDOMISED TRIAL (ARES STUDY) - (05/01/14)
     
  824. EASL: Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study: The NEED study - (05/01/14)
     
  825. EASL: Response-Guided Peginterferon Alfa-2a (PegIFN Alfa-2a) Therapy in Patients with HBeAg-Positive Chronic Hepatitis B (CHB) - (05/01/14)
     
  826. EASL: EFFECTIVENESS OF TENOFOVIR FOR CHRONIC HEPATITIS B IN FIELD PRACTICE - (04/30/14)
     
  827. EASL: Nucleos(t)ide Analogue (NA) Therapy for Persons in the Immunotolerant Phase of CHB Is Associated With Significant Declines in HBeAg and HBsAg Levels - (04/30/14)
     
  828. EASL: THE EFFICACY OF ENTECAVIR IN BOTH NAIVE AND LAMIVUDINE EXPERIENCED WITHOUT RESISTANCE CHRONIC HEPATITIS B PATIENTS - (04/30/14)
     
  829. EASL: ENTECAVIR AND TENOFOVIR HAVE A COMPARABLE EFFICACY IN TREATMENT OF NUCLEOS(T)IDE ANALOGUE NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A REAL LIFE EXPERIENCE - (04/30/14)
     
  830. EASL: RANDOMIZED TRIAL OF TENOFOVIR MONOTHERAPY VERSUS TENOFOVIR PLUS ENTECAVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B PATIENTS WITH GENOTYPIC RESISTANCE MUTATIONS TO ADEFOVIR - (04/30/14)
     
  831. EASL: LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY - (04/30/14)
     
  832. EASL: LONG-TERM EFFICACY OF TENOFOVIR IN PREVIOUSLY TREATED AND NAIVE PATIENTS. RESULTS FROM THE SPANISH CHRONIC HEPATITIS B REGISTRY (CIBERHEP) - (04/30/14)
     
  833. EASL: Determinants of Variability in ISG15 Gene Expression in Patients With Chronic Hepatitis B (CHB) Infection During Treatment With Oral TLR-7 Agonist GS-9620 - (04/28/14)
     
  834. EASL: Peginterferon Lambda for the Treatment of Chronic Hepatitis B (CHB): A Phase 2b Comparison With Peginterferon Alfa in Patients With HBeAg-Positive Disease (LIRA-B) - (04/21/14)
     
  835. EASL: REDUCED INCIDENCE OF HEPATOCELLULAR CARCINOMA IN HIV/HBV-COINFECTED PATIENTS RECEIVING TENOFOVIR - (04/21/14)
     
  836. APASL: Twenty-Eight Day Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B Patients - (03/19/14)
     
  837. Hepatitis B Screening - U.S. Preventive Services Task Force New Draft Recommendation Statement - (02/14/14)
     
  838. Potential Benefit of Telbivudine on Renal Function Does Not Outweigh Its High Rate of Antiviral Drug Resistance and Other Adverse Effects - Editorial - (01/17/13)
     
  839. Management of Hepatitis B: Our Practice and How It Relates to the Guidelines - (01/16/13)
     
  840. hepDART: Efficient Hepatic Delivery of Tenofovir by Prodrug Tenofovir Alafenamide in Nonclinical Studies Supports Low-Dose Treatment of Hepatitis B Virus (12/20/11)
     
  841. AASLD: Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies - (12/04/13)
     
  842. AASLD: Sustained Immune Control in HBeAg-Positive Chronic Hepatitis B Patients Who Switched From Long-Term Entecavir Therapy to Peginterferon Alfa-2a (40KD): 1-Year Follow-Up of the OSST Study - (11/25/13)
     
  843. AASLD: Entecavir Plus Tenofovir Combination Therapy in Patients with Multi-drug Resistant Chronic Hepatitis B - A multicenter, Prospective Study - Early Experience - (11/25/13)
     
  844. AASLD: Sustained Immune Control in HBeAg-Positive Chronic Hepatitis B Patients Who Switched From Long-Term Entecavir Therapy to Peginterferon Alfa-2a (40KD): 1-Year Follow-Up of the OSST Study - (11/25/13)
     
  845. AASLD: Shifting scales: comparing viral hepatits and HIV/AIDS mortality in the Global Burden of Disease Study 2010 - (11/20/13)
     
  846. AASLD: Virologic Response to Boceprevir Plus Peginterferon Alfa-2a (40KD) and Ribavirin in Treatment-naive Patients with Chronic Hepatitis C and HCV Genotype 1 Infection: Interim Analysis of Data From the International TriCo Study - (11/20/13)
     
  847. AASLD: Outcome of Treatment with Peginterferon alfa-2a (40KD) in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B (CHB) in the Real-World: Interim Analysis of Data from the Large European S-Collate Cohort - (11/20/13)
     
  848. AASLD: Morphometric Assessment of Quantitative Collagen and Liver Fibrosis in Patients With Chronic Hepatitis B Treated for Up to Five Years With Tenofovir Disoproxil Fumarate (TDF) - (11/19/13)
     
  849. AASLD: Seven Years of Treatment With Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection Is Safe and Well Tolerated and Associated With Sustained Virological, Biochemical, and Serological Responses With No Detectable Resistance - (11/19/13)
     
  850. AASLD: Long Term Nucleo(t)ide Treatment (entecavir, lamivudine) Reduces Mortality in Chronic Hepatitis B Patients - (11/19/13)
     
  851. AASLD: Twenty-Eight Day Safety and Efficacy of Tenofovir Alafenamide (TAF) Fumarate in Chronic Hepatitis B (CHB) Patients - (11/18/13)
     
  852. AASLD: Hepatitis B Virus Screening and Prevalence in US Veterans in Department of Veterans Affairs Care - (11/16/13)
     
  853. AASLD: Safety, Tolerability, and Immunogenicity of GS-4774, an HBV-Specific Therapeutic Vaccine, in Healthy Volunteers - (11/14/13)
     
  854. EACS: 'Acute HCV BUT No HBV Reported' - Reports of Viral Hepatitis B and C in HIV Patients Participating in Clinical Trials of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF and Cobicistat-boosted Atazanavir plus Emtricitabine/Tenofovir DF - (10/21/13)
     
  855. EACS: Bristol-Myers Squibb Launches Initiative to support search for a cure in chronic viral diseases (HIV/HBV/HCV) - (10/16/13)
     
  856. IDSA: Entecavir Versus Tenofovir in Treatment-Naive Chronic Hepatitis B Patients: Third Year Results of a Real World Study - (10/11/13)
     
  857. New York State Updated HBV Guidelines in HIV+ - (08/30/13)
     
  858. Regression of Cirrhosis With Long-Term Tenofovir Treatment - (07/31/13)
     
  859. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection; Does Hepatitis B Treatment Reduce the Incidence of Hepatocellular Carcinoma? Editorial - (07/22/13)
     
  860. APASL: Hepatitis B Virus Infection in Western Region of China - (07/01/13)
     
  861. Targeting Innate HBV Immunity: A New Step in the Development of Combination Therapy for Chronic Hepatitis B; GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees - (06/26/13)
     
  862. HCV & HBV Therapy Reverses Fibrosis & Cirrhosis, several studies in HCV monoinfection, HCV/HIV coinfection & in HBV - (06/23/13)
     
  863. APASL: No Detectable Tenofovir Resistance With Tenofovir Disoproxil Fumarate (TDF) or TDF+Emtricitabine (FTC/TDF) Through 96 Weeks in Lamivudine-Resistant CHB Patients - (06/19/13)
     
  864. APASL: Six Years of Treatment With Tenofovir DF for Chronic Hepatitis B Virus Infection is Safe and Well Tolerated and Associated With Sustained Virological, Biochemical, and Serological Responses With No Detectable Resistance - (06/19/13)
     
  865. APASL: 48 Weeks TDF Treatment Results in Potent Viral Suppression and A Favorable Safety Profile in Chinese Chronic Hepatitis B Patients - (06/19/13)
     
  866. APASL: Tenofovir Disoproxil Fumarate (TDF) in Asian Patients With High Baseline HBV-DNA Viral Load (HBV DNA ≥9 log10 copies/mL) - (06/19/13)
     
  867. APASL: High Prevalence of Vitamin D Deficiency Among Chronic Hepatitis B Patients Entering a Large Global Prospective Trial (Study GS-US-174-0149) - (06/19/13)
     
  868. APASL: Chronic Hepatitis B Treatment With Tenofovir DF (TDF): 2-Year Efficacy and Safety Results in a Real-Life Cohort - (06/19/13)
     
  869. APASL: Regression of Cirrhosis After HBsAg Seroconversion in a Cirrhotic 38 Year-Old Bangladeshi Man Treated with Tenofovir Disoproxil Fumarate - (06/19/13)
     
  870. APASL: HBsAg level predicts sustained response in peginterferon alfa-2a (40KD)-treated HBeAg-positive patients: initial post-treatment results from the 'real-life' S-Collate cohort - (06/17/13)
     
  871. APASL: Early on-treatment HBsAg level predicts response in HBeAg-positive chronic hepatitis B patients switched from long-term entecavir to peginterferon alfa-2a (40KD) - (06/17/13)
     
  872. APASL: The Relative Disease Burden of Viral Hepatitis C: A Comparison with Viral Hepatitis B - (06/17/13)
     
  873. APASL: Peginterferon Lambda for the Treatment of HBeAg-Positive Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa - (06/14/13)
     
  874. APASL: No Detectable Tenofovir Resistance With Tenofovir Disoproxil Fumarate (TDF) or TDF+Emtricitabine (FTC/TDF) Through 96 Weeks in Lamivudine-Resistant CHB Patients - (06/12/13)
     
  875. APASL: Efficacy and Safety of Tenofovir DF (TDF) in Chronic Hepatitis B Virus Infected Patients With Documented Lamivudine Resistance (LAM-R) - (06/12/13)
     
  876. Resistance Patterns and Response to Entecavir Intensification Among HIV-HBV-Coinfected Adults With Persistent HBV Viremia - (05/30/13)
     
  877. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection - (05/25/13)
     
  878. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score - (05/25/13)
     
  879. (HBV) Risk score (REACH-B) for development of HCC: ready for use in practice? - (05/25/13)
     
  880. Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients - (05/25/13)
     
  881. Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment - (05/25/13)
     
  882. EASL: 5-year Entecavir treatment in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics - (05/15/13)
     
  883. EASL: Liver Disease in HBV-HIV Coinfection- Significant Fibrosis is Present Despite HBV Suppression and Anti-Retroviral Therapy - (05/15/13)
     
  884. EASL: Virological Response Does Not Lower Liver Disease Progression Among Chronic Hepatitis B Cirrhotic Patients Treated with Long-Term Nucleo(t)ide-Analogue - (05/15/13)
     
  885. EASL: INCIDENCE AND CLINICAL CONSEQUENCES OF REDUCED TUBULAR PHOSPHATE REABSORPTION IN NAIVE CHB PATIENTS TREATED WITH TENOFOVIR: A TWO-YEAR FIELD STUDY - (05/15/13)
     
  886. EASL: HARPE Study: Prevalence of Renal Abnormalities in Chronic Hepatitis B Virus Infection - (05/15/13)
     
  887. EASL: FROM COMBINATION-THERAPY TO MONO-THERAPY IN TREATMENT EXPERIENCED CHB PATIENTS WITH VIRAL RISISTENCE OR PARTIAL RESPONSES: FIRST RESULTS OF AN INTERNATIONAL MULTICENTER COHORT STUDY - (05/15/13)
     
  888. EASL: Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study - (05/15/13)
     
  889. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection - (05/13/13)
     
  890. EASL: Efficacy and Safety of Peginterferon Alfa-2a (40KD) in HBeAg-Positive Chronic Hepatitis B PatientsParticipating in a Response-Guided Therapy Study: An Interim Analysis at Week 72 - (05/09/13)
     
  891. EASL: S-collate cohort 'real-life' study: efficacy and safety of peginterferon alfa-2a (40KD) in 1233 patients with chronic hepatitis B according to Asian and Caucasian race - (05/09/13)
     
  892. EASL: Impact of Entecavir Versus Lamivudine on Hepatic HBV Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients - (05/08/13)
     
  893. EASL: Long-term Tenofovir Disoproxil Fumarate (TDF) Therapy and the Risk of Hepatocellular Carcinoma - (05/08/13)
     
  894. EASL: Tenofovir Disoproxil Fumarate in Chronic HBV Patients With Normal ALT Levels and High HBV DNA Levels, also titled: TENOFOVIR DF (TDF) COMPARED TO EMTRICITABINE (FTC)/TDF IN HBeAg-POSITIVE, CHRONIC HEPATITIS B (CHB) VIRUS-INFECTED PATIENTS IN THE IMMUNE TOLERANT (IT) PHASE - (05/08/13)
     
  895. EASL: Comparison of Serum HBsAgDeclines During Tenofovir Disoproxil Fumarate (TDF) Treatment in Different Chronic Hepatitis B (CHB) Patient Populations - (05/08/13)
     
  896. EASL: HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBE-) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HEPNET.GREECE COHORT STUDY - (05/08/13)
     
  897. EASL: ALT Flares During Treatment with Peginterferon Lambda-1a or Peginterferon Alfa in Patients With HBeAg-positive Chronic Hepatitis B Infection (CHB) - (05/08/13)
     
  898. EASL: IMPROVED HBsAgLOSS RATE IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PROLONGED PEGINTERFERON α-2A COMBINED WITH NUCLEOS(T)IDE ANALOGUE - (05/08/13)
     
  899. EASL: Tenofovir Disoproxil Fumarate (TDF) Is Safe and Well Tolerated in Chronic Hepatitis B (CHB) Patients With Pre-Existing Mild Renal Impairment - (05/08/13)
     
  900. CROI: Protective Effect of HBV-active c-ART against primary HBV-Infection - (03/05/13)
     
  901. Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses - (02/19/13)
     
  902. GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus (and HCV) in Chronically Infected Chimpanzees - (02/19/13)
     
  903. Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis - (02/19/13)
     
  904. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis - (01/25/13)
     
  905. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study - & Commentary....."long-term suppression of HBV can lead to regression of fibrosis and cirrhosis....." - (01/12/13)
     
  906. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort (ACTG) - (12/20/12)
     
  907. AASLD: Chronic hepatitis B patients with advanced fibrosis/compensated cirrhosis can benefit from peginterferon alfa-2a (40KD): improved or comparable response rates versus mild fibrosis in the phase III studies - (11/26/12)
     
  908. AASLD: New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a (40 kD) induces HBeAg seroconversion/HBsAgloss in patients with HBeAg-positive chronic hepatitis B (The OSST study) - (11/19/12)
     
  909. AASLD: Six Years of Treatment With Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection Is Safe and Well Tolerated and Associated With Sustained Virological, Biochemical, and Serological Responses With No Detectable Resistance - (11/19/12)
     
  910. AASLD: Antiviral Efficacy of Entecavir in Black/African American and Hispanic Patients with Chronic Hepatitis B who are Nucleos(t)ide Naïve - (11/19/12)
     
  911. AASLD: SWITCHING TO TENOFOVIR IS SAFE IN MOST CHRONIC HEPATITIS B PATIENTS WITH A REDUCED GLOMERULAR FILTRATION RATE DUE TO PREVIOUS EXPOSURE TO ADEFOVIR DIPIVOXIL - (11/19/12)
     
  912. AASLD: Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment - (11/19/12)
     
  913. AASLD: Tenofovir monotherapy suppressed viral replication in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study - (11/19/12)
     
  914. AASLD: Nucleos(t)ide analogues can be safely discontinued in CHB patients achieving HBsAgclearance - (11/19/12)
     
  915. U.S. Food and Drug Administration Approves Labeling Update for BARACLUDE® (entecavir) (0.5 mg/1 mg Tablets) to Include Data on African Americans and Liver Transplant Recipients with Chronic Hepatitis B in Adult Patients - (10/16/12)
     
  916. ICAAC: Tenofovir Replacing AZT of ABC, Keeping 3TC, Suppresses HBV DNA - written by Mark Mascolini - (09/11/12)
     
  917. Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients With Chronic Hepatitis B - (08/28/12)
     
  918. The patient, the doctor, and the system: Underdiagnosis and undertreatment of hepatitis B - (08/23/12)
     
  919. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Renal function improves with long-term telbivudine therapy in patients with chronic hepatitis B Analysis of the Clinical data Base - (08/20/12)
     
  920. Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence- 1 in 5 were tested for HBV infection and 1 of 8 for HCV infection in 4 US HCOs - (08/17/12)
     
  921. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection 2012 - (07/18/12)
     
  922. Hepatitis B in the united states: a major health disparity affecting many foreign-born populations - (06/03/12)
     
  923. EASL: Response-guided peginterferon alfa-2a therapy based on HBsAglevels at week 12 and week 24 or 48 improves response rates in HBeAg-negative, genotype D patients - (05/10/12)
     
  924. EASL: Improved predictive value for sustained immune control in peginterferon (PEGASYS)-treated HBeAg-positive patients using combined HBsAgand HBV DNA levels at week 24 - (05/10/12)
     
  925. EASL: Relationship between Precore / Core Promoter Mutants, HBeAg levels and Serological Response in HBeAg-Positive Chronic Hepatitis B Patients treated with Nucleos(t)ide Analogues 2 - (05/08/12)
     
  926. EASL: Relationship between precore / core promoter mutants, HBeAg levels and serological response in HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues - (05/07/12)
     
  927. EASL: Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B - (05/07/12)
     
  928. EASL: OUTCOMES OF ENTECAVIR (ETV) AND TENOFOVIR (TDF) COMBINATION THERAPY IN CHRONIC HEP-B PATIENTS WITH PREVIOUS TREATMENT FAILURE - (05/04/12)
     
  929. EASL: Safety and Efficacy of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B - (05/04/12)
     
  930. EASL: Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months - (05/04/12)
     
  931. EASL: Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B : a 4-year field practice, multicenter study - (05/04/12)
     
  932. Natural history of chronic hepatitis B: what exactly has REVEAL Revealed? "Serum HBV DNA level was identified as the most important risk predictor for progressing to end-stage liver disease outcomes" - (04/30/12)
     
  933. High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load: "in patients with HBV DNA level <2000 IU/mL who had a similar risk of HCC, HBsAglevel ≥1000 IU/mL was identified as a new independent risk factor for HCC development. These data suggested that HBsAglevel might complement HBV DNA level in predicting HCC development, especially in the lowly viremic HBV carriers" - (04/30/12)
     
  934. Identifying Hepatitis B Carriers at Low Risk for Hepatocellular Carcinoma - editorial - (04/30/12)
     
  935. APASL: Early HBsAgdecline as a predictor of HBsAgclearance in 'real life': results of the S-Collate cohort study in683 HBeAg-negative patients - (02/27/12)
     
  936. APASL: S-Collate cohort study: on-treatment HBsAglevel analysis in 'real-life' confirms prediction of response observed in NEPTUNE and phase III studies of peginterferon alfa-2a in HBeAg-positive patients - (02/27/12)
     
  937. APASL: Five Years of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Associated with Sustained Viral Suppression and Significant Regression of Fibrosis and Cirrhosis - (02/27/12)
     
  938. APASL: No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg- Chronic Hepatitis B Virus Infection - (02/27/12)
     
  939. APASL: Low Baseline Hepatitis B Surface Antigen (HBsAg) Levels and HBV Genotypes B/C are Associated with Persistently Low HBsAgin HBeAg+ Patients Treated with Tenofovir Disoproxil Fumarate (TDF) - (02/27/12)
     
  940. APASL: Asians have Different Hepatitis B Surface Antigen (HBsAg) Kinetics than Non-Asians while Undergoing Treatment with Tenofovir Disoproxil Fumarate (TDF) or Adefovir (ADV) Followed by TDF up to 192 Weeks - (02/27/12)
     
  941. APASL: Hepatitis B Surface Antigen (HBsAg) Loss in HBeAg+ Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumarate (TDF) - (02/25/12)
     
  942. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome - (02/03/12)
     
  943. HBV Viral Load is Associated with Risk for Liver Cancer (HCC) & HBV Disease Progression - (01/12/12)
     
  944. Preventing Deaths in Persons With HIV/Hepatitis B Virus Coinfection: A Call to Accelerate Prevention and Treatment Efforts - EDITORIAL - (01/02/12)
     
  945. Hepatitis B Virus Coinfection Negatively Impacts HIV Outcomes in HIV Seroconverters - (01/02/12)
     
  946. The Economic Cost of Advanced Liver Disease - (01/02/12)
     
  947. Hepatitis B (HBV) - (11/30/11)
     
  948. AASLD: Baseline and early on-treatment characteristics in HBeAg-positive patients with chronic hepatitis B infection achieving an early on-treatment response to pegylated interferon alfa-2a (40KD): interim results from the RGT study - (11/20/11)
     
  949. AASLD: Patients with HBeAg-positive chronic hepatitis B with a maintained virologic response to entecavirachieved HBsAgclearance when switched to peginterferon alfa-2a (40KD) therapy (the OSST study) - (11/16/11)
     
  950. AASLD: A novel combination regimen of peginterferon alfa-2a (40KD) and entecavir results in sustained post-treatment HBsAgclearance in HBeAg-positive chronic hepatitis B - (11/16/11)
     
  951. AASLD: Peginterferon alfa-2a monotherapy as a strategy for achieving sustained response in patientsswitched from long-term nucleos(t)ide analog therapy: the results of 1 year follow up - (11/16/11)
     
  952. AASLD: A response-guided approach to pegylated interferon alpha-2a (40KD) therapyto improve response rates in HBeAg-negative, genotype D patients - (11/16/11)
     
  953. AASLD: Response rates are similar for patients with and without advanced fibrosis/cirrhosis, and highest with peginterferon alfa-2a (40KD) 180 μg for 48 weeks in the NEPTUNE study - (11/16/11)
     
  954. AASLD: Five years of Treatment with Tenofovir DF for Chronic Hepatitis B Infection is Associated with Sustained Viral Suppression and Significant Regression of Histological Fibrosis and Cirrhosis - (11/14/11)
     
  955. AASLD: No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg-Chronic Hepatitis B Virus Infection - (11/14/11)
     
  956. AASLD: Five years of Treatment with Tenofovir DF for Chronic Hepatitis B Infection in Asian Patients is Associated with Sustained Viral Suppression and Significant Regression of Histological Fibrosis and Cirrhosis - (11/14/11)
     
  957. AASLD: Gilead Announces Positive Five-Year Data Showing Effect of Viread(R) on Liver Fibrosis and Cirrhosis Caused by Chronic Hepatitis B: '88% of patients on tenofovir in studies experienced reversal of fibrosis/cirrhosis' - press release - (11/14/11)
     
  958. AASLD: Disease burden in patients with chronic hepatitis C virus (HCV) infection in a United States (US) private health insurance claims database analysis from 2003 to 2010 - (11/10/11)
     
  959. AASLD: Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naïve patients with chronic hepatitis B (CHB): the BE-LOW study - (11/10/11)
     
  960. AASLD: Phase IIIb Comparison of BARACLUDE® (entecavir) Monotherapy Versus BARACLUDE Plus Tenofovir Combination Shows No Statistical Difference Between Study Arms - press release - (11/10/11)
     
  961. Hepatitis delta in HIV-infected individuals in Europe - (09/07/11)
     
  962. Hepatitis B (HBV) - (06/17/11)
     
  963. Economic Analysis of Hepatitis B Screening and Treatment - Editorial - (06/01/11)
     
  964. The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States - (06/01/11)
     
  965. ENTECAVIR TREATMENT FOR CHRONIC HEPATITIS B: ADAPTATION IS NOT NEEDED FOR THE MAJORITY OF NAïVE PATIENTS WITH A PARTIAL VIROLOGICAL RESPONSE - (05/23/11)
     
  966. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients - (05/09/11)
     
  967. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogs in clinical practice - pdf attached - (05/04/11)
     
  968. EASL: Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA) Assessments in Patients with Chronic Hepatitis B (CHB) - (04/18/11)
     
  969. EASL: Effects of Tenofovir DF on Renal Function of Chronic HBV Patients in Three Global Randomized Studies - (04/18/11)
     
  970. EASL: NEPTUNE STUDY: ON-TREATMENT HBsAgLEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBeAg-POSITIVE PATIENTS - (04/13/11)
     
  971. EASL: Baseline Genotype And HBsAgWere Found To Have Significant Association With HBeAg Seroconversion Following Up To 4 Years Of Tenofovir Disoproxil Fumarate Treatment - (04/13/11)
     
  972. EASL: Highest Rates of Response at Week 72 of the NEPTUNE Study are Achieved with Peginterferon Alfa-2a 180 μg for 48 weeks - (04/13/11)
     
  973. EASL: Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees - (04/07/11)
     
  974. EASL: Anti-Viral Efficacy and Induction of an Antibody Response Against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection - (04/07/11)
     
  975. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues - (03/29/11)
     
  976. CROI: Fibrosis Predicts Renal Trouble With Tenofovir in HIV/HBV-Coinfected - written by Mark Mascolini - (03/8/11)
     
  977. APASL: Efficacy and Safety of Entecavir Treatment in a Heterogeneous CHB Population in a Real-Life Setting in China - (02/24/11)
     
  978. APASL: Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation: Week 96 Results - (02/24/11)
     
  979. APASL: No Resistance to Tenofovir Disoproxil Fumarate (TDF) Detected Following up to 192 Weeks of Treatment in Subjects Mono-Infected with Chronic Hepatitis B Virus - (02/23/11)
     
  980. APASL: HBV rtN236T Mutant Subpopulations Respond Like Wild-Type During Tenofovir DF (TDF) Monotherapy or Combination Therapy with Emtricitabine (FTC) - (02/21/11)
     
  981. APASL: Four Year Efficacy and Safety of Tenofovir DF in HBeAg-Negative and HBeAg-Positive Patients with Chronic Hepatitis B (CHB) - (02/21/11)
     
  982. APASL: Tenofovir Disoproxil Fumurate (TDF) Demonstrates Good Efficacy and Safety in Asians with Chronic Hepatitis B (CHB) in Real-Life Settings - (02/21/11)
     
  983. APASL: Tenofovir Disoproxil Fumurate (TDF) Shows Similar Virologic Suppression and Safety between Asians and Non-Asians with Chronic Hepatitis B (CHB) - (02/21/11)
     
  984. APASL: Treatment patterns for hepatocellular carcinoma (HCC) in China: findings from the global HCC BRIDGE study - (02/21/11)
     
  985. APASL: Recent trends in hepatocellular carcinoma (HCC) practice in Taiwan: report from the global HCC BRIDGE study - (02/21/11)
     
  986. APASL: Response rates with shorter duration and lower doses of peginterferon alfa-2a are inferior to those with 180 μg for 48 weeks - (02/21/11)
     
  987. APASL: Peginterferon alfa-2a (180 μg/48 weeks) is well tolerated with high rates of treatment adherence: results of the NEPTUNE study - (02/21/11)
     
  988. APASL: Multicenter Evaluation of the Elecsys® HBsAgII Quant Assay - (02/21/11)
     
  989. Study of adherence comes to the treatment of chronic hepatitis B - (02/14/11)
     
  990. Association Between the Various Mutations in Viral Core Promoter Region to Different Stages of Hepatitis B, Ranging of Asymptomatic Carrier State to Hepatocellular Carcinoma - pdf atached - (02/14/11)
     
  991. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure - pdf attached - (02/14/11)
     
  992. Editorial: Viral Factors and Outcomes of Chronic HBV Infection - (02/14/11)
     
  993. A Simulation Shows That Early Treatment Of Chronic Hepatitis B Infection Can Cut Deaths And Be Cost-Effective - pdf attached - (02/11/11)
     
  994. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease - pdf attached - (01/16/11)
     
  995. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus - published pdf attached - (01/03/11)
     
  996. SF HBV Test/Treat Program - Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic - published pdf attached - (12/30/10)
     
  997. Is chronic hepatitis B being undertreated in the United States? - published pdf attached - (12/19/10)
     
  998. AASLD: Gilead's New HCV Drugs Studies & HBV at AASLD - (11/15/10)
     
  999. AASLD: Long Term (4 Year) Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B (Study 103) - (11/04/10)
     
  1000. AASLD: Continued Efficacy and Safety Through 4 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/04/10)
     
  1001. AASLD: Viread(R) for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment - (11/29/10)
     
  1002. AASLD: Efficacy and Safety of Entecavir in Nucleos(t)ide Naïve Asians With HBeAg-Positive and -Negative Chronic Hepatitis B: Results from Studies ETV-022/027 - (11/21/10)
     
  1003. AASLD: Long-term Entecavir Treatment for Up to 5 Years in Asians With HBeAg-positive Chronic Hepatitis B: Results From ETV-022 and -901 - (11/21/10)
     
  1004. AASLD: Effectiveness and safety of Tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B - (11/21/10)
     
  1005. AASLD: Safety Findings From S-Collate, A Large, Multinational, Non-Interventional Cohort Study Of Patients With Chronic Hepatitis B Infection Treated With Peginterferon Alfa-2a [40kd] - (11/21/10)
     
  1006. AASLD: Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience - (11/21/10)
     
  1007. AASLD: Safety and tolerability of extended (96 weeks) treatment with peginterferon alfa-2a [40KD] in genotype D patients with HBeAg-negative chronic hepatitis B - (11/21/10)
     
  1008. AASLD: Changes In HBsAgLevels Among Patients With Chronic Hepatitis B Treated With Peginterferon Alfa-2a [40kd] Enrolled In The S-Collate Cohort Study - (11/21/10)
     
  1009. AASLD: Changes In HBeAg Levels Among Patients With HBeAg-Positive Chronic Hepatitis B Treated With Peginterferon Alfa-2a [40KD] Enrolled In The S-Collate Cohort Study - (11/21/10)
     
  1010. AASLD: Effectiveness and safety of Tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B - (11/15/10)
     
  1011. AASLD: No Resistance to Tenofovir Disoproxil Fumarate (TDF) Detected Following up to 192 Weeks of Treatment in Subjects Mono-Infected with Chronic Hepatitis B Virus - (11/08/10)
     
  1012. AASLD: Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 µg: NEPTUNE study - (11/08/10)
     
  1013. Virologic and Clinical Outcomes in HIV/HBV Coinfected Patients on Tenofovir-Containing HAART - pdf attached - (10/27/10)
     
  1014. Long-Term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus - pdf attached - (10/27/10)
     
  1015. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B - pdf attached - (10/27/10)
     
  1016. Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection - pdf attached - (10/27/10)
     
  1017. Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-Analyses - pdf published attached - (08/25/10)
     
  1018. HBV Drug Therapy: Tenofovir....IFN, Entecavir publication pdf attached - (08/11/10)
     
  1019. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis B patients - publication pdf attached - (08/11/10)
     
  1020. HBV infection as a risk factor for non-Hodgkin lymphoma - Comment - (08/06/10)
     
  1021. Chronic HBV Raises Lymphoma Risk - full text of published article below & pdf attached of published study - (08/06/10)
     
  1022. HBV Viral Load/Fibrosis/ALT/Inflammation HBeAg+/HBeAg-: "Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B" - (08/06/10)
     
  1023. HBV infection as a risk factor for non-Hodgkin lymphoma - Comment - (08/06/10)
     
  1024. Chronic HBV Raises Lymphoma Risk - full text of published article below & pdf attached of published study - (08/06/10)
     
  1025. HBV Viral Load/Fibrosis/ALT/Inflammation HBeAg+/HBeAg-: "Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B" - (08/06/10)
     
  1026. HBV Antiviral Therapy in HCC Can Prevent Death & Transplant - (06/30/10)
     
  1027. Intrn Wrkshp Pharm Hep Therapy: A European Perspective: EMA and his critical standpoint, Prof. Jean-Michel Pawlotsky, MD, PhD - (07/23/10)
     
  1028. The Prevalence of Hepatitis B Virus Infection in the United States in the Era of Vaccination - (06/20/10)
     
  1029. EASL: Evaluation of Potential Virologic Resistance in HBV Polymerase Among Subjects with Persistent Viremia Following up to 144 Weeks of Therapy with Tenofovir DF - (04/22/10)
     
  1030. EASL: HBsAgKinetics of Decay and Baseline Characteristics of HBeAg-Positive Patients with Chronic Hepatitis B Following 3 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment - (04/22/10)
     
  1031. EASL: From Ash To Cure - EASL April 14-18 2010 - (04/21/10)
     
  1032. EASL: Efficacy of Tenofovir DF Treatment in Patients with a Suboptimal Response to Adefovir Dipivoxil - (04/21/10)
     
  1033. EASL: Risk and Predictors of Mortality or Hepatocellular Carcinoma among Entecavir- or Adefovir-Treated Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation - (04/21/10)
     
  1034. EASL: Low Rates of Nucleos(t)ide-associated Adverse Events in the Long-term Experience with Entecavir - (04/21/10)
     
  1035. A new role for an old marker, HBsAg - (04/07/10)
     
  1036. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia - (04/07/10)
     
  1037. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective - (04/07/10)
     
  1038. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection - The current long-term study of entecavir presents results for a cohort of patients treated continuously for 3years. - (03/31/10)
     
  1039. APASL: Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40KD] (PEGASYS) plus lamivudine or adefovir for 96 weeks results in high rates of HBsAgclearance / seroconversion - (03/31/10)
     
  1040. APASL: Identification of a baseline algorithm to select chronic hepatitis B patients for therapy with peginterferon alfa-2a [40KD] (PEGASYS) - (03/31/10)
     
  1041. APASL: A pilot study of interferon alpha/peginterferon alfa-2a combined with response-guided short-term nucleoside analog therapy in HBeAg-positive hepatitis B patients - (03/31/10)
     
  1042. APASL: Tenofovir 3- Year Efficacy, Safety and Resistance - Treatment in HBeAg Positive and Negative Patients with Chronic Hepatitis B - (03/31/10)
     
  1043. APASL: 3 Years Efficacy and Safety of Tenofovir in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B - (03/31/10)
     
  1044. APASL: Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation - (03/31/10)
     
  1045. APASL: The Antiviral Effects and Safety of Entecavir Versus Lamivudine Treatment in Nucleos(t)ide-naïve HBeAg-negative Korean Chronic Hepatitis B Patients: Week 48 Interim Analysis - (03/31/10)
     
  1046. APASL: On-Treatment Decline in Serum HBsAgLevels Predicts Sustained Immune Control 1 Year Post-Treatment and Subsequent HBsAgClearance in HBeAg-Negative Hepatitis B Virus-Infected Patients Treated with Peginterferon Alfa-2a [40KD] (PEGASYS) - (03/31/10)
     
  1047. APASL: On-Treatment Decline in Serum HBsAgLevels Predicts Sustained Immune Control and HBsAgClearance 6 Months Post-Treatment in HBeAg-Positive Hepatitis B Virus-Infected Patients Treated with Peginterferon Alfa-2a [40KD] (PEGASYS) - (03/31/10)
     
  1048. APASL: Sustained Immune Control 1 Year Post-Treatment with Peginterferon Alfa-2a [40KD] (PEGASYS) is Durable up to 5 Years Post-Treatment and is Associated with a High Rate of HBsAgClearance in HBeAg-Negative Chronic Hepatitis B - (03/31/10)
     
  1049. APASL: Large International, Observational Study of Patients with Chronic Hepatitis B Infection Treated with Peginterferon Alfa-2a [40KD] (PEGASYS): the S-Collate Cohort - (03/31/10)
     
  1050. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus - (03/19/10)
     
  1051. CROI: Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus - (03/04/10)
     
  1052. CROI: Positive HBV Vaccine Response Halves HIV Progression and Death Risk in US Military - written by Mark Mascolini - (02/25/10)
     
  1053. Longer HAART (tenofovir) Use Predicts Hepatitis B Clearance - (02/04/10)
     
  1054. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease - (01/26/10)
     
  1055. HCV & HBV Medican/Medicare Training by NYS DOH - (01/26/10)
     
  1056. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis - (01/21/10)
     
  1057. Liver cancer: From molecular pathogenesis to new therapies: Summary of the EASL single topic conference - (01/21/10)
     
  1058. Entecavir in decompensated HBV cirrhosis: The future is looking brighter - (01/20/10)
     
  1059. Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIV-Infected Individuals during the Past 20 Years - (01/17/09)
     
  1060. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B - (01/11/10)
     
  1061. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues - (01/06/10)
     
  1062. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety - (01/06/10)
     
  1063. AASLD: Parenchymal Fibrosis and Cancer Specific Outcomes Following Liver Resection in Patients with HBV Associated Hepatocellular Carcinoma - (12/10/09)
     
  1064. AASLD: Prevalence and Characteristics of Hepatitis B Virus Mutations in Chronic Hepatitis B Patients on Oral Antiviral Therapy: The CHARM Study - (12/07/09)
     
  1065. AASLD: Higher Sustained Post-Treatment Virologic Response Following Peginterferon Alfa-2a ± Adefovir Compared With Adefovir Monotherapy in HBeAg-Positive Patients - (12/02/09)
     
  1066. AASLD: Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation - (12/02/09)
     
  1067. AASLD: Diagnosis and Management of Chronic Hepatitis B in Asian-American Patients Among Primary Care Physicians in the United States - (12/02/09)
     
  1068. AASLD: Adherence to AASLD Guideline Recommendations for Laboratory Monitoring of Chronic Hepatitis B Patients Who are Not Receiving Antiviral Treatment - (12/02/09)
     
  1069. AASLD:HBsAgDecline in HBeAg-Negative Patients Treated With Peginterferon Alfa-2a is Associated With Sustained Response up to 5 Years Post-Treatment: Patients with Continuous HBsAgDecline Starting Before Week 24 Achieve Highest Rates of Response - (12/01/09)
     
  1070. AASLD: A Finite Course of Peginterferon Alfa-2a Results in Inactive Chronic Hepatitis B and HBsAgClearance 5 Years Post-Treatment in Patients With HBeAg-Negative Disease: Baseline Characteristics and Predictive Factors of Long-Term Response - (12/01/09)
     
  1071. AASLD: HBsAgClearance Continues to Increase Post-Treatment in Patients with HCV/HBV Coinfection Treated With Peginterferon Alfa-2a Plus Ribavirin: 1.5 Year Follow up - (12/01/09)
     
  1072. AASLD: Extended Treatment With Peginterferon Alfa-2a Benefits Patients With HBeAg-Positive Chronic Hepatitis B With a Partial Response After 48 Weeks of Therapy - Clinical Experience From a Chinese Center - (12/01/09)
     
  1073. AASLD: Extending Peginterferon Alfa-2a Therapy in Patients With HBeAg-Positive Chronic Hepatitis B Who Did Not Achieve a Response at Week 48 Can Lead to HBeAg Seroconversion and HBsAgClearance - (12/01/09)
     
  1074. AASLD: On-Treatment Quantification of HBsAgin Difficult-to-Treat Patients With Lamivudine Resistance Can Help Identify Those Most Likely to Achieve Sustained Post-Treatment Response to Peginterferon Alfa-2a Rescue Therapy - (12/01/09)
     
  1075. AASLD: Physician Country of Birth and Hepatitis B Virus (HBV) Screening Practices of Asian-American Primary Care Providers (PCPs) Who Treat Asian Adults Living in the US - (11/30/09)
     
  1076. AASLD: Tenofovir Disoproxil Fumarate-Containing Regimens in Pregnancy: Report From the Antiretroviral Pregnancy Registry - (11/30/09)
     
  1077. AASLD: Resistance Surveillance for up to 144 Weeks in HBeAg+ and HBeAg- Hepatitis B Patients Treated with Tenofovir DF Showed No Relationship Between Virologic Breakthrough and Emergence of Genotypic Changes in HBV Polymerase - (11/30/09)
     
  1078. AASLD: Three Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B - (11/30/09)
     
  1079. AASLD: In Vitro Tenofovir Sensitivity of HBV Populations from Clinical Specimens Containing rtA181T/V and/or rtN236T - (11/30/09)
     
  1080. AASLD: TENOFOVIR (TDF) IS EFFECTIVE IN LAMIVUDINE (LAM)-RESISTANT CHRONIC HEPATITIS B PATIENTS WHO HARBOUR rtA194T AT BASELINE - (11/30/09)
     
  1081. Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries - (11/25/09)
     
  1082. Hepatitis B Virus Resistance to Nucleos(t)ide Analogues - (11/11/09)
     
  1083. AASLD: Entecavir and Tenofovir combination therapy in chronic Hepatitis B: Rescue therapy in patients with advanced fibrosis and multiple previous treatment failures. Results from an international multicenter cohort study. - (11/10/09)
     
  1084. AASLD: High rates of HBeAg seroconversion and HBsAgloss with Tenofovir + Emtricitabine in patients with HBV-HIV co-infection irrespective of CD4+ cell count - (11/10/09)
     
  1085. AASLD: Loss of HBsAgin Nucleoside-Naïve HBeAg(+) Chronic Hepatitis B Patients Following Treatment with Entecavir or Lamivudine: Evaluation of HBV Genotypes - (11/10/09)
     
  1086. AASLD: Long-term Follow-up Evaluation of the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in a European Multicenter (Nucleos(t)ide Experienced) Hepatitis B Virus HBV-infected Cohort - (11/10/09)
     
  1087. AASLD: Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from a large multicenter cohort study in 376 patients - (11/10/09)
     
  1088. AASLD: Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/06/09)
     
  1089. AASLD: Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) With Chronic Hepatitis B (Study 103) - (11/06/09)
     
  1090. AASLD: Resistance Surveillance for up to 144 Weeks in HBeAg+ and HBeAg- Hepatitis B Patients Treated with Tenofovir DF Showed No Relationship Between Virologic Breakthrough and Emergence of Genotypic Changes in HBV Polymerase - (11/06/09)
     
  1091. AASLD: A Phase 2, Double-Blind, Randomized Study Comparing The Safety of Tenofovir Disoproxil Fumarate (TDF), Emtricitabine Plus TDF (Truvada, TVD) and Entecavir (ETV) in Subjects with Decompensated Chronic Hepatitis B Liver Disease - (11/06/09)
     
  1092. AASLD: Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States - (11/06/09)
     
  1093. AASLD: HBsAgDecline in HBeAg-Negative Patients Treated With Peginterferon Alfa-2a is Associated With Sustained Response up to 5 Years Post-Treatment: Patients with Continuous HBsAgDecline Starting Before Week 24 Achieve Highest Rates of Response - (11/01/09)
     
  1094. Rep Honda Introduces Bi-Partisan Bill to End Hepatitis Epidemic in America - (10/29/09)
     
  1095. ICAAC: Acute HBV & HCV Infection Among MSM: CDC Data from Population-Based Surveillance, 2006-2008 - (09/25/09)
     
  1096. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients - (09/11/09)
     
  1097. Chronic hepatitis B: Update 2009 AASLD Guidelines - (09/11/09)
     
  1098. Racial Differences in HBV Liver Transplant Linked to Underlying Disease - (09/03/09)
     
  1099. Loss of HBsAgantigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B - (08/17/09)
     
  1100. Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a - (06/26/09)
     
  1101. HIV Resistance Wksp: HBV Resistance to Lamivudine at Undetectable and Low Levels of Viremia - written by Mark Mascolini - (06/15/09)
     
  1102. DDW: Association between HBV Replication and Serum ALT Changes is not Dependent on HBV Genotype and Mutants - (06/08/09)
     
  1103. DDW: Regression of Fibrosis/Cirrhosis with Long-Term Entecavir Therapy in Chronic Hepatitis B (CHB) Patients with Baseline Bridging Fibrosis or Cirrhosis: Results from Studies ETV-022, -027 and -901 - (06/08/09)
     
  1104. DDW: Long-Term Histological Improvement with Entecavir (ETV) Therapy in Patients with Chronic Hepatitis B (CHB) from Japanese and Worldwide Development Programs - (06/08/09)
     
  1105. DDW: Risk and Predictors of HCC in People Less than 40 years of Age: Update from the R.E.V.E.A.L.-HBV Study - (06/08/09)
     
  1106. DDW: Entecavir (ETV) Therapy in Chronic Hepatitis B Patients Previously Treated with Adefovir (ADV) with Incomplete Response On-Treatment or Relapse Off-Treatment - (06/08/09)
     
  1107. DDW: Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients - (06/08/09)
     
  1108. Hepatitis B antiviral drug resistance common but avoidable - by 'using tenofovir or entecavir firstline' - (06/05/09)
     
  1109. CDC Updated Viral Hepatitis Surveillance - (06/05/09)
     
  1110. Liver Cancer Rates Triple: Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 - (06/03/09)
     
  1111. Clevudine myopathy in patients with chronic hepatitis B - (06/02/09)
     
  1112. Benefits and risks of interferon therapy for hepatitis B Meeting Report Review Robert Perillo - (05/09/09)
     
  1113. EASL: Evolution of Viral Load and Genome Sequence in a Clinical Trial of Tenofovir/Emtricitabine Combination Versus Tenofovir Monotherapy for Patients with Previous Adefovir Dipivoxil Failure - (05/07/09)
     
  1114. EASL: Characteristics of HBeAg-Positive Patients with HBsAgLoss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF) - (05/07/09)
     
  1115. EASL: Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients - (05/06/09)
     
  1116. EASL: Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB) - (05/06/09)
     
  1117. EASL: Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil - (05/06/09)
     
  1118. EASL: BASELINE HBsAgLEVEL PREDICT HBsAgLOSS IN CHRONIC HEPATITIS B PATIENTS TREATED WITH A COMBINATION OF PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS - (05/06/09)
     
  1119. EASL: HBsAgDecline Appears To Predict Clearance- Increasing Rates of HBsAgClearance and Seroconversion in Patients With HBeAg-Negative Disease Treated With Peginterferon Alfa-2a ± Lamivudine: Results of 5-Year Post-Treatment Follow-up - (05/06/09)
     
  1120. EASL: Hepatitis B Virus Drugs in Pregnancy: Findings from the Antiretroviral Pregnancy Registry - (05/06/09)
     
  1121. EASL: On-Treatment Monitoring of HBsAgLevels to Predict Response to Peginterferon Alfa-2a in Patients With HBeAg-Positive Chronic Hepatitis B - (05/05/09)
     
  1122. EASL: Tenofovir 2 Years Safety, Efficacy & Resistance in Patients with Cirrhosis - (05/01/09)
     
  1123. EASL: Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naive Patients - (04/29/09)
     
  1124. EASL: Entecavir (ETV) Therapy in Chronic Hepatitis B Patients Previously Treated with Adefovir (ADV) with Incomplete Response On-Treatment or Relapse Off-Treatment - (04/29/09)
     
  1125. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients - (04/22/09)
     
  1126. Celsion Receives Orphan Drug Designation for ThermoDox to Treat Primary Liver Cancer - (04/20/09)
     
  1127. Researchers Uncover Low-Frequency Hepatitis B Drug-Resistant Mutations Using 454 Sequencing Systems - (04/08/09)
     
  1128. Ultra-Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse-Transcriptase Inhibitor (NRTI)-Treated Patients and NRTI-Naive Patients - (04/08/09)
     
  1129. Early serum HBsAgdrop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients - (04/06/09)
     
  1130. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B - (04/06/09)
     
  1131. Hepatitis B surface antigen quantification as a current-day paradox: Obtaining the gold in the face of diminishing returns - Editorial - (04/06/09)
     
  1132. Preventing HCC by HBV Treatment - (04/06/09)
     
  1133. Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses - (04/02/09)
     
  1134. Treatment of HBV/HCV Coinfection: Releasing the Enemy Within - (04/02/09)
     
  1135. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening - (03/30/09)
     
  1136. EHDRW: Minority Clusters of K103N Mutation in Antiretroviral-Naive People in B & non-B Subtypes - Written by Mark Mascolini (03/27/09)
     
  1137. ISHLVD: Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 mg QD - (03/27/09)
     
  1138. ISHLVD: Long-term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with HBeAg(+) and (-) Chronic Hepatitis B: Results from Studies ETV-022, -027 and -901 - (03/26/09)
     
  1139. ISHLVD: Five-Years of Continuous Entecavir for Nucleoside-Naive HBeAg(+) Chronic Hepatitis B: Results from Studies ETV-022/-901 - (03/26/09)
     
  1140. ISHLVD: Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Positive Patients With Chronic Hepatitis B (Study 103) - (03/26/09)
     
  1141. ISHLVD: Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (03/26/09)
     
  1142. ISHLVD: Telaprevir (TVR, T) q8h or q12h Combined With Either Peginterferon (PEG-IFN, P) Alfa-2a or Alfa-2b and Ribavirin (RBV, R) in Treatment-Naive Genotype 1 Hepatitis C: Week 12 Interim Results of the Randomized, Open-Label, Multicenter Phase 2 Study C208 - (03/26/09)
     
  1143. ISHLVD: Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Participating in Studies 102 and 103 - (03/25/09)
     
  1144. ISHLVD: Developing HBV/HCV Associated Liver Cancer At A Young Age < 40 Yrs Old - (03/25/09)
     
  1145. ISHLVD: Study Reports Asain-Americans Not Getting Screened and Not Being Perceived As Being At Risk for HBV by Asian Primary Care Providers - (03/23/09)
     
  1146. CROI: Review of HIV+ Patient's Immunological Response Rate to High-dose HBV Re-vaccination Series: Cd4 & viral load predict response - (03/17/09)
     
  1147. CROI: Predictors of Chronic HBV Infection in HIV-infected Individuals: HAART Can Prevent Chronic HBV - (03/17/09)
     
  1148. CROI: The Long-term Use of Tenofovir in HIV/HBV Co-infection Induces a Marked Decrease in Liver Fibrosis - (03/17/09)
     
  1149. CROI: ART Reinitiation and HBV Rebound among HIV/HBV-co-infected Patients following ART Interruption in the Strategies for the Management of ART Study - (03/17/09)
     
  1150. Eisai Announces Approval of Clevudine for the Treatment of Chronic Hepatitis B in the Philippines - (03/16/09)
     
  1151. APASL: Quantitative HBsAgfor early prediction of response to PEGASYS therapy in patients with HBeAg-negative disease - (03/12/09)
     
  1152. APASL: Histologic Assessment of Long-term Entecavir (ETV) Treatment in Chronic Hepatitis B (CHB) Patients - (03/12/09)
     
  1153. APASL: HBsAgClearance Continues to Increase After the End of Treatment With PEGASYS ± Lamivudine: 5-year Follow-up Study in Patients with HBeAg-Negative Disease - (03/12/09)
     
  1154. APASL: HBsAgDecline in Patients Treated With PEGASYS and its Association with Post-treatment Response in HBeAg-Positive Chronic Hepatitis B - (03/12/09)
     
  1155. APASL: PEGASYS But Not Adefovir Results in Significant Decline in HBsAgin Chinese Patients with HBeAg-Positive Disease Harboring Lamivudine-Resistant YMDD Mutations - (03/12/09)
     
  1156. APASL: Use of the Elecsys® HBsAgII assay for simple and accurate quantification of HBsAglevels in sera of patients infected with HBV - (03/12/09)
     
  1157. APASL: Evaluation of Long-term Entecavir (ETV) Treatment in Chronic Hepatitis B (CHB) Patients Switched from 24-week Lamivudine (LVD) Therapy - (03/11/09)
     
  1158. CROI: The Long Term Use of Tenofovir Disoproxil in HIV-HBV Co-Infection Induces a Marked Decrease in Liver Fibrosis - (03/04/09)
     
  1159. For the first time, doctors can predict which hepatitis B patients have the highest chance to achieve treatment success with Pegasys: new data reported at APASL, Asian Liver meeting - (02/27/09)
     
  1160. CROI: HBV Blippers and Rebounders under Treatment with Tenofovir in HIV/HBV Co-infection - (02/27/09)
     
  1161. Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: Phase II clinical study in Japan - (01/30/09)
     
  1162. Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV - (01/22/09)
     
  1163. EASL Clinical Practice Guidelines: Management of chronic hepatitis B - (01/20/09)
     
  1164. NIH Consensus Development Conference: Management of Hepatitis B - (01/07/08)
     
  1165. Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis - (01/05/08)
     
  1166. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study - (12/30/08)
     
  1167. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update - (12/23/08)
     
  1168. AASLD: Pattern of serial HBV DNA level and HCC development in Patients with Liver Cirrhosis - (12/19/08)
     
  1169. AASLD: On-Treatment HBsAgDecline During Peginterferon alfa-2a (40KD) ± Lamivudine in Patients With HBsAg-Positive CHB As A Potential Predictor Of Durable Off-Treatment Response - (12/05/08)
     
  1170. AASLD: Efficacy And Safety Of Peginterferon Alfa-2a Versus Adefovir Dipivoxil (ADV) In Treating Lamivudine Resistant HBeAg-Positive CHB: An Interim Analysis Of A Prospective Randomized Study - (12/05/08)
     
  1171. AASLD: Response Patterns Of Chinese Patients With Chronic Hepatitis B Who Achieved HBsAgClearance Through Treatment With Peginterferon Alfa-2a - (12/05/08)
     
  1172. AASLD: A Multicenter, Open-Label Study Of Efficacy And Safety Of Peginterferon Alfa-2a (40KD) In Korean Patients With HBeAg-Positive CHB Harboring Lamivudine-Resistant YMDD Mutants - (12/05/08)
     
  1173. ICAAC: Chronic Hepatitis B Virus (HBV) Infection in the HIV Outpatient Study (HOPS), 1996-2006: Prevalence in the Era of Evolving Interventions (12/02/08)
     
  1174. AASLD: Correlation Between HBV cccDNA And HBsAgLevels And Their Reduction By Peginterferon Alfa-2a-Based Therapy In Patients With Chronic Hepatitis B - (12/01/08)
     
  1175. AASLD: In Patients With HBeAg-Negative Chronic Hepatitis B, HBsAgSerum Levels Early During Treatment With Peginterferon Alfa-2a Predict HBsAgClearance up to 4 Years Post-Treatment - (12/01/08)
     
  1176. AASLD: Kinetics Of HBsAgDecline During And Following Treatment of CHB: Early And Rapid HBsAgDecline During Peginterferon alfa-2a Is Predictive Of HBsAgClearance - (12/01/08)
     
  1177. AASLD: Kinetics Of HBsAgDecline in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Peginterferon alfa-2a According to Genotype and its Association With Sustained HBsAgClearance 4 Years Post Treatment - (12/01/08)
     
  1178. AASLD: Quantitative Assessment Of Serum HBsAgLevels Using The Elecsys HBsAgII Screening Assay: Results Of A Feasibility Study - (12/01/08)
     
  1179. AASLD: New Data Suggest Long-Term Treatment with BARACLUDE (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B - (11/17/08)
     
  1180. AASLD: Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 mg QD - (11/17/08)
     
  1181. AASLD: PRESENCE OF rtA194T AT BASELINE DOES NOT REDUCE EFFICACY TO TENOFOVIR (TDF) IN PATIENTSWITH LAMIVUDINE (LAM)-RESISTANT CHRONIC HEPATITIS B - (11/17/08)
     
  1182. AASLD: Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Participating in Studies 102 and 103 - (11/17/08)
     
  1183. AASLD: Evaluation of Long-term Entecavir Treatment in Stable Chronic Hepatitis B Patients Switched from Lamivudine Therapy - (11/17/08)
     
  1184. AASLD: Three Years of Entecavir (ETV) Re-treatment of HBeAg(-) ETV Patients Who Previously Discontinued Treatment: Results from Study ETV-901 - (11/17/08)
     
  1185. AASLD: Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Positive Patients With Chronic Hepatitis B (Study 103) - (11/06/08)
     
  1186. AASLD: Histologic Assessment of Long-term Entecavir Treatmentin Chronic Hepatitis B Patients - (11/14/08)
     
  1187. AASLD: Five Years of Continuous Entecavir for Nucleoside-naïve HBeAg(+) Chronic Hepatitis B: Results from Studies ETV-022/-901 - (11/14/08)
     
  1188. AASLD: Long-term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with HBeAg(+) and (-) Chronic Hepatitis B: Results from Studies ETV-022, -027 and -901 - (11/14/08)
     
  1189. AASLD: Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/06/08)
     
  1190. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? - (10/23/08)
     
  1191. NIH Consensus Development Conference: Management of Hepatitis B - (10/23/08)
     
  1192. New CDC Hepatitis B plan seeks to aid high-risk groups - (09/22/08)
     
  1193. New CDC HBV Guidelines: focus on treatment/care/education instead of only screening/testing - (09/22/08)
     
  1194. Risk factors for decreased bone density and effects of HIV on bone in the elderly - (09/03/08)
     
  1195. U.S. Food and Drug Administration Approves Viread(R) [tenofovir] for Chronic Hepatitis B in Adults - (08/12/08)
     
  1196. High-Dose HBV Vaccination Rechallenge - (07/16/08)
     
  1197. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) - (07/09/08)
     
  1198. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks - (07/01/08)
     
  1199. EASL: SUSTAINED DURABILITY OF HBeAg SEROCONVERSION IN CHRONIC HEPATITIS B PATIENTS AFTER TREATMENT WITH TELBIVUDINE AND LAMIVUDINE - (05/28/08)
     
  1200. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-β2b and ribavirin in patients with HBV/HCV co-infection - (05/27/08)
     
  1201. EASL: An open-label, comparative, multicentre study of peginterferon alfa-2a (40KD) plus ribavirin in the treatment of patients chronically infected with HCV/HBV or HCV alone - (05/15/08)
     
  1202. EASL: On-treatment HBsAgdecline in HBeAg-negative patients as a predictor of response to peginterferon alfa-2a (40KD) therapy 3 years off-treatment: potential for response-guided therapy - (05/15/08)
     
  1203. EASL: HBV DNA suppression induced by peginterferon alfa-2a (40KD) but not by lamivudine results in HBsAgclearance and seroconversion at 3 years off-treatment - (05/15/08)
     
  1204. EASL: Efficacy and safety of peginterferon alfa-2a (40KD) in Chinese patients with HBeAg-positive chronic hepatitis B - (05/15/08)
     
  1205. EASL: Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with PEGASYS with or without lamivudine: results of 4-year follow-up: 11% HBsAgClearance - (05/02/08)
     
  1206. EASL: Entecavir (ETV) Results in Higher HBV DNA Reduction versus Adefovir (ADV) in Antiviral-naive HBeAg(+) Adults with High HBV DNA: Week 96 Results (E.A.R.L.Y. Study) - (05/01/08)
     
  1207. EASL: Important Progress Toward Control of Hepatitis B and C - (05/01/08)
     
  1208. EASL: Increasing HBV Viral Load Increases Risk for Liver Cancer--Serial Monitoring of Viral load and Serum Alanine Aminotransferase (ALT) Level and the Risk of Hepatocellular Carcinoma: R.E.V.E.A.L- HBV Study Update - (04/30/08)
     
  1209. EASL: Three Years of Continuous Treatment with Entecavir Results in High Proportions of Chinese Nucleoside-Naive Patients with Undetectable HBV DNA: Results from Studies ETV-023 and -050 - (04/30/08)
     
  1210. EASL: Three Years of Continuous Treatment in Chinese Patients who had Previously Failed Lamivudine: Results from Studies ETV-056 and ETV-050 - (04/30/08)
     
  1211. EASL: Long Term (3 Years) Efficacy, Safety and Resistance Analyses of Entecavir (ETV) Treatment in Japanese Nucleoside-naive Patients with Chronic Hepatitis B (CHB) - (04/30/08)
     
  1212. EASL: Increasing Serial HBV Viral Load & ALT Predicts HCC - (04/29/08)
     
  1213. EASL: BARACLUDE (ENTECAVIR) TREATMENT RESULTED IN GREATER VIRAL LOAD SUPPRESSION COMPARED TO ADEFOVIR AT 96 WEEKS IN ANTIVIRAL-NAIVE ADULT CHRONIC HEPATITIS B E-ANTIGEN POSITIVE PATIENTS - (04/29/08) BMS press release
     
  1214. EASL: Hepatitis B an issue 'too hot to handle' in Australia - (04/29/08)
     
  1215. EASL: A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV MONO-INFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOGUE EXPERIENCE - (04/29/08)
     
  1216. EASL: The Antiviral Response To Tenofovir Disoproxil Fumarate (TDF) is Comparable in Lamivudine (LAM)-NaIve and LAM-Experienced Subjects Treated for Chronic Hepatitis B (CHB) - (04/29/08)
     
  1217. EASL: Tenofovir Disoproxil Fumarate (TDF) is Highly Active for Treatment of Chronic Hepatitis B (CHB) in Patients With Cirrhosis - (04/29/08)
     
  1218. EASL: Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102) - (04/29/08)
     
  1219. EASL: Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Positive Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 103) - (04/29/08)
     
  1220. EASL: Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) - (04/29/08)
     
  1221. EASL: Liver Disease Progression in Chronic Hepatitis B Infected Persons With Persistently Normal Serum Alanine Aminotransferase Level: Update From the R.E.V.E.A.L.-HBV Study - (04/29/08)
     
  1222. EASL: Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) - (04/29/08)
     
  1223. EASL: European Commission Approves Viread(R) for Chronic Hepatitis B - (04/25/08)
     
  1224. EASL: GILEAD ANNOUNCES 72-WEEK DATA FROM TWO PIVOTAL PHASE III STUDIES EVALUATING VIREAD (tenofovir) FOR THE TREATMENT OF CHRONIC HEPATITIS B - (04/24/08)
     
  1225. Chronic Hepatitis B: Preventing, Detecting, and Managing Viral Resistance - (04/21/08)
     
  1226. Entecavir Therapy Induces de Novo HIV Reverse-Transcriptase M184V Mutation in an Antiretroviral Therapy-Naive Patient BRIEF REPORT - (04/04/08)
     
  1227. APASL: Entecavir at Five Years Shows Long Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance - (03/25/08)
     
  1228. APASL: BARACLUDE (ENTECAVIR) DATA CONTINUE TO DEMONSTRATE LOW INCIDENCE OF RESISTANCE THROUGH FIVE YEARS OF TREATMENT IN NUCLEOSIDE-NAIVE CHRONIC HEPATITIS B PATIENTS (BMS press announcement) - (03/25/08)
     
  1229. APASL: Efficacy and Safety of 3 Years Treatment with Entecavir (ETV) in Japanese Nucleoside-Naive Patients with Chronic Hepatitis B (CHB) - (03/25/08)
     
  1230. APASL: Three Years of Continuous Treatment in Chinese Patients who had Previously Failed Lamivudine: Results from Studies ETV-056 and ETV-050 - (03/25/08)
     
  1231. EUROPEAN CHMP ISSUES POSITIVE OPINION FOR VIREAD (tenofovir) FOR THE TREATMENT OF CHRONIC HEPATITIS B - (03/20/08)
     
  1232. HIV and hepatitis B co-infection in Africa Reflection and Reaction - (03/20/08)
     
  1233. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa Review - (03/20/08)
     
  1234. CROI: Immunopathogenesis of Hepatic Flares after Initiation of ART in HIV/HBV-co-infected Individuals - (03/19/08)
     
  1235. Occult hepatitis B virus in liver tissue of individuals without hepatic disease - (03/14/08)
     
  1236. Combination therapy for chronic hepatitis B: Ready for prime time? Editorial - Written by Ira M. Jacobson - (03/10/08)
     
  1237. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations - (03/05/08)
     
  1238. Potency of tenofovir in chronic hepatitis B: Mono or combination therapy? Editorial - (03/05/08)
     
  1239. Goal of HBV Therapy - Prevent Resistance - (01/07/08)
     
  1240. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART - (12/12/07)
     
  1241. Thousands of Canadians may be denied access to effective new hepatitis B treatment: Drug review committee recommends against full reimbursement of Baraclude (TM) (entecavir) - (12/05/07)
     
  1242. Hepatitis B Clinical Research Network Starts - (12/04/07)
     
  1243. The clinical significance of persistently normal ALT in chronic hepatitis B infection - (12/04/07)
     
  1244. Frequent Occurrence of Chronic Hepatitis B Virus Infection among West African HIV Type-1-Infected Children - (01/03/08)
     
  1245. Hepatitis B Virus and HIV Coinfection in Low-Income Countries: Unmet Needs EDITORIAL COMMENTARY - (01/03/08)
     
  1246. Tenofovir-Based Rescue Therapy for Advanced Liver Disease in 6 Patients Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine BRIEF REPORT - (01/03/08)
     
  1247. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART - (12/12/07)
     
  1248. Thousands of Canadians may be denied access to effective new hepatitis B treatment: Drug review committee recommends against full reimbursement of Baraclude(TM) (entecavir) - (12/05/07)
     
  1249. Hepatitis B Clinical Research Network Starts - (12/04/07)
     
  1250. The clinical significance of persistently normal ALT in chronic hepatitis B infection - (12/04/07)
     
  1251. New wave of immigration blamed for doubling of hepatitis B cases in UK - (11/28/07)
     
  1252. Most UK citizens susceptible to hep B infection - (11/28/07)
     
  1253. Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus - (11/27/07)
     
  1254. AASLD: Decline in the Need for Liver Transplantation for Endstage Liver Disease Secondary to Hepatitis B in the US - (11/26/07)
     
  1255. Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B - (11/19/07)
     
  1256. Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients - (11/19/07)
     
  1257. Hepatitis B: Explosion of New Knowledge; Comments by E Keefe - (11/19/07)
     
  1258. AASLD: Reduction in serum HBsAglevel in patients with chronic hepatitis B infected with genotype D induced by (pegylated) interferon alfa-2a alone or in combination with nucleos(t)ide analogs: a long-term single centre cohort study - (11/16/07)
     
  1259. AASLD: Long-term follow-up of HBsAgclearance in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (PEGASYS): increase in HBsAgclearance rate from 3% 6 months post-treatment to 8% after 3 years - (11/16/07)
     
  1260. AASLD: An Open Label, Comparative, Multicenter Study Of Peginterferon Alfa-2a Plus Ribavirin In The Treatment Of Patients With Chronic Hepatitis C/Hepatitis B Dual Infection Versus Those With Chronic Hepatitis C Mono-infection - (11/16/07)
     
  1261. AASLD: Real-Time PCR Quantification of Total Intracellular HBV DNA and cccDNA in HBsAg-Positive Patients with and without HDV co-Infection and in Patients with Occult HBV Infection - (11/16/07)
     
  1262. AASLD: First Multicenter Evaluation of the Efficacy of Tenofovir in Nucleo(t)ide Analog Experienced Patients with HBV Monoinfection - (11/14/07)
     
  1263. AASLD: Efficacy of Tenofovir DF for the Treatment of Adefovir Resistance - (11/14/07)
     
  1264. AASLD: Fatty Liver Associated with Metabolics in HBV+ - (11/14/07)
     
  1265. AASLD: Large Scale Longitudinal Study of Chronic Hepatitis B Patients with Hepatitis B Surface Antigen Seroclearance - (11/7/07)
     
  1266. AASLD: A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg Positive Chronic Hepatitis B (CHB): Study GS-US-174-0103 - (11/7/07)
     
  1267. AASLD: A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg-Negative Chronic Hepatitis B (CHB): Study GS-US-174-0102 - (11/7/07)
     
  1268. AASLD: HBV Viral Load Less Than 10,000 copies/mL Is Associated with Significant Risk of Hepatocellular Carcinoma in Chronic Hepatitis B (CHB) Patients: An Update from the R.E.V.E.A.L.-HBV Study - (11/7/07)
     
  1269. AASLD: Impact of chronically elevated HBV DNA viral load on risk of HCC occurrence: An update from The R.E.V.E.A.L.-HBV Study - (11/7/07)
     
  1270. AASLD: Changes in Serum HBV DNA Level Using a Trajectory Model to Predict the Risk of HCC in Chronic Hepatitis B Patients: The R.E.V.E.A.L.-HBV Study - (11/7/07)
     
  1271. AASLD: Gilead's Tenofovir beats Hepsera in second big HBV trial - (11/7/07)
     
  1272. AASLD: Four-Year Entecavir Treatment in Nucleoside-Naive, HBeAg(+) Patients: Results from Studies ETV-022 and -901 - (11/5/07)
     
  1273. AASLD: Long-Term Follow-Up of Entecavir Treated Protocol-Defined 'Non-Responders' in Rollover Study ETV-901 - (11/5/07)
     
  1274. Why we should routinely screen Asian American adults for hepatitis B: A cross-sectional study of Asians in California - (10/17/07)
     
  1275. GILEAD SUBMITS MARKETING APPLICATIONS IN THE UNITED STATES AND EUROPEAN UNION FOR VIREAD (TENOFOVIR DISOPROXIL FUMARATE) FOR THE TREATMENT OF CHRONIC HEPATITIS B - (10/12/07)
     
  1276. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV - (10/02/07)
     
  1277. Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B - (08/20/07)
     
  1278. Prevalence and Long-Term Effects of Occult Hepatitis B Virus Infection in HIV-Infected Women - (08/17/07)
     
  1279. Novartis/Idenix Launch Free Telbivudine HBV Drug Program for HBV Therapy - (08/14/07)
     
  1280. Screening for and Treating Hepatitis B Virus in Patients with HIV Infection EDITORIAL - (08/10/07)
     
  1281. Impact of HAART) on the Natural History of Hepatitis B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART and HBV Surface and Early Antigen Seroconversion - (08/10/07)
     
  1282. Hepatitis B Virus and HIV Coinfection: Results of a Survey on Treatment Practices and Recommendations for Therapy - (08/10/07)
     
  1283. Incidence (3 times higher) of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection - (07/16/07)
     
  1284. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis - (07/16/07)
     
  1285. The HBV Asian Epidemic You Don't Know About - (07/06/07)
     
  1286. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection - (07/05/07)
     
  1287. The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points (HBV-DNA, ALT) - (07/03/07)
     
  1288. SECOND PHASE III STUDY EVALUATING GILEAD'S VIREAD (Tenofovir) FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS MEETS PRIMARY ENDPOINT - (06/27/07)
     
  1289. Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint - (06/07/07)
     
  1290. DDW: Patient survey, Many hepatitis B patients stop taking meds - (05/31/07)
     
  1291. Predicting response to peginterferon a-2a (Pegasys), lamivudine and the two combined for HBeAg-negative chronic hepatitis B; genotype may predict response to combination therapy - (05/25/07)
     
  1292. DDW: A Randomized Trial of Telbivudine vs Adefovir for HBeAg-Positive Chronic Hepatitis B: Efficacy Through Week 76, Predictors of Response and Effects of Switching to Telbivudine - (05/25/07)
     
  1293. DDW: A Phase III Comparative Trial of Telbivudine vs Lamivudine in Chinese Patients With Chronic Hepatitis B: Two-Year Results - (05/25/07)
     
  1294. DDW: Causes of Death Associated With Hepatitis B or Hepatitis C Virus Infections in a Long-Term Population-Based Cohort Study - (05/24/07)
     
  1295. DDW: Salvage Therapy With Adefovir for Virologic Breakthrough in Telbivudine-Treated Patients From the GLOBE Study - (05/23/07)
     
  1296. DDW: Presence of Biopsy-Proven Histologic Damage (Necroinflammation and Fibrosis) is Common Even When ALT is Less Than 2 x ULN in Patients with Chronic Hepatitis B (CHB) in Entecavir Studies ETV-022 (HBeAg+) and ETV-027 (HBeAg-) - (05/23/07)
     
  1297. DDW: Genotypic Analysis of Patients with Evaluable HBV DNA After 1 Year of Telbivudine Therapy in the GLOBE Registration Trial - (05/23/07)
     
  1298. DDW: Resistance Determination in Patients Experiencing Virologic Breakthrough Following Telbivudine or Lamivudine Therapy in the International GLOBE Trial - (05/23/07)
     
  1299. DDW: BARACLUDE (ENTECAVIR) TREATMENT DEMONSTRATED GREATER VIRAL LOAD REDUCTION COMPARED TO ADEFOVIR AT 48 WEEKS IN STUDY OF ANTIVIRAL-NAIVE CHRONIC HEPATITIS B E-ANTIGEN POSITIVE PATIENTS - (05/23/07)
     
  1300. DDW: Telbivudine GLOBE Trial at Year Two: Efficacy, Safety, and Predictors of Outcome in Patients with Chronic Hepatitis B - (05/21/07)
     
  1301. DDW: HBV DNA & Genotype Predict HCC - (05/21/07)
     
  1302. DDW: HBV DNA & ALT Predict HCC in HBV+ - (05/21/07)
     
  1303. HBV Exposure May Increase HCC Risk Among HCV+ with Cirrhosis, Japan study reports - (05/04/07)
     
  1304. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B - (05/04/07)
     
  1305. Novartis gets European OK for hepatitis B drug Sebivo (telbivudine) - (05/01/07)
     
  1306. EASL: An open label, comparative, multi-center study of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B dual infection versus with mono-infected chronic hepatitis C: An interim report - (04/25/07)
     
  1307. EASL: EFFECTS OF INSULIN SENSITIZING AGENTS IN NONALCOHOLIC FATTY LIVER DISEASE, METABOLICS: metformin, rosiglitazone, metformin+rosiglitazone - (04/23/07)
     
  1308. EASL: 76 Week Follow-up of HBeAg-Positive Chronic Hepatitis B Patients Treated with Telbivudine, Adefovir or Switched from Adefovir to Telbivudine - (04/23/07)
     
  1309. EASL: HBV rtI233V Polymerase Variant Remains Sensitive to Adefovir - (04/23/07)
     
  1310. EASL: Pegasys Superior to Lamivudine Over 3 Years in HBV DNA Decline, ALT Normalization & HBsAgLoss (8% vs 0) & Seroconversion (4% vs 0) - (04/23/07)
     
  1311. EASL: Peginterferon a-2a Plus adefovir vs Peginterferon a-2a for 48 Weeks in HBeAg-Negative Chronic Hepatitis B: Preliminary 24-Week Results of the PEG FOR B Randomized Multicenter Trial - (04/23/07)
     
  1312. EASL: Efficacy of Entecavir and Lamivudine in Chronic Hepatitis B Patients with Advanced Liver Fibrosis/Cirrhosis - (04/19/07)
     
  1313. EASL: Presence of Biopsy-Proven Histologic Damage (Necroinflammation and Fibrosis) is Common even when ALT is less than 2 X ULN in Patients with Chronic Hepatitis B - (04/19/07)
     
  1314. EASL: Entecavir (ETV) Results in Higher HBV-DNA Reduction vs Adefovir (ADV) in Chronically Infected HBeAg(+) Antiviral-Naive Adults: 48-Wk Results (E.A.R.L.Y. Study) - (04/17/07)
     
  1315. EASL: Four Year Assessment Of Entecavir Resistance In Nucleoside Naive and Lamivudine Refractory Patients - (04/17/07)
     
  1316. EASL: Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients (press release from BMS) - (04/17/07)
     
  1317. EASL: BARACLUDE (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment (press release from BMS) - (04/17/07)
     
  1318. EASL: ETV Re-treatment of Nucleoside-Naive HBeAg(-) Patients with Recurrent Viremia - (04/17/07)
     
  1319. China Approves Schering-Plough's Pegintron for Hepatitis B - (04/05/07)
     
  1320. Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, Marion Peters - (04/05/07)
     
  1321. CROI: Hepatitis B Virus (HBV) Dynamics in HIV-HBV Co-infected Patients: Significant Difference in the Viral Activity of Adefovir (ADV) or Tenofovir (TDF) (03/09/07)
     
  1322. SEBIVO(R) (telbivudine) Recommended for Approval in European Union as a new Treatment for Patients with Chronic Hepatitis B - (02/27/07)
     
  1323. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B - (02/12/07)
     
  1324. Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years - (01/30/06)
     
  1325. New and Emerging Treatment of Chronic Hepatitis B - (01/30/06)
     
  1326. Hepatitis B Virus Treatment in HIV-infected Patients - (01/30/06)
     
  1327. Effect of Lowering HBV DNA Levels by Initial Antiviral Therapy Before Adding Immunomodulator Peginterferon on Treatment of Chronic Hepatitis B - (12/17/06)
     
  1328. Combination Therapy for Chronic Hepatitis B: Simultaneous or Sequential? EDITORIAL - (12/17/06)
     
  1329. Idenix announces telbivudine for chronic hepatitis B patients approved in Switzerland - (12/07/06)
     
  1330. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient - (12/07/06)
     
  1331. Hepatitis B virus resistance to entecavir in nucleoside naive patients: Does it exist Editorial - (12/07/06)
     
  1332. Entecavir resistance is rare in nucleoside naive patients with hepatitis B - (12/07/06)
     
  1333. AASLD: No Novel Adefovir Mutations - (11/08/06)
     
  1334. AASLD: Pegasys/RBV Prophylaxisly Administered After Liver Transplant - (11/08/06)
     
  1335. AASLD: RBV Exposure During weeks 1-12 of Treatment Improves SVR Rate in Canadian Pegasys EAP - (11/08/06)
     
  1336. AASLD: Pegasys + Adefovir Reduces HBsAgin HDV-Coinfected - (11/07/06)
     
  1337. AASLD: Pegasys+Lamivudine for HBeAg-negative, 2 Year Follow-up - (11/07/06)
     
  1338. AASLD: Anti-HBV Activity of In Vitro Combinations of Tenofovir with Nucleoside Analogs - (11/06/06)
     
  1339. AASLD: In Vitro Susceptibility of HBV Polymerase Encoding Mutations Acquired During Adefovir Dipivoxil Therapy to Other Anti-HBV Agents - (11/06/06)
     
  1340. AASLD: Entecavir Resistance 3-Year Update at AASLD - (11/02/06)
     
  1341. AASLD: Entecavir 3-Year Resistance Update - (11/02/06)
     
  1342. AASLD: Entecavir 3-Year Efficacy/Safety Update in HBeAg+ Naives - (11/02/06)
     
  1343. AASLD: Entecavir 3-Year Update on Efficacy & Safety - (11/02/06)
     
  1344. AASLD: Two-Year Results from the GLOBE Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine - (11/01/06)
     
  1345. ICAAC: Can Razor Blades Transmit Hepatitis B? - (10/02/06)
     
  1346. World Hepatitis Awareness Day October 1, 2006 - (10/02/06)
     
  1347. BMS Announces Baraclude (entecavir) Now Available In The UK For Treatment Of Chronic Hepatitis B - (09/21/06)
     
  1348. Novartis wins first major nod for hep B drug - (09/21/06)
     
  1349. Antiretroviral Therapy for Hepatitis B Virus-HIV-Coinfected Patients: Promises and Pitfalls - (09/18/06)
     
  1350. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-α2b plus ribavirin treatment in a patient with hepatitis B and C coinfection - (09/15/06)
     
  1351. Treatment Alternatives for Hepatitis B Cirrhosis: A Cost-Effectiveness Analysis - (09/11/06)
     
  1352. Liver transplants can be successful in HIV patients with hepatitis B - (09/07/06)
     
  1353. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response - (09/05/06)
     
  1354. Past HBV Viral Load as Predictor of Mortality and Morbidity from HCC and Chronic Liver Disease in a Prospective Study - (08/01/06)
     
  1355. Tenofovir disoproxil fumarate: Role in hepatitis B treatment - (08/01/06)
     
  1356. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy - (08/01/06)
     
  1357. Tenofovir disoproxil fumarate: Role in hepatitis B treatment - (08/01/06)
     
  1358. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy - (08/01/06)
     
  1359. Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B - (07/30/06)
     
  1360. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update - (07/27/06)
     
  1361. FDA committee favors Nabi hepatitis B drug for Post-Transplant - (07/14/06)
     
  1362. Hepatitis B Vaccination Coverage Among Adults --- United States, 2004 - (07/07/06)
     
  1363. European Commission Grants Approval for BARACLUDE(R) (entecavir) for Treatment of Chronic Hepatitis B - (06/29/06)
     
  1364. DDW: Safety and Efficacy of Adefovir Dipivoxil in Patients with Lamivudine-Resistant Chronic HBV Undergoing Liver Transplantation - (05/26/06)
     
  1365. DDW: A COMPARATIVE TRIAL OF TELBIVUDINE AND ADEFOVIR DIPIVOXIL FOR TREATMENT OF HBeAg-POSITIVE, COMPENSATED CHRONIC HEPATITIS B: 24 WEEK RESULTS - (05/26/06)
     
  1366. DDW: Predictive Factors for Exacerbation of Hepatitis B After Discontinuation of Oral Therapy in HBeAg-Negative Patients - (05/26/06)
     
  1367. DDW: Entecavir 96 Weeks in Lamivudine-Refractory HBeAg(+): efficacy, safety, resistance - (05/26/06)
     
  1368. 15% HBV Prevalence in NYC Among Asians - (05/16/06)
     
  1369. EASL: HBV Resistance Determination From the Telbivudine GLOBE Registration Trial - (05/16/06)
     
  1370. EASL: Pharmacokinetics and Pharmacodynamics of Pradefovir Mesylate, a Liver-Targeting Pro-Drug of PMEA, in HBV Patients - (05/16/06)
     
  1371. EASL: Clevudine 48 Weeks - (05/16/06)
     
  1372. EASL: Safety, Tolerability and Antiviral Activity of Pradefovir Mesylate in Patients with Chronic Hepatitis B Virus Infection: 48-Week Analysis of a Phase 2 Study - (05/16/06)
     
  1373. EASL: Telbivudine, New HBV Drug: Early Viral Response Predicts Outcomes - (05/10/06)
     
  1374. EASL: A Randomized Trial of Telbivudine (LdT) vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Results of the Primary Week 24 Analysis - (05/10/06)
     
  1375. EASL: Association Between HBeAg Seroconversion and Sustained HBV DNA Suppression in Patients Treated with Peginterferon Alfa-2a (40 KD) (Pegasys) for HBeAg-positive Chronic Hepatitis B - (05/08/06)
     
  1376. EASL: Durability of HBeAg Seroconversion Following Adefovir Dipivoxil Treatment for Chronic Hepatitis B - (05/08/06)
     
  1377. Association Between HBeAg Seroconversion and Sustained HBV DNA Suppression in Patients Treated with Peginterferon Alfa-2a (40 KD) (Pegasys) for HBeAg-positive Chronic Hepatitis B - (05/05/06)
     
  1378. EASL: Combination HBV Therapy (lamivudine+adefovir) Prevented HBV-DNA Viral Rebound and Adefovir Resistance Compared to Adefovir Monotherapy in Cirrhotics - (05/04/06)
     
  1379. EASL: Entecavir Improved Fibrosis in Advanced Liver Disease More Than Lamivudine in 3 Pivotol Studies After 48 Weeks Therapy - (05/04/06)
     
  1380. EASL: Entecavir vs Lamivudine in 515 Treatment-Naives: safety & efficacy - (05/04/06)
     
  1381. Outcome of patients with hepatitis B virus and HIV referred for liver transplantation - (05/03/06)
     
  1382. HBV/HIV Coinfection: Timing in Treatment & Referral for Transplantation and Suppression HBV Replication Are Crucial - (05/03/06)
     
  1383. EASL: Adefovir 5 years Viral & Resistance Outcomes in HBeAg-negatives - (05/03/06)
     
  1384. EASL: High Barrier To Resistance Results In No Emergence Of Entecavir Resistance In Nucleoside Naive Subjects During The First Two Years Of Therapy - (05/02/06)
     
  1385. EASL: Entecavir 96 weeks in HBeAg(-), study ETV-027 - (04/19/06)
     
  1386. Entecavir (ETV) vs. Adefovir (ADV): HBV DNA Reduction In Chronically Infected HBeAg(+) Nucleoside-Naive Adults In A 12-Week Viral Kinetics Study - (04/07/06)
     
  1387. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome - (04/05/06)
     
  1388. Idenix Files in china for Telbivudine Approval, new HBV Drug - (04/05/06)
     
  1389. Idenix Announces 13 Abstracts on Hepatitis B and C Accepted for the 2006 Annual Meeting of the European Association for the Study of the Liver (EASL) - (04/05/06)
     
  1390. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection - (04/05/06)
     
  1391. Role of Hepatitis B Viral Load and Basal Core Promoter Mutation in Hepatocellular Carcinoma in Hepatitis B Carriers - (04/05/06)
     
  1392. Novartis files telbivudine in China for Hep B - (03/29/06)
     
  1393. Personal view: the management of chronic hepatitis B infection - (03/21/06)
     
  1394. HBV Drug Pradefovir Phase 2 48 Week Study Results - (03/15/06)
     
  1395. Management of Recurrent Viral Hepatitis B and C After Liver Transplantation - (03/15/06)
     
  1396. HBV DNA Early Response Predicts IFN Nonresponse - (03/15/06)
     
  1397. Entecavir, Hepatitis B Drug Phase III Study Results in HBsAg - (03/09/06)
     
  1398. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B - (03/09/06)
     
  1399. Hepatitis Delta Virus Levels May Predict Disease Severity in HBV - (03/09/06)
     
  1400. CROI: Tenofovir + Lamivudine (3TC) for HBV/HIV Coinfection (03/07/06)
     
  1401. Tenofovir in HBV/HIV Coinfection, added to Lamivudine - (03/03/06)
     
  1402. Combination therapy for chronic hepatitis B: A one-two knockout punch, or a swing and a miss? - (03/03/06)
     
  1403. CROI: Hepatitis D Virus Can Worsen the Outcome of HBV-HIV Coinfected Patients (02/23/06)
     
  1404. Gilead Sciences Launches Stop Hep B Campaign - (02/10/06)
     
  1405. Idenix/Novartis Apply for Telbivudine European OK - (02/08/06)
     
  1406. Treatment with Peg-Interferon a-2b for HBeAg-Positive Chronic Hepatitis B: HBsAgLoss Is Associated with HBV Genotype - (02/08/06)
     
  1407. Therapeutic Options for Chronic Hepatitis B: Considerations and Controversies, part 1 - (02/02/06)
     
  1408. Looking to the Future: New Agents for Chronic Hepatitis B, part 2 - (02/02/06)
     
  1409. Advancing Patient Care: Integrating New Data, part 3 - (02/02/06)
     
  1410. Selecting Appropriate Management Strategies for Chronic Hepatitis B: Who to Treat, part 4 - (02/02/06)
     
  1411. Optimizing Management Strategies in Special Patient Populations, part 5 - (02/02/06)
     
  1412. Introduction to Chronic Hepatitis B Infection, last part 6 of 6 - (02/02/06)
     
  1413. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV: HBV genotype G found to be associated with liver fibrosis - (01/31/06)
     
  1414. Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons - (01/31/06)
     
  1415. HBV+HCV+HDV-dynamic diseases when in combination - (01/30/06)
     
  1416. Vaccination of Infants of Hepatitis B Mothers - (01/30/06)
     
  1417. Virologic response and resistance to adefovir in patients with chronic hepatitis B, & Entecavir Salvage Therapy - (01/25/06)
     
  1418. Candidates for therapy: HBV - (01/24/06)
     
  1419. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management - (01/24/06)
     
  1420. Natural history of chronic hepatitis B in co-infected patients - (01/24/06)
     
  1421. "Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine?" - (01/23/06)
     
  1422. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication - (01/23/06)
     
  1423. Management of hepatocellular carcinoma in HIV- infected patients - (01/23/06)
     
  1424. Intl Coinfection Wrkshp: HBV Drug Resistance & Cross-Resistance (01/20/06)
     
  1425. Intl Coinfection Wrkshp: New Drugs for HCV & HBV (01/17/06)
     
  1426. New Drug HepeX-B To Prevent HBV Post-Transplant Reinfection - (01/04/06)
     
  1427. Telbivudine Continues to Show Superior Efficacy over Lamivudine in Chronic HBV in Continuing GLOBE trial, 18 Mos: Presented at HEP DART - (01/04/06)
     
  1428. Adefovir Dipivoxil Produces sustained improvement in HBV over Long-Term; Presented at HEP DART - (01/04/06)
     
  1429. New HBV Drug Telbivudine: NDA submitted to FDA - (01/04/06)
     
  1430. HBV DNA (viral load) Predicts Risk for Liver Cancer - (01/04/06)
     
  1431. EACS: HAART & SVR in APRICOT Study (12/29/05)
     
  1432. Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Efficacy In Phase 2/3 Clinical Trial - (12/21/05)
     
  1433. Impact of tenofovir-containing ART on chronic HBV in a cohort co-infected with HIV - (12/12/05)
     
  1434. Treat HBV Immediately Upon Detecting Genotypic Resistance - (12/08/05)
     
  1435. AASLD: Pradefovir, New HBV Drug: 24 Wks (12/05/05)
     
  1436. AASLD: 5 Years Adefovir in HBeAg-Negatives (12/05/05)
     
  1437. AASLD: Clevudine, new HBV Drug: 24 week study results (12/05/05)
     
  1438. AASLD: Long-term effect of tenofovir in the treatment of lamivudine-resistant HBV in comparison to adefovir (12/02/05)
     
  1439. AASLD: Normal ALT & Low HBV-DNA May Be Risk for Cirrhosis & HCC (11/28/05)
     
  1440. AASLD: Serum Leptin Level Associated with Severity of Liver Fibrosis & Decreased After Pegasys Treatment in Chronic Hepatitis B (11/28/05)
     
  1441. AASLD: Low Rate of Viral Rebound Seen in HBV Patients Treated With Entecavir (11/28/05)
     
  1442. AASLD: Entecavir 2 Years Study Results in HBeAg+ HBV+ Patients (study ETV-22) (11/16/05)
     
  1443. AASLD: Five-Year Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented at AASLD Annual Meeting (11/15/05)
     
  1444. AASLD: BARACLUDE (entecavir) TWO-YEAR DATA ANALYSIS DID NOT DETECT EMERGENCE OF RESISTANCE IN NUCLEOSIDE-NAIVE CHRONIC HEPATITIS B PATIENTS (11/14/05)
     
  1445. AASLD: SEVERE IMPAIRMENT IN QUALITY OF LIFE IN HIV+ WITH HCV BUT NOT WITH HBV (11/14/05)
     
  1446. AASLD: HEPATITIS B: SCIENCE & TREATMENT 2005 (11/11/05)
     
  1447. New Liver Cancer Therapy Approach Improves Survival - (11/07/05)
     
  1448. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women - (11/07/05)
     
  1449. INTERFERON THERAPY FOR CHRONIC HEPATITIS B and Combination Interferon + Lamivudine - (11/07/05)
     
  1450. HCC (Liver Cancer) Deaths Doubled & Hospital Services Costs Increase Significantly - (11/05/05)
     
  1451. Entecavir RESISTANCE - (11/03/05)
     
  1452. Hepatitis B Survey Among Asians Highlights Lack of Information About HBV - (11/03/05)
     
  1453. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity - (11/03/05)
     
  1454. Entecavir Treatment for HBV in Woodchucks - (10/27/05)
     
  1455. Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project) - (10/27/05)
     
  1456. Epidemiology, Natural History, Impact of Therapy of Hepatitis B - (10/24/05)
     
  1457. Hepatits B Treatment - (10/24/05)
     
  1458. "Predicting survival in hepatitis B" Should Targeted HBV DNA Suppression Be the Goal of Therapy? - (10/21/05)
     
  1459. Hep B Booster Shot Unnecessary: Study - (10/21/05)
     
  1460. Hepatitis B and Liver Transplantation - (10/21/05)
     
  1461. The impact of maternal HBsAgcarrier status on pregnancy outcomes: A case-control study - (10/14/05)
     
  1462. Hepatitis B in India: 3% HBsAg+ - (10/13/05)
     
  1463. Long-Term Interferon+Lamivudine for HBV in HBeAg-Negatives - (10/13/05)
     
  1464. Hepatitis B Vaccine: is it associated with Autism? - (10/11/05)
     
  1465. Resistance to adefovir: A new challenge in the treatment of chronic hepatitis B - (10/11/05)
     
  1466. Adefovir Resistance: clinical outcomes - (10/11/05)
     
  1467. Asian Americans & Hepatitis B - (10/06/05)
     
  1468. New HCV Drug NM283 HBV Drug LdT at AASLD - (10/03/05)
     
  1469. New HBV Therapy Research for siRNAs - (10/03/05)
     
  1470. Hepatitis B in children: Complexities in management - (10/03/05)
     
  1471. NIH Hepatitis B Management Conference: 2006 - (09/28/05)
     
  1472. Broadeining Hepatitis B Vaccination considered for all adults - (09/21/05)
     
  1473. Hepatitis B and HIV co-infection in sub-Saharan Africa: a call for further investigation - (09/21/05)
     
  1474. 6.3% Prevalence of hepatitis B and C in pregnant women who are infected with HIV - (09/21/05)
     
  1475. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics - (09/20/05)
     
  1476. Covalently Closed Circular DNA Is the Predominant Form of Duck Hepatitis B Virus DNA That Persists following Transient Infection.....inactive/nonreplicating cccDNA - (09/20/05)
     
  1477. Peginterferon for HBV Therapy: review of studies - (09/19/05)
     
  1478. September is Liver Cancer Awareness Month - (09/19/05)
     
  1479. (Marijuana/Hash) Endocannabinoids and liver disease - review - (09/19/05)
     
  1480. Stressgen Granted U.S. Patent Covering Therapeutic Products to Treat Hepatitis B Virus - (09/06/05)
     
  1481. HBV, pathogenesis and natural course - (09/06/05)
     
  1482. Promising Therapy for Human Hepatoma (liver cancer, HCC): Telomerase Inhibition by GRN163 - (09/13/05)
     
  1483. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain - (09/13/05)
     
  1484. Pegasys for HBV: what is the treatment role? - (09/06/05)
     
  1485. HBV Genotype May Predict Cirrhosis - (09/06/05)
     
  1486. Does HBV Genotype Predict Response to IFN - (09/06/05)
     
  1487. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy - (08/15/05)
     
  1488. Telbivudine (LdT) Achieves Primary Endpoint in Phase III GLOBE Trial, Largest Ever Registration Trial in HBV - (08/04/05)
     
  1489. Gilead Announces Initiation of Phase III Study of Tenofovir for the Treatment of Chronic Hepatitis B Virus - (07/22/05)
     
  1490. New Hep B Drug Pradefovir: 24 week data - (07/22/05)
     
  1491. Peginterferon more effective than lamivudine for chronic hepatitis B - (07/05/05)
     
  1492. Long-Term Therapy Required for HBeAg-Negative Patients: Adefovir HBV Therapy in HBeAg-negative Patients Maintains Benefits on Therapy for 144 Weeks; Upon Discontinuation of Therapy Rebound Occurs - (06/30/05)
     
  1493. The Maze of Treatments for Hepatitis B - (06/30/05)
     
  1494. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B - (06/30/05)
     
  1495. Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B - (06/30/05)
     
  1496. Pharmasset to Develop Clevudine for the Treatment of Chronic Hepatitis B under a License from Bukwang Pharmaceuticals - (06/28/05)
     
  1497. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study - (06/27/05)
     
  1498. DDW: Resistance to Adefovir (Hepsera) Can Be Associated with Significant Virologic Breakthough and Fatal Hepatic Decompensation (06/20/05)
     
  1499. HBV & Risk for Cancers Outside the Liver - (06/01/05)
     
  1500. New HCV & HBV Drugs: toll-like receptors - (06/01/05)
     
  1501. New Perspectives in the Treatment of HBeAg-positive and HBeAg-negative Chronic Hepatitis B pegylated interferon - (05/31/05)
     
  1502. Hepatitis virus-positive livers OK for transplants - (05/27/05)
     
  1503. HBV Drug LdT: 2 years followup: Phase IIb Extended-Treatment Trial of Telbivudine (LdT) vs. Lamivudine vs. Combination Treatment in Hepatitis B Patients: Two-Year Results - (05/26/05)
     
  1504. New Perspectives in the Treatment of HBeAg-positive and HBeAg-negative Chronic Hepatitis B - (05/25/05)
     
  1505. Hepatitis virus-positive livers OK for transplants - (05/27/05)
     
  1506. HBV Drug LdT: 2 years followup: Phase IIb Extended-Treatment Trial of Telbivudine (LdT) vs. Lamivudine vs. Combination Treatment in Hepatitis B Patients: Two-Year Results - (05/26/05)
     
  1507. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate - (05/25/05)
     
  1508. DDW: HBV DNA Elevations & Risk for Liver Cancer (05/23/05)
     
  1509. DDW: HBV Viral Load Predicts Cirrhosis Risk (05/19/05)
     
  1510. DDW: "Viral Load is a Strong Predictor of Hepatocellular Carcinoma (HCC) Risk in People Chronically Infected With Hepatitis B Virus (HBV) Independent of Serum Alanine Aminotransaminase Level (ALT)" (05/19/05)
     
  1511. DDW: Entecavir 24 Week Followup Off-Treatment in HBeAg+ (05/19/05)
     
  1512. DDW: HEPATITIS B: SCIENCE & TREATMENT 2005 (05/16/05)
     
  1513. DDW: Pioglitazone Improves Fatty Liver (05/16/05)
     
  1514. FDA Approves Pegasys(R) as the First and Only Pegylated Interferon for the Treatment of Chronic Hepatitis B   - (05/16/05)
     
  1515. Can HBV Replicate Extrahepatically? - (05/16/05)
     
  1516. HIV-infected patients with isolated anti-HBc antigen may require HBV vaccine - (05/13/05)
     
  1517. Tenofovir Dosing in HBV - (05/09/05)
     
  1518. Effect of Lamivudine Therapy on the Serum Covalently Closed-Circular (ccc) DNA of Chronic Hepatitis B Infection - (05/09/05)
     
  1519. Is HBV Curable: effect of lamivudine (3TC) on cccDNA - (05/09/05)
     
  1520. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B - (05/09/05)
     
  1521. Hepatitis B Immunity in United States Military Recruits - (05/09/05)
     
  1522. May 13 is Hepatitis B Awareness Day - (05/09/05)
     
  1523. EASL: Lack of Pharmacokinetic Interaction When Entecavir is Co-Administerd with Lamivudine,, Adefovir, or Tenofovir and Entecavir Dosing with Renal Impairment (05/05/05)
     
  1524. EASL: HBV DNA (viral load) Predicts Liver Cirrhosis (05/02/05)
     
  1525. EASL: Tenofovir in HIV/HBV Coinfection (05/02/05)
     
  1526. EASL: Effect of Previous HBV Therapy on Pegasys+Lamivudine for HBV (05/02/05)
     
  1527. EASL: HBV Viral Load Risk Factor for Liver Cancer (04/27/05)
     
  1528. EASL: Diabetes & Lipids Associated with Liver Disease (04/27/05)
     
  1529. EASL: Adefovir for HBV HBeAg-negative: 4 years- safety, antiviral efficacy, resistance, ALT normalization, creatinine & phosphorous (04/27/05)
     
  1530. EASL: HBV DNA Decline & ALT Normalization Associated with Histologic Improvement (04/27/05)
     
  1531. EASL: Pegasys for HBV, 72 Weeks: HBsAgSeroconversion Response (04/26/05)
     
  1532. EASL: SUSTAINED RESPONSE TO PEGASYS IN HBeAg-NEGATIVE CHRONIC HEPATITIS B. (04/25/04)
     
  1533. EASL: Adefovir Resistance report: 4 years update (04/22/05)
     
  1534. EASL: Adefovir Week 144 Efficacy in HBeAg+ (04/20/05)
     
  1535. EASL: HBV: Entecavir Compared to Adefovir & Lamivudine (04/20/05)
     
  1536. EASL: Valtorcitabine (LdC) New HBV Drug Phase I/II Study Results (04/19/05)
     
  1537. EASL: PegIFN+Adefovir Combination for HBV: cccDNA, seroconversion (04/19/05)
     
  1538. EASL:Adefovir HBV Resistance Update (04/15/05)
     
  1539. Effect of Antiviral Treatment with Entecavir on Age- and Dose-Related Outcomes of Duck Hepatitis B Virus Infection - (04/14/05)
     
  1540. Dual hepatitis B virus and hepatitis C virus infection: To treat or not to treat, and how? EDITORIAL - (04/09/05)
     
  1541. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort (04/06/05)
     
  1542. HBV DNA Can Persist After HBsAgSeroconversion (04/05/05)
     
  1543. Hepatitis B or hepatitis C and HIV (04/05/05)
     
  1544. Occult Hepatitis B May Progress to Cirrhosis & Liver Cancer Editorial (04/05/05)
     
  1545. 1st Study of Occult Hepatitis B prevalence in Community Setting (04/05/05)
     
  1546. FDA Approves New Treatment Baraclude (entecavir) for Chronic Hepatitis B (03/31/05)
     
  1547. FDA Antiviral Drug Advisory Committee Recommends Unanymously to Approve Entecavir for Hepatitis B (03/15/05)
     
  1548. ART May Reconstitute HBV Immunity (03/15/05)
     
  1549. Disease Status & Therapeutic End Points in Hepatitis B (03/09/05)
     
  1550. CROI: "Entecavir in HIV/HBV Co-Infected Patients: Safety and Efficacy in a Phase II Study (ETV-038)" - (03/08/05)
     
  1551. CROI: Tenofovir for HBV/HIV Coinfection - (03/03/05)
     
  1552. PegIntron+Lamivudine vs LAM for HBV - (03/01/05)
     
  1553. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel - (02/24/05)
     
  1554. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA - (02/16/05)
     
  1555. Hepatitis B or Hepatitis C and HIV-infection Diagnosis/Care/Treatent - (02/11/05)
     
  1556. Study Finds Interferon Reduces Cancer Risk in HCV+ Cirrhotics - (02/10/05)
     
  1557. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance - (02/10/05)
     
  1558. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma (liver cancer) - (02/09/05)
     
  1559. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B - (02/09/05)
     
  1560. Liver & Kidney Transplant in HIV Study - (02/03/05)
     
  1561. Chronic Hepatitis B & HIV/HBV Coinfection - (01/31/05)
     
  1562. Hepatitis New Drug Research - (01/26/05)
     
  1563. Pegasys Receives Positive Opinion for HBV in Europe; HBV/HIV Coinfection Medical Management - (01/24/05)
     
  1564. The potential of RNA interference as a tool in the management of viral hepatitis - (01/13/05)
     
  1565. PegIntron with or without 3TC for Hepatitis B Treatment - (01/07/05)
     
  1566. Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Epidemiology, Natural History, and Treatment - (12/30/05)
     
  1567. Medicinal Herbs for HCV (oxymatrin) - (12/30/05)
     
  1568. PEGASYS Approved for Chronic Hepatitis B in Switzerland - (12/28/05)
     
  1569. Management of hepatitis B patients with antiviral resistance - (12/21/05)
     
  1570. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment - (12/15/05)
     
  1571. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination - (12/13/05)
     
  1572. AASLD: Entecavir Resistance - (11/16/05)
     
  1573. AASLD: LB80380, new HBV Drug - (11/15/05)
     
  1574. AASLD: PegIFN for HBV, HDV, & HCV - (11/10/05)
     
  1575. AASLD: ADEFOVIR FOR HBV- 144 WEEK FOLLOW-UP - (11/10/05)
     
  1576. AASLD: CLINICAL PHARMACOKINETICS OF TELBIVUDINE, A POTENT ANTIVIRAL FOR HEPATITIS B, IN SUBJECTS WITH IMPAIRED HEPATIC OR RENAL FUNCTION - (11/09/05)
     
  1577. AASLD: LdT & HBV Therapy Viral Dynamics - (11/09/05)
     
  1578. AASLD: LdC, new HBV Drug: 4-week Dosing, Safety & Antiviral Efficacy Study - (11/08/05)
     
  1579. AASLD: Remofovir, new HBV drug: prodrug of PMEA - (11/08/05)
     
  1580. AASLD: Clevudine, new HBV drug, 3 studies - (11/08/05)
     
  1581. AASLD: FTC for HBV - (11/08/05)
     
  1582. AASLD: LdT, new HBV Drug: week 52 phase II results; Viral Dynamics - (11/08/05)
     
  1583. AASLD: In Vitro Cross-Resistance HBV Drugs - (11/08/05)
     
  1584. AASLD: Pegasys+Lamivudine, Pegasys, or Lamivudine for HBV Therapy - (11/05/05)
     
  1585. AASLD: Entecavir in Lamivduine Experienced Patients - (11/05/05)
     
  1586. AASLD: Entecavir: new HBV drug, phase III study in nucleoside-naïve HBeAg-negative patients - (11/02/05)
     
  1587. AASLD: Entecavir: new hepatitis B drug-phase III study results of 48-weeks therapy in HBeAg+ nucleoside-naïve patients - (11/01/05)
     
  1588. AASLD: Report 1 on Hepatitis B at the Liver Conference AASLD - (11/01/05)
     
  1589. Review article: current management of chronic hepatitis B - (10/25/05)
     
  1590. Occult hepatitis B in HCV+ - (10/25/05)
     
  1591. High Prevalence of HBV in HIV+ & HIV- Women -WIHS - (10/21/05)
     
  1592. Treatments for Hepatitis B - (10/19/05)
     
  1593. Occult HBV Seen in 26% of HCV+ - (10/14/05)
     
  1594. Prevention of (HBV) Hepatocellular Carcinoma - (10/08/05)
     
  1595. Lamivudine Reduced Risk of Hepatic Decompensation & Liver Cancer by Half - (10/08/05)
     
  1596. Valeant Pharmaceuticals to Present New HBV Drug Remofovir Pharmacokinetic and Pharmacodynamic Data From Phase 1 Clinical Trial - (10/07/05)
     
  1597. Significance of HBV DNA Levels in Liver Histology of HBeAg and Anti-HBe Positive Patients with Chronic Hepatitis B - (10/07/05)
     
  1598. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study - (10/05/05)
     
  1599. Entecavir, New Hep B Drug, BMS Files NDA with FDA - (10/05/05)
     
  1600. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine - (09/30/05)
     
  1601. Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection? - (09/30/05)
     
  1602. Genotype C HBV-infection is associated with an increased risk of hepatocellular carcinoma - (09/29/05)
     
  1603. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures - (09/28/05)
     
  1604. Hepatitis B virus genotype C linked to increased hepatocellular carcinoma risk - (09/24/05)
     
  1605. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance - (09/22/05)
     
  1606. Combination Therapy in HBV: will it improve response? - (09/22/05)
     
  1607. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B - (09/22/05)
     
  1608. HBV/HIV Coinfection Medical Management - (09/20/05)
     
  1609. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B - (09/16/05)
     
  1610. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients - (09/03/05)
     
  1611. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection - (09/03/05)
     
  1612. Risk of HIV & Hepatitis Infections From Blood & Tissue Donors - (08/25/05)
     
  1613. Outcome of liver transplantation for hepatitis B in the United States - (08/09/05)
     
  1614. HEPATITIS B IN CORRECTIONAL FACILITIES: hi prevalence & successful vaccination programs - (08/09/05)
     
  1615. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR - (08/09/05)
     
  1616. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B - (08/05/05)
     
  1617. Roche Files for Application with FDA to Market Pegasys for Chronic Hepatitis B Treatment - (07/22/05)
     
  1618. XV International AIDS Conference in Bangkok: Adefovir for HBV/HIV Coinfection with 3TC Resistance: 4 years followup - (07/19/05)
     
  1619. FDA UPDATE ON VIREAD (TENOFOVIR) LABEL - (07/06/05)
     
  1620. Hepatitis B Transmission in Prisons: sharing needles, sex, mother-to-child, vaccine for prevention - (07/06/05)
     
  1621. Isolated Presence of Antibody to Hepatitis B Core Antigen in Patients Coinfected With HIV - (06/30/05)
     
  1622. Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy--Naive and --Experienced Patients Coinfected with HIV-1 and Hepatitis B Virus - (06/28/05)
     
  1623. Long-term benefit of interferon therapy of chronic hepatitis D: regression of advanced hepatic fibrosis - (06/22/05)
     
  1624. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy - (06/22/05)
     
  1625. Occult Hepatitis B in HIV-Infected Patients - (06/22/05)
     
  1626. DDW: Significant and Sustained Efficacy of Adefovir After 4 Years of Treatment in Chronic HBV Patients with Lamivudine-Resistant HBV and HIV Coinfection - (05/25/05)
     
  1627. DDW: Three year Results from a Double-Blind, Randomized, Pacebo-Controlled, Study of Adefovir (ADV) in HBeAg-negative Chronic Hepatitis B (CHB) - (05/25/05)
     
  1628. DDW: Combination of Pegylated IFN and Lamivudine is superior to Lamivudine alone in the treatment of HBV - (05/24/05)
     
  1629. DDW: ADEFOVIR RESISTANCE REPORT - (05/20/05)
     
  1630. DDW: Adefovir Reduced HBV Viral Reservoir & HBsAgin Parallel - (05/20/05)
     
  1631. Occult HBV: Clinical Significance of Hepatitis B Core Antibody Positivity in HCV-Infected and HCV/HIV Coinfected Individuals - (05/10/05)
     
  1632. HBV/HIV Coinfection & Tenofovir - (05/10/05)
     
  1633. EASL: The Long-Term Outcome of HBeAg-negative Patients with Cirrhosis Treated with Lamivudine Monotherapy: a 5 year prospective cohort - (04/27/05)
     
  1634. EASL: Long-Term Incidence of Adefovir Resistance in Chronic Hepatitis B Patients after 144 weeks of Therapy - (04/27/05)
     
  1635. EASL: DURABILITY OF HBeAg SEROCONVERSION AFTER ADEFOVIR DIPIVOXIL TREATMENT FOR CHRONIC HEPATITIS B - (04/27/05)
     
  1636. EASL: Adefovir 3 Year Study Results in Presumed Precore Mutant Chronic Hepatitis B: safety and efficacy - (04/27/05)
     
  1637. EASL: HBsAgSeroconversion in Adefovir Treated Chronic Hepatitis B Patients - (04/26/05)
     
  1638. EASL: Entecavir Resistance in Lamivudine Resistant Patients - (04/26/05)
     
  1639. EASL: Results of a 1-Year International Phase IIB Trial of LdT, and LdT plus Lamivudine, in Patients with Chronic Hepatitis B - (04/26/05)
     
  1640. EASL: EASL Hepatitis B Report 2: Pegasys Study in Hepatitis B - (04/22/05)
     
  1641. Hepatitis A - (04/05/05)
     
  1642. HBV Epidemiology - (04/02/05)
     
  1643. Interferon for HBV Can Increase Survival & Risk for Developing Liver Cancer: study authors recommend interferon as first-line therapy - (04/02/05)
     
  1644. CROI: Quantification of Hepatitis B Virus-specific T-cell Responses in HIV/HBV Co-infected Individuals - (03/15/05)
     
  1645. Hepatitis B: Treatment Strategies for Currently Available Drugs - (03/08/05)
     
  1646. CROI: Tenofovir is Effective Against HBV in HBV/HIV Coinfection - (03/03/05)
     
  1647. CROI: Hepatitis B Treatment Update - Nancy Shulman, MD, Stanford University (03/02/05)
     
  1648. CROI: Three Year Treatment with Adefovir in Chronic Hepatitis B Patients with Lamivudine (3TC) Resistant HBV and HIV Coinfection Results in Significant and Sustained Clinical Improvement - (03/02/05)
     
  1649. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States - (02/05/05)
     
  1650. HEP DART: Differences between Hepatitis B and C in the Prediction of Success of Treatment Using Early Viral Kinetics - (01/26/05)
     
  1651. HEP DART: Clinical Development of Entecavir for the Treatment of Chronic Hepatitis B - (01/26/05)
     
  1652. HEP DART: L-Thymidine (LdT) and Related Compounds - (01/26/05)
     
  1653. HEP DART: A 12 Week Randomized Placebo-Controlled Double Blind Trial of Clevudine in Patients with Chronic Hepatitis B with Post-Treatment Follow-up for 24 weeks - (01/26/05)
     
  1654. HHV-8 seropositivity linked with prostate cancer - (01/26/05)
     
  1655. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B - (01/15/05)
     
  1656. EDITORIAL: Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? - (01/15/05)
     
  1657. EDITORIAL: Rescue therapy for drug resistant hepatitis B: Another argument for combination chemotherapy? - (01/15/05)
     
  1658. Viral features of lamivudine resistant hepatitis B genotypes A and D - (01/14/05)
     
  1659. High prevalence of occult hepatitis B in Baltimore injection drug users - (01/14/05)
     
  1660. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection - (01/14/05)
     
  1661. Viral features of lamivudine resistant hepatitis B genotypes A and D - (01/14/05)
     
  1662. Oral feeding of hepatitis B proteins a promising treatment for chronic infection - (01/05/05)
     
  1663. Hepatitis B Rates in the United States - (01/05/05)
     
  1664. Incidence of Acute Hepatitis B - United States, 1990-2002 - (01/05/05)